



Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/208813/>

Version: Published Version

Article:

Al Said, S., Kaier, K., Sumaya, W. et al. (2024) Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis. Cochrane Database of Systematic Reviews, 2024 (1). ISSN: 1469-493X

<https://doi.org/10.1002/14651858.cd014678.pub2>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



Cochrane
Library

Cochrane Database of Systematic Reviews

Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis (Review)

Al Said S, Kaier K, Sumaya W, Alsaid D, Duerschmied D, Storey RF, Gibson CM, Westermann D, Alabed S

Al Said S, Kaier K, Sumaya W, Alsaid D, Duerschmied D, Storey RF, Gibson CM, Westermann D, Alabed S.
Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis.
Cochrane Database of Systematic Reviews 2024, Issue 1. Art. No.: CD014678.
DOI: [10.1002/14651858.CD014678.pub2](https://doi.org/10.1002/14651858.CD014678.pub2).

www.cochranelibrary.com

Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis (Review)

Copyright © 2024 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

WILEY

TABLE OF CONTENTS

ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	4
BACKGROUND	7
Figure 1.	8
Figure 2.	9
Figure 3.	10
OBJECTIVES	10
METHODS	10
RESULTS	14
Figure 4.	15
Figure 5.	17
Figure 6.	18
DISCUSSION	21
AUTHORS' CONCLUSIONS	23
ACKNOWLEDGEMENTS	23
REFERENCES	25
CHARACTERISTICS OF STUDIES	32
DATA AND ANALYSES	43
Analysis 1.1. Comparison 1: NOACs (all doses combined) versus placebo: all-cause mortality, Outcome 1: All-cause mortality (apixaban versus placebo)	44
Analysis 1.2. Comparison 1: NOACs (all doses combined) versus placebo: all-cause mortality, Outcome 2: All-cause mortality (rivaroxaban versus placebo)	44
Analysis 1.3. Comparison 1: NOACs (all doses combined) versus placebo: all-cause mortality, Outcome 3: All-cause mortality (dabigatran versus placebo)	45
Analysis 2.1. Comparison 2: NOACs (all doses combined) versus placebo: cardiovascular mortality, Outcome 1: Cardiovascular mortality (apixaban versus placebo)	45
Analysis 2.2. Comparison 2: NOACs (all doses combined) versus placebo: cardiovascular mortality, Outcome 2: Cardiovascular mortality (rivaroxaban versus placebo)	46
Analysis 2.3. Comparison 2: NOACs (all doses combined) versus placebo: cardiovascular mortality, Outcome 3: Cardiovascular mortality (dabigatran versus placebo)	46
Analysis 3.1. Comparison 3: NOACs (all doses combined) versus placebo: major bleeding, Outcome 1: Major bleeding (apixaban versus placebo)	47
Analysis 3.2. Comparison 3: NOACs (all doses combined) versus placebo: major bleeding, Outcome 2: Major bleeding (rivaroxaban versus placebo)	47
Analysis 3.3. Comparison 3: NOACs (all doses combined) versus placebo: major bleeding, Outcome 3: Major bleeding (dabigatran versus placebo)	47
Analysis 4.1. Comparison 4: Apixaban (different doses) versus placebo, Outcome 1: All-cause mortality	49
Analysis 4.2. Comparison 4: Apixaban (different doses) versus placebo, Outcome 2: Cardiovascular mortality	50
Analysis 4.3. Comparison 4: Apixaban (different doses) versus placebo, Outcome 3: Major bleeding	51
Analysis 4.4. Comparison 4: Apixaban (different doses) versus placebo, Outcome 4: Myocardial infarction	52
Analysis 4.5. Comparison 4: Apixaban (different doses) versus placebo, Outcome 5: Stroke	53
Analysis 4.6. Comparison 4: Apixaban (different doses) versus placebo, Outcome 6: Stent thrombosis	53
Analysis 4.7. Comparison 4: Apixaban (different doses) versus placebo, Outcome 7: Non-major bleeding	54
Analysis 5.1. Comparison 5: Rivaroxaban (different doses) versus placebo, Outcome 1: All-cause mortality	58
Analysis 5.2. Comparison 5: Rivaroxaban (different doses) versus placebo, Outcome 2: Cardiovascular mortality	59
Analysis 5.3. Comparison 5: Rivaroxaban (different doses) versus placebo, Outcome 3: Major bleeding	60
Analysis 5.4. Comparison 5: Rivaroxaban (different doses) versus placebo, Outcome 4: Myocardial infarction	61
Analysis 5.5. Comparison 5: Rivaroxaban (different doses) versus placebo, Outcome 5: Stroke	62
Analysis 5.6. Comparison 5: Rivaroxaban (different doses) versus placebo, Outcome 6: Stent thrombosis	63
Analysis 5.7. Comparison 5: Rivaroxaban (different doses) versus placebo, Outcome 7: Non-major bleeding	64
Analysis 5.8. Comparison 5: Rivaroxaban (different doses) versus placebo, Outcome 8: Systemic embolism	65

Analysis 6.1. Comparison 6: Dabigatran (different doses) versus placebo, Outcome 1: All-cause mortality	68
Analysis 6.2. Comparison 6: Dabigatran (different doses) versus placebo, Outcome 2: Cardiovascular mortality	69
Analysis 6.3. Comparison 6: Dabigatran (different doses) versus placebo, Outcome 3: Major bleeding	70
Analysis 6.4. Comparison 6: Dabigatran (different doses) versus placebo, Outcome 4: Myocardial infarction	71
Analysis 6.5. Comparison 6: Dabigatran (different doses) versus placebo, Outcome 5: Stroke	72
Analysis 7.1. Comparison 7: Apixaban 5 mg versus apixaban 10 mg, Outcome 1: All-cause mortality	73
Analysis 7.2. Comparison 7: Apixaban 5 mg versus apixaban 10 mg, Outcome 2: Cardiovascular mortality	73
Analysis 7.3. Comparison 7: Apixaban 5 mg versus apixaban 10 mg, Outcome 3: Major bleeding	73
Analysis 7.4. Comparison 7: Apixaban 5 mg versus apixaban 10 mg, Outcome 4: Myocardial infarction	74
Analysis 7.5. Comparison 7: Apixaban 5 mg versus apixaban 10 mg, Outcome 5: Stroke	74
Analysis 7.6. Comparison 7: Apixaban 5 mg versus apixaban 10 mg, Outcome 6: Non-major bleeding	74
Analysis 8.1. Comparison 8: Rivaroxaban 5 mg versus rivaroxaban 10 mg, Outcome 1: All-cause mortality	75
Analysis 8.2. Comparison 8: Rivaroxaban 5 mg versus rivaroxaban 10 mg, Outcome 2: Cardiovascular mortality	75
Analysis 8.3. Comparison 8: Rivaroxaban 5 mg versus rivaroxaban 10 mg, Outcome 3: Major bleeding	75
Analysis 8.4. Comparison 8: Rivaroxaban 5 mg versus rivaroxaban 10 mg, Outcome 4: Myocardial infarction	76
Analysis 8.5. Comparison 8: Rivaroxaban 5 mg versus rivaroxaban 10 mg, Outcome 5: Stroke	76
Analysis 8.6. Comparison 8: Rivaroxaban 5 mg versus rivaroxaban 10 mg, Outcome 6: Stent thrombosis	76
Analysis 8.7. Comparison 8: Rivaroxaban 5 mg versus rivaroxaban 10 mg, Outcome 7: Non-major bleeding	76
Analysis 9.1. Comparison 9: Rivaroxaban 5 mg versus rivaroxaban 15 mg, Outcome 1: All-cause mortality	77
Analysis 9.2. Comparison 9: Rivaroxaban 5 mg versus rivaroxaban 15 mg, Outcome 2: Cardiovascular mortality	77
Analysis 9.3. Comparison 9: Rivaroxaban 5 mg versus rivaroxaban 15 mg, Outcome 3: Major bleeding	77
Analysis 9.4. Comparison 9: Rivaroxaban 5 mg versus rivaroxaban 15 mg, Outcome 4: Myocardial infarction	78
Analysis 9.5. Comparison 9: Rivaroxaban 5 mg versus rivaroxaban 15 mg, Outcome 5: Stroke	78
Analysis 9.6. Comparison 9: Rivaroxaban 5 mg versus rivaroxaban 15 mg, Outcome 6: Non-major bleeding	78
Analysis 10.1. Comparison 10: Rivaroxaban 5 mg versus rivaroxaban 20 mg, Outcome 1: All-cause mortality	79
Analysis 10.2. Comparison 10: Rivaroxaban 5 mg versus rivaroxaban 20 mg, Outcome 2: Cardiovascular mortality	79
Analysis 10.3. Comparison 10: Rivaroxaban 5 mg versus rivaroxaban 20 mg, Outcome 3: Major bleeding	79
Analysis 10.4. Comparison 10: Rivaroxaban 5 mg versus rivaroxaban 20 mg, Outcome 4: Myocardial infarction	80
Analysis 10.5. Comparison 10: Rivaroxaban 5 mg versus rivaroxaban 20 mg, Outcome 5: Stroke	80
Analysis 10.6. Comparison 10: Rivaroxaban 5 mg versus rivaroxaban 20 mg, Outcome 6: Non-major bleeding	80
Analysis 11.1. Comparison 11: Rivaroxaban 10 mg versus rivaroxaban 15 mg, Outcome 1: All-cause mortality	81
Analysis 11.2. Comparison 11: Rivaroxaban 10 mg versus rivaroxaban 15 mg, Outcome 2: Cardiovascular mortality	81
Analysis 11.3. Comparison 11: Rivaroxaban 10 mg versus rivaroxaban 15 mg, Outcome 3: Major bleeding	81
Analysis 11.4. Comparison 11: Rivaroxaban 10 mg versus rivaroxaban 15 mg, Outcome 4: Myocardial infarction	81
Analysis 11.5. Comparison 11: Rivaroxaban 10 mg versus rivaroxaban 15 mg, Outcome 5: Stroke	82
Analysis 11.6. Comparison 11: Rivaroxaban 10 mg versus rivaroxaban 15 mg, Outcome 6: Non-major bleeding	82
Analysis 12.1. Comparison 12: Rivaroxaban 10 mg versus rivaroxaban 20 mg, Outcome 1: All-cause mortality	82
Analysis 12.2. Comparison 12: Rivaroxaban 10 mg versus rivaroxaban 20 mg, Outcome 2: Cardiovascular mortality	83
Analysis 12.3. Comparison 12: Rivaroxaban 10 mg versus rivaroxaban 20 mg, Outcome 3: Major bleeding	83
Analysis 12.4. Comparison 12: Rivaroxaban 10 mg versus rivaroxaban 20 mg, Outcome 4: Myocardial infarction	83
Analysis 12.5. Comparison 12: Rivaroxaban 10 mg versus rivaroxaban 20 mg, Outcome 5: Stroke	83
Analysis 12.6. Comparison 12: Rivaroxaban 10 mg versus rivaroxaban 20 mg, Outcome 6: Non-major bleeding	84
Analysis 13.1. Comparison 13: Rivaroxaban 15 mg versus rivaroxaban 20 mg, Outcome 1: All-cause mortality	84
Analysis 13.2. Comparison 13: Rivaroxaban 15 mg versus rivaroxaban 20 mg, Outcome 2: Cardiovascular mortality	84
Analysis 13.3. Comparison 13: Rivaroxaban 15 mg versus rivaroxaban 20 mg, Outcome 3: Major bleeding	85
Analysis 13.4. Comparison 13: Rivaroxaban 15 mg versus rivaroxaban 20 mg, Outcome 4: Myocardial infarction	85
Analysis 13.5. Comparison 13: Rivaroxaban 15 mg versus rivaroxaban 20 mg, Outcome 5: Stroke	85
Analysis 13.6. Comparison 13: Rivaroxaban 15 mg versus rivaroxaban 20 mg, Outcome 6: Non-major bleeding	85
Analysis 14.1. Comparison 14: Dabigatran 50 mg BD versus dabigatran 75 mg BD, Outcome 1: All-cause mortality	86
Analysis 14.2. Comparison 14: Dabigatran 50 mg BD versus dabigatran 75 mg BD, Outcome 2: Cardiovascular mortality	86
Analysis 14.3. Comparison 14: Dabigatran 50 mg BD versus dabigatran 75 mg BD, Outcome 3: Major bleeding	86
Analysis 14.4. Comparison 14: Dabigatran 50 mg BD versus dabigatran 75 mg BD, Outcome 4: Myocardial infarction	87

Analysis 14.5. Comparison 14: Dabigatran 50 mg BD versus dabigatran 75 mg BD, Outcome 5: Stroke	87
Analysis 15.1. Comparison 15: Dabigatran 50 mg BD versus dabigatran 110 mg BD, Outcome 1: All-cause mortality	87
Analysis 15.2. Comparison 15: Dabigatran 50 mg BD versus dabigatran 110 mg BD, Outcome 2: Cardiovascular mortality	88
Analysis 15.3. Comparison 15: Dabigatran 50 mg BD versus dabigatran 110 mg BD, Outcome 3: Major bleeding	88
Analysis 15.4. Comparison 15: Dabigatran 50 mg BD versus dabigatran 110 mg BD, Outcome 4: Myocardial infarction	88
Analysis 15.5. Comparison 15: Dabigatran 50 mg BD versus dabigatran 110 mg BD, Outcome 5: Stroke	88
Analysis 16.1. Comparison 16: Dabigatran 50 mg BD versus dabigatran 150 mg BD, Outcome 1: All-cause mortality	89
Analysis 16.2. Comparison 16: Dabigatran 50 mg BD versus dabigatran 150 mg BD, Outcome 2: Cardiovascular mortality	89
Analysis 16.3. Comparison 16: Dabigatran 50 mg BD versus dabigatran 150 mg BD, Outcome 3: Major bleeding	89
Analysis 16.4. Comparison 16: Dabigatran 50 mg BD versus dabigatran 150 mg BD, Outcome 4: Myocardial infarction	90
Analysis 16.5. Comparison 16: Dabigatran 50 mg BD versus dabigatran 150 mg BD, Outcome 5: Stroke	90
Analysis 17.1. Comparison 17: Dabigatran 75 mg BD versus dabigatran 110 mg BD, Outcome 1: All-cause mortality	90
Analysis 17.2. Comparison 17: Dabigatran 75 mg BD versus dabigatran 110 mg BD, Outcome 2: Cardiovascular mortality	91
Analysis 17.3. Comparison 17: Dabigatran 75 mg BD versus dabigatran 110 mg BD, Outcome 3: Major bleeding	91
Analysis 17.4. Comparison 17: Dabigatran 75 mg BD versus dabigatran 110 mg BD, Outcome 4: Myocardial infarction	91
Analysis 17.5. Comparison 17: Dabigatran 75 mg BD versus dabigatran 110 mg BD, Outcome 5: Stroke	91
Analysis 18.1. Comparison 18: Dabigatran 75 mg BD versus dabigatran 150 mg BD, Outcome 1: All-cause mortality	92
Analysis 18.2. Comparison 18: Dabigatran 75 mg BD versus dabigatran 150 mg BD, Outcome 2: Cardiovascular mortality	92
Analysis 18.3. Comparison 18: Dabigatran 75 mg BD versus dabigatran 150 mg BD, Outcome 3: Major bleeding	92
Analysis 18.4. Comparison 18: Dabigatran 75 mg BD versus dabigatran 150 mg BD, Outcome 4: Myocardial infarction	93
Analysis 18.5. Comparison 18: Dabigatran 75 mg BD versus dabigatran 150 mg BD, Outcome 5: Stroke	93
Analysis 19.1. Comparison 19: Dabigatran 110 mg BD versus dabigatran 150 mg BD, Outcome 1: All-cause mortality	93
Analysis 19.2. Comparison 19: Dabigatran 110 mg BD versus dabigatran 150 mg BD, Outcome 2: Cardiovascular mortality	94
Analysis 19.3. Comparison 19: Dabigatran 110 mg BD versus dabigatran 150 mg BD, Outcome 3: Major bleeding	94
Analysis 19.4. Comparison 19: Dabigatran 110 mg BD versus dabigatran 150 mg BD, Outcome 4: Myocardial infarction	94
Analysis 19.5. Comparison 19: Dabigatran 110 mg BD versus dabigatran 150 mg BD, Outcome 5: Stroke	94
ADDITIONAL TABLES	94
APPENDICES	98
HISTORY	109
CONTRIBUTIONS OF AUTHORS	109
DECLARATIONS OF INTEREST	109
SOURCES OF SUPPORT	109
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	109
INDEX TERMS	110

[Intervention Review]

Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis

Samer Al Said¹, Klaus Kaier², Wael Sumaya³, Dima Alsaid⁴, Daniel Duerschmied^{5,6}, Robert F Storey⁷, C. Michael Gibson⁸, Dirk Westermann¹, Samer Alabed⁷

¹Department of Cardiology and Angiology, University Heart Center Freiburg Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany. ²Institute for Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany. ³Department of Medicine, Faculty of Medicine, Dalhousie University, QE II Health Sciences Centre, Halifax Infirmary, Halifax, Canada. ⁴Institute for Evidence in Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. ⁵Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. ⁶European Center for AngioScience (ECAS) and German Center for Cardiovascular Research (DZHK) partner site Heidelberg/Mannheim, Mannheim, Germany, Mannheim, Germany. ⁷Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK. ⁸Cardiology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Contact: Samer Al Said, sameral said@gmail.com.

Editorial group: Cochrane Heart Group.

Publication status and date: New, published in Issue 1, 2024.

Citation: Al Said S, Kaier K, Sumaya W, Alsaid D, Duerschmied D, Storey RF, Gibson CM, Westermann D, Alabed S. Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis. *Cochrane Database of Systematic Reviews* 2024, Issue 1. Art. No.: CD014678. DOI: [10.1002/14651858.CD014678.pub2](https://doi.org/10.1002/14651858.CD014678.pub2).

Copyright © 2024 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. This is an open access article under the terms of the [Creative Commons Attribution Licence](https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background

Balancing the risk of bleeding and thrombosis after acute myocardial infarction (AMI) is challenging, and the optimal antithrombotic therapy remains uncertain. The potential of non-vitamin K antagonist oral anticoagulants (NOACs) to prevent ischaemic cardiovascular events is promising, but the evidence remains limited.

Objectives

To evaluate the efficacy and safety of non-vitamin-K-antagonist oral anticoagulants (NOACs) in addition to background antiplatelet therapy, compared with placebo, antiplatelet therapy, or both, after acute myocardial infarction (AMI) in people without an indication for anticoagulation (i.e. atrial fibrillation or venous thromboembolism).

Search methods

We searched CENTRAL, MEDLINE, Embase, the Conference Proceedings Citation Index – Science, and two clinical trial registers in September 2022 with no language restrictions. We checked the reference lists of included studies for any additional trials.

Selection criteria

We searched for randomised controlled trials (RCTs) that evaluated NOACs plus antiplatelet therapy versus placebo, antiplatelet therapy, or both, in people without an indication for anticoagulation after an AMI.

Data collection and analysis

Two review authors independently checked the results of searches to identify relevant studies, assessed each included study, and extracted study data. We conducted random-effects pairwise analyses using Review Manager Web, and network meta-analysis using the R package 'netmeta'. We ranked competing treatments by P scores, which are derived from the P values of all pairwise comparisons and allow ranking of treatments on a continuous 0-to-1 scale.

Main results

We identified seven eligible RCTs, including an ongoing trial that we could not include in the analysis. Of the six RCTs involving 33,039 participants, three RCTs compared rivaroxaban with placebo, two RCTs compared apixaban with placebo, and one RCT compared dabigatran with placebo. All participants in the six RCTs received concomitant antiplatelet therapy.

The available evidence suggests that rivaroxaban compared with placebo reduces the rate of all-cause mortality (risk ratio (RR) 0.82, 95% confidence interval (CI) 0.69 to 0.98; number needed to treat for an additional beneficial outcome (NNTB) 250; 3 studies, 21,870 participants; high certainty) and probably reduces cardiovascular mortality (RR 0.83, 95% CI 0.69 to 1.01; NNTB 250; 3 studies, 21,870 participants; moderate certainty). There is probably little or no difference between apixaban and placebo in all-cause mortality (RR 1.09, 95% CI 0.88 to 1.35; number needed to treat for an additional harmful outcome (NNTH) 334; 2 studies, 8638 participants; moderate certainty) and cardiovascular mortality (RR 0.99, 95% CI 0.77 to 1.27; number needed to treat not applicable; 2 studies, 8638 participants; moderate certainty). Dabigatran may reduce the rate of all-cause mortality compared with placebo (RR 0.57, 95% CI 0.31 to 1.06; NNTB 63; 1 study, 1861 participants; low certainty). Dabigatran compared with placebo may have little or no effect on cardiovascular mortality, although the point estimate suggests benefit (RR 0.72, 95% CI 0.34 to 1.52; NNTB 143; 1 study, 1861 participants; low certainty).

Two of the investigated NOACs were associated with an increased risk of major bleeding compared to placebo: apixaban (RR 2.41, 95% CI 1.44 to 4.06; NNTH 143; 2 studies, 8544 participants; high certainty) and rivaroxaban (RR 3.31, 95% CI 1.12 to 9.77; NNTH 125; 3 studies, 21,870 participants; high certainty). There may be little or no difference between dabigatran and placebo in the risk of major bleeding (RR 1.74, 95% CI 0.22 to 14.12; NNTH 500; 1 study, 1861 participants; low certainty).

The results of the network meta-analysis were inconclusive between the different NOACs at all individual doses for all primary outcomes. However, low-certainty evidence suggests that apixaban (combined dose) may be less effective than rivaroxaban and dabigatran for preventing all-cause mortality after AMI in people without an indication for anticoagulation.

Authors' conclusions

Compared with placebo, rivaroxaban reduces all-cause mortality and probably reduces cardiovascular mortality after AMI in people without an indication for anticoagulation. Dabigatran may reduce the rate of all-cause mortality and may have little or no effect on cardiovascular mortality. There is probably no meaningful difference in the rate of all-cause mortality and cardiovascular mortality between apixaban and placebo. Moreover, we found no meaningful benefit in efficacy outcomes for specific therapy doses of any investigated NOACs following AMI in people without an indication for anticoagulation. Evidence from the included studies suggests that rivaroxaban and apixaban increase the risk of major bleeding compared with placebo. There may be little or no difference between dabigatran and placebo in the risk of major bleeding. Network meta-analysis did not show any superiority of one NOAC over another for our prespecified primary outcomes.

Although the evidence suggests that NOACs reduce mortality, the effect size or impact is small; moreover, NOACs may increase major bleeding. Head-to-head trials, comparing NOACs against each other, are required to provide more solid evidence.

PLAIN LANGUAGE SUMMARY

What are the benefits and harms of non-vitamin K antagonist oral anticoagulants (which help to prevent blood clot formation) after a heart attack

Key messages

- Compared with placebo (dummy treatment), rivaroxaban reduces death from any cause (all-cause death) and probably reduces death from diseases of the heart and blood vessels (cardiovascular death) after a heart attack. Dabigatran may reduce all-cause death but may have little or no effect on cardiovascular death. Apixaban is probably no more effective than placebo for reducing all-cause death or cardiovascular death after a heart attack.
- Apixaban and rivaroxaban increase the risk of major bleeding compared to placebo.
- There is a need for studies that compare non-vitamin K antagonist oral anticoagulants (NOACs) directly against each other.

What is heart attack?

Heart attack is a life-threatening event that happens when the blood supply to the heart muscle is suddenly interrupted, causing tissue damage. Choosing the best treatment for people after a heart attack remains challenging in clinical practice. Despite treatment with

antiplatelet medicines (which prevent platelets from sticking together and forming a blood clot), heart attack survivors are at increased risk of death.

Why did we do this Cochrane review?

The aim of this review was to investigate whether adding next-generation blood thinners (NOACs) to antiplatelet medicines is safe and more effective than antiplatelet medicines alone after a heart attack. NOACs help to prevent blood clot formation by slowing blood clotting time or changing the way in which clotting occurs.

What did we do?

We searched for studies that tested the benefits and risks of NOACs in combination with background antiplatelet therapy compared with placebo, antiplatelet therapy, or both, after a heart attack.

How up-to-date is this review?

We included evidence up to September 2022.

What did we find?

We included six studies that involved 33,039 people (two studies compared apixaban with placebo, three studies compared rivaroxaban with placebo, and one study compared dabigatran with placebo). All participants in all studies received antiplatelet medicines. We compared all the NOACs with each other using a mathematical method called a network meta-analysis.

What are the main results of our review?

Compared to placebo, rivaroxaban added to antiplatelet medicines reduces all-cause death and probably reduces cardiovascular death after heart attack. Dabigatran may reduce all-cause death. Apixaban may provide no additional benefits compared with placebo in terms of all-cause death or cardiovascular death. However, apixaban and rivaroxaban increase the risk of major bleeding compared with placebo. We found no clear difference between individual doses of NOACs for death or major bleeding. However, apixaban (combined dose) is probably less effective than rivaroxaban or dabigatran for preventing all-cause death after a heart attack.

What are the limitations of the evidence?

We have little confidence in the evidence for dabigatran because the study recruited fewer than 2000 participants and the results are consistent with no effect as well as considerable benefit, considerable harm, or both. We are moderately confident in some of the evidence for apixaban and rivaroxaban because the results are consistent with no effect as well as considerable benefit or considerable harm.

How up to date is this evidence?

The evidence is current to September 2022.

SUMMARY OF FINDINGS

Summary of findings 1. Non-vitamin-K-antagonist oral anticoagulants versus placebo in adults with acute myocardial infarction and without an indication for anticoagulation: all-cause mortality

Patient or population: adults after AMI without an indication for anticoagulation

Settings: secondary care

Intervention: NOACs (apixaban, rivaroxaban, dabigatran), all doses combined

Comparison: placebo

Outcome: all-cause mortality

Comparison	No. of participants (no. of studies)	Direct evidence RR (95% CI)	Indirect evidence RR (95% CI)	NMA RR (95% CI)	Anticipated absolute effects estimate of the NMA			Certainty of the evidence of the NMA
					Risk with placebo	Risk with intervention	Risk difference with intervention	
Apixaban (all doses combined) vs placebo	8638 (2)	1.09 (0.88 to 1.35)	—	1.09 (0.88 to 1.35)	36 per 1000	39 per 1000 (32 to 49)	3 more per 1000 (4 fewer to 13 more)	⊕⊕⊕⊖ Moderate^a
Rivaroxaban (all doses combined) vs placebo	21,870 (3)	0.82 (0.69 to 0.98)	—	0.82 (0.69 to 0.98)	25 per 1000	20 per 1000 (17 to 24)	4 fewer per 1000 (8 fewer to 0 fewer)	⊕⊕⊕⊕ High
Dabigatran (all doses combined) vs placebo	1861 (1)	0.57 (0.31 to 1.06)	—	0.57 (0.31 to 1.06)	38 per 1000	22 per 1000 (12 to 40)	16 fewer per 1000 (26 fewer to 2 more)	⊕⊕⊖⊖ Low^b

AMI: acute myocardial infarction; CI: confidence interval; NMA: network meta-analysis; NOAC: non-vitamin K antagonist oral anticoagulant; RR: risk ratio.

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

^a Downgraded one level for imprecision: 95% CI includes no effect and default value for appreciable harm (> 1.25).

^b Downgraded two levels for imprecision: 95% CI includes no effect and default value for appreciable benefit (< 0.75), or both, and the optimal information size was not met (i.e. sample size < 2000 participants).

Summary of findings 2. Non-vitamin-K-antagonist oral anticoagulants versus placebo in adults with acute myocardial infarction and without an indication for anticoagulation: cardiovascular mortality

Patient or population: adults after AMI without an indication for anticoagulation

Settings: secondary care

Intervention: NOACs (apixaban, rivaroxaban, dabigatran), all doses combined

Comparison: placebo

Outcome: cardiovascular mortality

Comparison	No. of participants (no. of studies)	Direct evidence RR (95% CI)	Indirect evidence RR (95% CI)	NMA RR (95% CI)	Anticipated absolute effects estimate of the NMA			Certainty of the evidence of the NMA
					Risk with placebo	Risk with intervention	Risk difference with intervention	
Apixaban (all doses combined) vs placebo	8638 (2)	0.99 (0.77 to 1.27)	—	0.99 (0.77 to 1.27)	28 per 1000	28 per 1000 (21 to 35)	0 fewer per 1000 (6 fewer to 8 more)	⊕⊕⊕⊖ Moderate^a
Rivaroxaban (all doses combined) vs placebo	21,870 (3)	0.83 (0.69 to 1.01)	—	0.83 (0.69 to 1.01)	22 per 1000	18 per 1000 (15 to 22)	4 fewer per 1000 (7 fewer to 0 fewer)	⊕⊕⊕⊖ Moderate^a
Dabigatran (all doses combined) vs placebo	1861 (1)	0.72 (0.34 to 1.52)	—	0.72 (0.34 to 1.52)	24 per 1000	17 per 1000 (8 to 37)	7 fewer per 1000 (16 fewer to 13 more)	⊕⊕⊖⊖ Low^b

AMI: acute myocardial infarction; CI: confidence interval; NMA: network meta-analysis; NOAC: non-vitamin K antagonist oral anticoagulant; RR: risk ratio.

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

^a Downgraded one level for imprecision: 95% CI includes no effect and default value for appreciable harm (> 1.25) or appreciable benefit (< 0.75).

^b Downgraded two levels for imprecision: 95% CI includes no effect and default values for appreciable harm (> 1.25) and appreciable benefit (< 0.75), and the optimal information size was not met (i.e. sample size < 2000 participants).

Summary of findings 3. Non-vitamin-K-antagonist oral anticoagulants versus placebo in adults with acute myocardial infarction and without an indication for anticoagulation: major bleeding

Patient or population: adults after AMI without an indication for anticoagulation

Settings: secondary care

Intervention: NOACs (apixaban, rivaroxaban, dabigatran) - all doses combined

Comparison: placebo

Outcome: major bleeding

Comparison	No. of participants (no. of studies)	Direct evidence RR (95% CI)	Indirect evidence RR (95% CI)	NMA RR (95% CI)	Anticipated absolute effects estimate of the NMA			Certainty of the evidence of the NMA
					Risk with placebo	Risk with intervention	Risk difference with intervention	
Apixaban (all doses combined) vs placebo	8544 (2)	2.41 (1.44 to 4.06)	—	2.41 (1.44 to 4.06)	5 per 1000	11 per 1000 (7 to 19)	7 more per 1000 (2 more to 14 more)	⊕⊕⊕⊕ High
Rivaroxaban (all doses combined) vs placebo	21,870 (3)	3.31 (1.12 to 9.77)	—	3.31 (1.12 to 9.77)	4 per 1000	12 per 1000 (4 to 35)	8 more per 1000 (0 fewer to 32 more)	⊕⊕⊕⊕ High
Dabigatran (all doses combined) vs placebo	1861 (1)	1.74 (0.22 to 14.12)	—	1.74 (0.22 to 14.12)	3 per 1000	5 per 1000 (1 to 38)	2 more per 1000 (2 fewer to 35 more)	⊕⊕○○ Low^a

AMI: acute myocardial infarction; **CI:** confidence interval; **NMA:** network meta-analysis; **NOAC:** non-vitamin K antagonist oral anticoagulant; **RR:** risk ratio.

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

^a Downgraded two levels for imprecision: 95% CI includes no effect and default values for appreciable harm (> 1.25) and appreciable benefit (< 0.75), and the optimal information size was not met (i.e. sample size < 2000 participants).

BACKGROUND

Description of the condition

Acute myocardial infarction (AMI) is the death of the myocardial tissue due to ischaemia. AMI occurs secondary to an obstruction in one or more coronary arteries due to a rupture of an atherosclerotic plaque. AMI is divided into ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), according to the electrocardiographic appearance of the lesion.

Despite therapy, AMI remains a life-threatening disease: up to one in five affected people either die, suffer recurrent myocardial infarction, or develop a stroke within one year (Jernberg 2015). The estimated global incidence of AMI is 10 to 15 million episodes per year (James 2018; Vos 2016). AMI has a considerable economic burden: in the USA, hospitalisation due to AMI costs USD 14.3 billion each year (Liang 2020), while the annual medical costs of ischaemic heart disease in Europe are estimated at EUR 59 billion (Wilkins 2017). The economic burden associated with AMI in China is higher than in some high-income economies (Jan 2018).

The prognosis of AMI has improved markedly since the early 2000s because of advancements in treatment strategies (Ibanez 2018; Roffi 2016). One key contributor to improved outcomes is dual antiplatelet therapy (DAPT) with aspirin and a P2Y₁₂ receptor antagonist. DAPT has significantly reduced the risk of recurrent cardiovascular events, including stent thrombosis, particularly in people undergoing percutaneous coronary intervention (PCI; Leon 1998; Valgimigli 2017).

While DAPT reduces the incidence of stent thrombosis in the first few months after PCI, the impact of DAPT on late and particularly very late stent thrombosis is less certain (Garg 2015). Generally, the recommended strategy after AMI is DAPT for at least 12 months, followed by life-long single antiplatelet therapy (SAPT; Amsterdam 2014; Collet 2020; Ibanez 2018; O'Gara 2013; Roffi 2016). However, DAPT duration can be shortened or lengthened (beyond 12 months) according to each person's ischaemic or bleeding risk profile (Bonaca 2015; Kikkert 2018).

The potent P2Y₁₂ inhibitors prasugrel and ticagrelor are favoured over clopidogrel for DAPT without anticoagulation following AMI (Collet 2020; Ibanez 2018; Roffi 2016). However, even with DAPT, recurrent ischaemic events remain high (Al Said 2018), owing to excessive thrombin generation and adverse fibrin clots that resist lysis (Merlini 1994; Sumaya 2018a). Additional anticoagulation on top of DAPT may limit adverse fibrin properties (Sumaya 2018b; Varin 2013). Researchers have further evaluated this finding in clinical studies combining non-vitamin-K-antagonist oral anticoagulants (NOACs) with antiplatelet therapy in AMI management.

Description of the intervention

NOACs, also known as direct-acting oral anticoagulants (DOACs), have been developed as an alternative to vitamin K antagonists (VKAs) such as warfarin. While VKAs reduce the synthesis of functional vitamin K-dependent clotting factors II, VII, IX, and X, and proteins C and S, NOACs directly inhibit an activated clotting factor (factor IIa or factor Xa). Four NOACs are currently approved for clinical use: dabigatran, which is a thrombin inhibitor; and

rivaroxaban, apixaban, and edoxaban, which are direct factor Xa inhibitors (Bauer 2013).

NOACs are usually well tolerated and cause few side effects. However, unlike VKAs, NOACs cannot be easily reversed in major bleeding. NOAC reversal agents, such as idarucizumab and andexanet alfa, can help treat people with life-threatening bleeding or those needing immediate surgery (Cuker 2019; Glund 2015; Pollack 2015). Other disadvantages of NOACs compared to VKAs include their higher price and the absence of laboratory testing to objectively determine compliance. Moreover, dose adjustments of NOACs are necessary for people with renal impairment or with low or very high weight (Al Said 2019). The advantages of NOACs include a rapid onset of action without the need for regular monitoring or perioperative bridging with parenteral anticoagulants (Bauer 2013; Eriksson 2011). NOACs are at least as effective as warfarin in preventing stroke in non-valvular atrial fibrillation (Connolly 2009; Giugliano 2013; Granger 2011; Patel 2011). However, the key advantage is the safer profile of NOACs: compared with warfarin, they cause less major bleeding, particularly intracranial haemorrhage (Connolly 2009; Giugliano 2013; Granger 2011; Patel 2011). Moreover, compared with VKAs, NOACs may be safer and equally effective in people with an indication for anticoagulation due to non-valvular atrial fibrillation (Al Said 2019).

These safety and efficacy considerations have led to the exploration of NOACs in secondary prevention after AMI. Studies have found that VKAs alone, or in combination with aspirin, reduce rates of major adverse cardiovascular events (MACEs) but increase the rate of major bleeding, including intracranial haemorrhage (Anand 2003; Andreotti 2006; Hurlen 2002; Rothberg 2005; van Es 2002). The antithrombotic potential of NOACs after AMI in people without an indication for anticoagulation remains unclear.

Several studies have assessed the efficacy of NOACs combined with DAPT after acute coronary syndrome (ACS; Alexander 2009; Gibson 2011; Mega 2012; Oldgren 2011). Dabigatran and apixaban showed no significant clinical benefit in preventing new ischaemic cardiovascular events (Alexander 2009; Oldgren 2011). Moreover, apixaban was prematurely discontinued due to a significant increase in the risk of major bleeding events (Alexander 2011). On the other hand, a very low dose of rivaroxaban (2.5 mg twice daily (BD)) resulted in reduced MACEs after ACS (Gibson 2011; Mega 2012).

How the intervention might work

NOACs inhibit thrombin either directly (dabigatran) or indirectly by inhibiting factor Xa (rivaroxaban, apixaban, and edoxaban). AMIs lead to increased thrombin generation, and elevated thrombin concentrations are detectable for at least six months following the acute episode (Merlini 1994). Furthermore, elevated thrombin levels are linked to the recurrence of cardiovascular events. Multiple studies have demonstrated the importance of coagulation's protein arm, represented by the ability to lyse fibrin, in recurrent events following ACS (Farag 2019; Saraf 2010; Sumaya 2018a; Sumaya 2020). These studies indicate a significant role of thrombin generation in arterial thrombosis. NOACs may improve outcomes by limiting arterial thrombosis through their ability to inhibit thrombin formation. Furthermore, anticoagulation promotes fibrin clot lysis (Sumaya 2018a), which enhances reperfusion following a plaque rupture event. Anticoagulants

also exert an indirect antiplatelet effect by inhibiting thrombin generation (Sumaya 2018a).

Why it is important to do this review

Balancing the risk of bleeding and thrombosis after AMI is challenging, and the optimal antithrombotic therapy remains uncertain. The role of NOACs after AMI is not fully understood, and treatment decisions rely on limited evidence. Current European guidelines provide a class IIb recommendation (usefulness/efficacy is less well established by evidence/opinion) for considering the use of rivaroxaban 2.5 mg BD, in combination with aspirin and clopidogrel, for people with NSTEMI who have high ischaemic and low bleeding risks (Collet 2020; Roffi 2016). Low-dose rivaroxaban may be suitable for selected people with low bleeding

risk who receive aspirin and clopidogrel after STEMI (class IIb recommendation; Ibanez 2018). The National Institute for Health and Care Excellence (NICE) has approved rivaroxaban with either aspirin alone or aspirin plus clopidogrel as an option to avoid additional blood clots after ACS in people with high ischaemic risk (NICE 2015). NOACs have not been approved for ACS treatment in the USA and are therefore not recommended in the STEMI or NSTEMI guidelines (Amsterdam 2014; O’Gara 2013).

This systematic review aims to assess the evidence for the safety and efficacy of NOACs after AMI to help establish the optimal level of anticoagulation and identify the patient group with the most favourable balance of benefit and risk associated with NOACs in combination with antiplatelets (Figure 1, Figure 2, Figure 3).

Figure 1. Network diagram for primary outcomes - primary analyses (non-vitamin-K-antagonist oral anticoagulants, all doses combined): all-cause death and cardiovascular death (Primary outcomes). Circles represent the drug as a node in the network; lines represent direct comparisons. Nodes are weighted according to the number of studies that included the respective intervention. Edges are weighted according to the number of participants included in the respective comparison. Numbers on the lines represent the number of trials and participants for each comparison. We combined these two primary outcomes in a single plot since they have the same number of interventions, studies, and participants.




Figure 2. Network diagram for primary outcomes - primary analyses (non-vitamin-K-antagonist oral anticoagulants, all doses combined): major bleeding (Primary outcomes). Circles represent the drug as a node in the network. Lines represent direct comparisons. Nodes are weighted according to the number of studies that included the respective intervention. Edges are weighted according to the number of participants included in the respective comparison. Numbers on the lines represent the number of trials and participants for each comparison.





Figure 3. Network plot for primary outcomes - secondary analyses (differences doses of non-vitamin-K-antagonist oral anticoagulants): all-cause death, cardiovascular death, and major bleeding (Primary outcomes). Circles represent the drug as a node in the network. Lines represent direct comparisons. Nodes are weighted according to the number of studies that included the respective intervention. Edges are weighted according to the number of participants included in the respective comparison. We combined these secondary outcomes in a single plot since they have the same number of interventions, studies, and participants.



Given the complexity of the condition and the absence of randomised controlled trials (RCTs) comparing different NOACs against each other, it is essential to carry out a comprehensive and comparative evaluation of all available treatment options within a network meta-analysis (NMA) framework. At the time of writing, there were no other published systematic reviews and NMAs assessing the efficacy and safety of NOACs after AMI. We therefore aimed to present the most current evidence for the use of patients, clinicians, policymakers, and researchers.

OBJECTIVES

To evaluate the efficacy and safety of non-vitamin-K-antagonist oral anticoagulants (NOACs) in addition to background antiplatelet therapy, compared with placebo, antiplatelet therapy, or both, after acute myocardial infarction (AMI) in people without an indication for anticoagulation (i.e. atrial fibrillation or venous thromboembolism).

METHODS

Criteria for considering studies for this review

Types of studies

Parallel-arm RCTs with individual or cluster randomisation were eligible for inclusion. We excluded cross-over trials as the different treatment alternatives can mutually affect each other and potentially contaminate the analysis. Because the interventions have a long elimination half-life, a carry-over effect is likely. Moreover, our outcomes of interest are either irreversible (such as mortality) or of long duration.

Types of participants

We included adults (aged 18 years or older) with an AMI (NSTEMI or STEMI) and without an indication for oral anticoagulation. We excluded participants with the following comorbidities/characteristics.

- Active bleeding or high bleeding risk
- Known coagulopathy
- Previous intracranial haemorrhage, ischaemic stroke, or transient ischaemic attack

- Severe renal dysfunction with a calculated creatinine clearance of less than 20 mL/minute
- A severe comorbid condition with a life expectancy of six months or less
- Pregnancy, breastfeeding, or, in women of childbearing potential, inability to use an acceptable method of contraception

In trials with mixed populations (i.e. where only some participants met the eligibility criteria), we included only the eligible participants if their data were reported separately or could be obtained from trial authors. Otherwise, we included studies with a mixed population if more than 50% of the participants met the eligibility criteria.

Types of interventions

We were interested in the following experimental interventions.

- Dabigatran-based therapy (i.e. dabigatran in combination with SAPT or DAPT)
- Rivaroxaban-based therapy (i.e. rivaroxaban in combination with SAPT or DAPT)
- Apixaban-based therapy (i.e. apixaban in combination with SAPT or DAPT)
- Edoxaban-based therapy (i.e. edoxaban in combination with SAPT or DAPT)

Eligible controls were placebo, an antiplatelet-based antithrombotic strategy (SAPT/DAPT), or both.

We included trials comparing any type of NOAC (dabigatran, rivaroxaban, apixaban, edoxaban) with control, and head-to-head trials of different NOACs.

Our assessment involved both direct and indirect comparisons. For direct comparisons, we investigated the efficacy and safety of each individual NOAC when compared to placebo. For indirect comparisons, we explored how NOACs (dabigatran, rivaroxaban, apixaban, edoxaban) performed relative to one another.

We excluded NOACs that were not licenced by the US Food and Drug Administration (FDA) or European Medicines Agency (EMA) due to lack of safety or effectiveness (e.g. betrixaban, darexaban, eribaxaban, letaxaban, nokxaban, AZD-0837, fidexaban, LY517717, odiparil, otamixaban, TTP889, and ximelagatran), as they were not clinically relevant. We assumed that people who fulfilled the inclusion criteria were equally eligible to be randomised to any of the interventions we planned to compare.

Types of outcome measures

Reporting one or more of the outcomes listed below in the trial was not an inclusion criterion for the review. Where a published study did not report one of these outcomes, we accessed the trial protocol and contacted the trial authors to ascertain whether the outcome was measured but not reported. For the outcomes that could occur more than once in a participant during the trial, we measured the number of participants with at least one event.

Primary outcomes

- All-cause mortality
- Cardiovascular mortality

- Major bleeding

Secondary outcomes

- Myocardial infarction
- Stroke (ischaemic, haemorrhagic, or of uncertain cause)
- Stent thrombosis
- Non-major bleeding
- Recurrent hospitalisation
- Systemic embolism
- Health-related quality of life, assessed using validated instruments (e.g. 36-Item Short-Form Health Survey (SF-36), EuroQol Five-Dimension Health Survey (EQ-5D))

We assessed all outcomes at the longest point of follow-up for each trial. We accepted the definitions of clinical event outcomes (e.g. stroke, myocardial infarction) provided in the individual trials. We defined major bleeding according to the Thrombolysis In Myocardial Infarction (TIMI) criteria ([Chesebro 1987](#); [Mehran 2011](#)). Non-major bleeding was any bleeding that did not fit the TIMI major bleeding criteria. We defined stent thrombosis according to the Academic Research Consortium (ARC) criteria ([Cutlip 2007](#)). Recurrent hospitalisation was a dichotomous outcome (more than one hospitalisation after randomisation and during follow-up, yes/no).

Search methods for identification of studies

Electronic searches

We identified trials through systematic searches of the following bibliographic databases.

- Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (Issue 9 of 12, 2022)
- MEDLINE ALL (Ovid, 1946 to 22 September 2022)
- Embase (Ovid, 1980 to 2022, week 37)
- Conference Proceedings Citation Index – Science (CPCI-S) on Web of Science (Clarivate Analytics, 1990 to 23 September 2022)

[Appendix 1](#) shows our preliminary search strategy for MEDLINE (Ovid). We applied the Cochrane sensitivity-maximising RCT filter to the MEDLINE strategy and adapted it to the other databases, except CENTRAL ([Lefebvre 2022](#)). We also searched ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP; trialsearch.who.int) for ongoing or unpublished trials on 23 September 2022.

We searched all databases from their inception and imposed no restrictions on language or status of publication. We did not perform a separate search for the adverse effects of NOACs, considering only those described in the included studies.

Searching other resources

We checked the reference lists of all included studies and any relevant systematic reviews for additional references to trials. We also examined any relevant errata and retraction statements related to included studies.

Data collection and analysis

Selection of studies

Two review authors (SAS, SA) independently screened the titles and abstracts of all the records identified in the search and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. A third review author (WS) arbitrated if any disagreements arose. We retrieved the full-text study reports/publications of eligible and potentially eligible/unclear studies. Two review authors (SAS, SA) independently screened the full texts and identified studies for inclusion. They also identified and recorded reasons for exclusion of the ineligible studies. We resolved any disagreement through discussion or, if required, by consulting a third review author (WS). We identified and excluded duplicates and collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a [Characteristics of excluded studies](#) table and a PRISMA flow diagram ([Page 2021](#)).

Data extraction and management

Two review authors (SAS, SA) independently extracted data from the included trials. We extracted and collated the following data using a standardised data extraction form.

- **Methods:** study design, total duration of study, details of any run-in period, number of study centres and location, study setting, date of study
- **Participants:** number randomised, number lost to follow-up/withdrawn, number analysed, mean age, age range, sex, inclusion criteria, exclusion criteria, type of myocardial infarction (NSTEMI, STEMI), kidney function
- **Interventions:** intervention, doses of the intervention, comparison, concomitant medications, excluded medications
- **Outcomes:** primary and secondary outcomes specified and collected, time points reported, number of participants with the events and total number of participants randomised for dichotomous outcomes, and relative treatment effects (e.g. risk ratio (RR)) with relative 95% confidence interval (CI)
- **Notes:** funding for trial, notable conflicts of interest of trial authors

From each study, we extracted the following potential effect modifiers: age, sex, lipid levels, body mass index (BMI), comorbidities and embolic risk. Two review authors (SAS, SA) independently extracted the outcome data from the included studies. We resolved any disagreements by consensus or by involving a third review author (WS), if necessary. One review author (SA) transferred the data to Review Manager Web ([Review Manager 2020](#)). We double-checked correct data entry by comparing the data presented in the systematic review with the data extraction form. A second review author (SAS) spot-checked study characteristics for accuracy against the trial reports.

Assessment of risk of bias in included studies

Two review authors (SAS, SA) independently assessed the risk of bias for each trial using the criteria outlined in the *Cochrane Handbook for Systematic Reviews of Interventions* ([Higgins 2017](#)). We resolved any disagreements by discussion or by involving another review author (WS). We assessed the risk of bias according to the following domains.

- Random sequence generation
- Allocation concealment
- Blinding of participants and personnel
- Blinding of outcome assessment
- Incomplete outcome data
- Selective outcome reporting
- Other bias

Had we identified any eligible cluster-RCTs, we would have considered the following additional risk of bias domains for those trials.

- Recruitment bias
- Baseline imbalance
- Loss of clusters
- Incorrect analysis
- Comparability with individually randomised trials

We graded each trial as being at high, low, or unclear risk of bias for each domain. We provided a quote from the study report, together with a justification for our judgement, in the risk of bias section of the [Characteristics of included studies](#) table. We summarised the risk of bias judgements across different studies for each of the domains listed. Where information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the risk of bias section. When examining treatment effects, we considered the risk of bias for the studies that contributed to that outcome.

Measures of treatment effect

We analysed dichotomous data using risk ratios (RRs) with 95% confidence intervals (CIs). For continuous data, we planned to use mean differences (MDs) with 95% CIs where different studies measured the outcome on the same scale. If we had identified studies that used different scales to measure the same continuous outcome, we would have used the standardised mean difference (SMD). We would have interpreted SMDs using generic effect size estimates, as follows ([Cohen 1998](#)).

- Small/minor SMD: 0.2 or less
- Medium SMD: 0.2 to 0.8
- Large SMD: 0.8 or greater

We did not include time-to-event data but did include dichotomous data at different time points.

We calculated the NNTB (number needed to treat for an additional beneficial outcome) or NNTH (number needed to treat for an additional harmful outcome) values from the RR according to the formula $NNTB \text{ or } NNTH = 1/ACR \times (1-RR)$, where ACR is the assumed control risk ([Higgins 2019](#)).

Unit of analysis issues

Our unit of analysis was the participant. If trials compared more than two interventions that were eligible for inclusion in this review, we divided the participants in the control group into two or more groups for the pairwise meta-analysis; in this way, we avoided double-counting participants in the control group. We presented the longest point of follow-up for each trial. We treated multiarm

studies as multiple independent comparisons in pairwise meta-analyses.

For the NMA, we accounted for the correlation between the effect sizes from multiarm studies using the approach suggested by R ucker and Schwarzer, which utilises back-calculated standard errors in the weighted least-square estimator to reflect the within-study correlation (R ucker 2012; R ucker 2014; R ucker 2015).

Cross-over trials were not eligible for inclusion, and we identified no eligible cluster-randomised trials.

Dealing with missing data

We contacted investigators or study sponsors to obtain missing numerical outcome data where possible. We obtained very few unpublished data on all individual doses of rivaroxaban from one phase II trial (ATLAS ACS). In the case of missing statistics (such as standard deviations), we had intended to contact the trial authors; however, this was not necessary.

Assessment of heterogeneity

In the pairwise meta-analyses, we assessed heterogeneity by visually inspecting the forest plots. We quantified heterogeneity using the I^2 statistic, interpreting the values according to the following thresholds, as recommended in the *Cochrane Handbook for Systematic Reviews of Interventions* (Deeks 2022).

- 0% to 40%: might not be important.
- 30% to 60%: may represent moderate heterogeneity.
- 50% to 90%: may represent substantial heterogeneity.
- 75% to 100%: represents considerable heterogeneity.

In the NMAs, we evaluated coherence, which is the statistical manifestation of the transitivity assumption. Transitivity refers to the assumption that the distribution of effect modifiers is balanced across treatment comparisons.

In the case of relevant incoherence in the NMAs for the primary outcomes, we had planned to explore possible sources and conduct subgroup and sensitivity analyses based on factors described in the [Subgroup analysis and investigation of heterogeneity](#) and [Sensitivity analysis](#) sections.

The link between transitivity and coherence is a critical aspect of the NMA. Transitivity, in the context of NMA, refers to the assumption that the distribution of effect modifiers is balanced across treatment comparisons. Coherence, on the other hand, is the statistical representation of transitivity, reflecting the agreement between the network's direct and indirect comparisons. Incoherence indicates possible violations of the transitivity assumption or other causes of bias (Chaimani 2022). To assess for local inconsistency, we employed the node-splitting approach using the 'netsplit' command of the 'netmeta' R package, which allowed us to separate network estimates into the contributions of direct and indirect evidence (R ucker 2017). Unfortunately, we were unable to create net heat plots due to the limited number of included studies (Jackson 2012; Krahn 2013).

Assessment of intransitivity across treatment comparisons

We considered transitivity by assessing clinical and methodological comparability. Given the similar inclusion criteria and comparable

included populations in the various RCTs, we considered the transitivity assumption withstanding, assuming the following.

- The common treatment used to compare different NOACs indirectly was similar in the different trials.
- No relevant variation in effect modifiers (age, sex, lipid levels, BMI, comorbidities, and embolic risk) was identified between trials.

Assessment of reporting biases

We sought to examine the risk of publication bias in our NMA by visually inspecting funnel plots for each direct comparison (edge) in the network. We would have examined funnel plots for any asymmetry, which could suggest publication bias or other reporting biases. However, due to the small number of studies in our network, we were unable to conduct a detailed analysis of small-study effects using funnel plots.

Data synthesis

Methods for direct treatment comparisons

We conducted pairwise meta-analyses using random-effects models in Review Manager Web (Review Manager 2020) for every treatment comparison with at least two studies. With a random-effects model, the true effect size may or may not vary from study to study, and the model does not assume that either is the case. As part of the analysis, the amount of variance in true effects is estimated across studies, and the estimate may or may not be zero. With a fixed-effect model, the true effect size does not vary from study to study. Therefore, the fixed-effect model is more restrictive: it imposes a constraint that is neither necessary nor plausible.

Methods for indirect and mixed treatment comparisons

To evaluate the feasibility of NMA, we conducted a thorough examination of the network diagrams' geometry. This assessment involved scrutinising the structure of the network to determine its suitability for NMA. Specifically, we analysed the relationships between different treatments to ensure that the network possessed adequate evidence for meaningful treatment comparisons.

Our evaluation focused on two key criteria: network connectivity and the sufficiency of information. A connected network (indicating relationships between treatments) and a substantial amount of evidence within the network are essential for meaningful NMA. When we refer to 'sufficiency of information,' we mean having a sufficient quantity and quality of data within the network of studies. This includes an adequate number of studies and participants for each treatment comparison and overall study quality.

If these criteria were met, we proceeded with NMA; otherwise, we opted for pairwise meta-analyses. Where the evidence was suitable for NMA, we performed a multivariate random-effects meta-analysis of the primary outcomes within a frequentist framework using the R package 'netmeta' (R ucker 2017). This technique allows for the inclusion of multiarm studies. We planned to perform the analyses by considering treatments collapsed according to doses and by considering different doses of the same treatment as single nodes in the network.

We performed NMAs for all primary outcomes at the latest point of follow-up for each trial (Primary outcomes): the primary analysis involved NMA where treatments with different doses were

combined, and the secondary analysis involved NMA where the treatments were split according to dose.

The nodes of the network are the interventions specified in the review inclusion criteria; we did not combine any. We added a network plot for each primary outcome (Figure 1; Figure 2; Figure 3).

We presented all results as summary relative effects (RRs) for each possible pair of treatments. We estimated the relative rankings for the primary outcomes using P scores, which are derived from the P values of all pairwise comparisons and enable ranking of treatments on a continuous 0-to-1 scale. P scores are based solely on the point estimates and standard errors of the frequentist NMA estimates under the normality assumption. P scores measure the mean extent of certainty that a treatment is better than the competing treatments (Rücker 2015). Larger P scores indicate a higher ranking of the included treatment. This interpretation is comparable to that of the surface under the cumulative ranking curve (SUCRA; Rücker 2015).

League table

We created league tables using the primary outcomes (all-cause mortality, cardiovascular mortality, and major bleeding). League tables use a matrix structure, where the upper triangle presents the results from direct (pairwise) meta-analyses, and the lower triangle presents the results from the NMAs (Chaimani 2022). Comparisons between treatments are read from left to right; the estimate is in the cell in common between the column-defining treatment and the row-defining treatment. We presented results as RRs (95% CIs), where an RR below 1 favours the row-defining treatment (Table 1; Table 2; Table 3).

Subgroup analysis and investigation of heterogeneity

We planned to carry out the following subgroup analyses for primary and secondary outcomes where we identified substantial heterogeneity.

- Type of myocardial infarction: NSTEMI versus STEMI
- Mean age of participants in each trial: 75 years and older versus younger than 75 years
- People with mild versus moderate kidney dysfunction as determined at screening according to the Cockcroft-Gault formula (mild impairment: creatinine clearance 60 mL/minute to < 90 mL/minute; moderate impairment: creatinine clearance 30 mL/minute to < 60 mL/minute)
- People with the usual full dose of NOAC versus reduced or adjusted dose
- Type of coronary stents: dual therapy stent, bioresorbable vascular scaffold, bio-engineered stent, drug-eluting stent, bare-metal stent
- Evaluation of the involved coronary vessel (left main coronary artery, left anterior descending artery, left circumflex artery, right coronary artery)

- Concomitant use of antiplatelet therapy (DAPT versus SAPT; aspirin versus clopidogrel versus ticagrolor versus prasugrel)
- Funding status (studies with industry funding versus studies without industry funding)

Owing to the limited number of included studies, we were unable to investigate heterogeneity through subgroup analysis.

Sensitivity analysis

We planned to conduct a sensitivity analysis of our primary outcomes to assess the effect of excluding studies judged at unclear or high risk of bias in any domain. This was not possible, as all included studies were at low risk of bias in all domains.

Summary of findings and assessment of the certainty of the evidence

We created a summary of findings table using the NMA results of the comparison 'NOACs (all doses) versus placebo' for the primary outcomes: all-cause mortality, cardiovascular mortality, and major bleeding (Primary outcomes). We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence as it related to the studies that contributed data to the meta-analyses for the prespecified primary outcomes. We also applied the four-step approach presented by Brignardello-Petersen and colleagues to rate the certainty of evidence in the NMA estimates (Brignardello-Petersen 2020).

We used methods and recommendations described in the *Cochrane Handbook for Systematic Reviews of Interventions* (Schünemann 2022), employing GRADEpro GDT software (GRADEpro GDT 2015).

Two review authors (SAS, SA) independently judged the certainty of the evidence, resolving any disagreements by discussion or by involving a third review author (WS), if necessary. Judgements were justified, documented, and incorporated into the reporting of results for each outcome. We extracted study data, formatted our comparisons in data tables, and prepared a summary of findings table before writing the results and conclusions of our review.


RESULTS

Description of studies

Results of the search

The literature search identified 2923 records, of which 876 were duplicates. We screened 2047 titles and abstracts and identified 73 records for full-text assessment. Of these full-text references, we included 53 and excluded 19. We also identified one ongoing trial (VaLiDate-R; NCT03775746; see Characteristics of ongoing studies). The 53 references reported findings of six completed studies (Characteristics of included studies); we included all six completed studies in the meta-analysis (APPRAISE 1; APPRAISE 2; ATLAS ACS; ATLAS ACS 2; GEMINI-ACS; REDEEM). See Figure 4 for details.

Figure 4. PRISMA study flow diagram.



Included studies

The [Characteristics of included studies](#) table and [Table 4](#) provide detailed characteristics of the six included studies. All included trials were international multicentre trials. Follow-up ranged from six to 13 months. Four trials were phase II RCTs ([APPRAISE 1](#); [ATLAS ACS](#); [GEMINI-ACS](#); [REDEEM](#)), and two were phase III RCTs ([APPRAISE 2](#); [ATLAS ACS 2](#)). The included trials randomised a total of 33,039 participants, of whom 1715 were from [APPRAISE 1](#), 7392 from [APPRAISE 2](#), 3491 from [ATLAS ACS](#), 15,526 from [ATLAS ACS 2](#), 3037 from [GEMINI-ACS](#), and 1878 from [REDEEM](#). All trials had more male participants (between 67% and 78%). The mean age ranged from 57 to 67 years.

The studies assessed the following NOACs.

- Apixaban
 - 2.5 mg twice daily (BD) and 10 mg once daily (QD) in [APPRAISE 1](#)
 - 5 mg BD in [APPRAISE 2](#)
- Rivaroxaban
 - 5 mg QD to 20 mg QD in [ATLAS ACS](#)
 - 2.5 mg BD and 5 mg BD in [ATLAS ACS 2](#)
 - 2.5 mg BD in [GEMINI-ACS](#)
- Dabigatran:
 - 50 mg BD, 75 mg BD, 110 mg BD, and 150 mg BD in [REDEEM](#)

All trials evaluated NOACs plus antiplatelet therapy versus placebo plus antiplatelet therapy. In all trials, participants in the NOAC and placebo arms received the same concomitant antiplatelet therapy; however, the antiplatelet regimens differed between trials.

All trials reported all-cause mortality, cardiovascular mortality, major bleeding, myocardial infarction, and stroke. Three trials provided rates of stent thrombosis ([APPRAISE 2](#), [ATLAS ACS 2](#), [GEMINI-ACS](#)). All trials except [REDEEM](#) reported TIMI minor bleeding. Only [ATLAS ACS](#) reported systemic embolism. No trials assessed recurrent hospitalisation or health-related quality of life.

Ongoing trials

We identified one ongoing trial, which is a randomised, open-label, single-centre trial comparing the effect of three antithrombotic regimens on endogenous fibrinolysis in 150 people with ACS ([NCT03775746](#)). People with impaired fibrinolytic status will be randomised to one of three treatment arms: clopidogrel 75 mg QD (Group 1), clopidogrel 75 mg QD plus rivaroxaban 2.5 mg BD (Group 2), and ticagrelor 90 mg BD (Group 3). All participants will also receive aspirin 75 mg QD. Participants will receive rivaroxaban for 30 days. The trialists will assess fibrinolytic status during admission and at two, four, and eight weeks. See the [Characteristics of ongoing studies](#) table.

Excluded studies

We excluded 19 studies after full-text assessment: eight had ineligible indications, five had ineligible populations, three had ineligible settings, two had ineligible study design, and one had an ineligible comparator. See the [Characteristics of excluded studies](#) table.


Risk of bias in included studies

[Figure 5](#) and [Figure 6](#) summarise the risk of bias of the included studies. See also the [Characteristics of included studies](#) table for further details.

Figure 5. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias): All outcomes	Blinding of outcome assessment (detection bias): All outcomes	Incomplete outcome data (attrition bias): All outcomes	Selective reporting (reporting bias)	Other bias
APPRAISE 1	+	+	+	+	+	+	+
APPRAISE 2	+	+	+	+	+	+	+
ATLAS ACS	+	+	+	+	+	+	+
ATLAS ACS 2	+	+	+	+	+	+	+
GEMINI-ACS	+	+	+	+	+	+	+
REDEEM	+	+	+	+	+	+	+

Figure 6. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.



Allocation

All trials randomised participants via an interactive voice-response system (low risk of bias).

Blinding

All trials blinded investigators and participants to treatment assignment in all included trials (low risk of bias).

Incomplete outcome data

Participants were analysed in the groups they were randomised to, and losses to follow-up were low (low risk of bias).

Selective reporting

All trials had preregistered protocols and reported all outcomes specified in their protocols (low risk of bias).

Other potential sources of bias

There was no indication of other potential sources of bias for any trial (low risk of bias).

Effects of interventions

See: [Summary of findings 1 Non-vitamin-K-antagonist oral anticoagulants versus placebo in adults with acute myocardial infarction and without an indication for anticoagulation: all-cause mortality](#); [Summary of findings 2 Non-vitamin-K-antagonist oral anticoagulants versus placebo in adults with acute myocardial infarction and without an indication for anticoagulation: cardiovascular mortality](#); [Summary of findings 3 Non-vitamin-K-antagonist oral anticoagulants versus placebo in adults with acute myocardial infarction and without an indication for anticoagulation: major bleeding](#)

Primary outcomes – primary analyses (NOACs, all doses combined)

For our primary outcomes in the primary analyses involving NOACs of combined doses, there were no closed loops in the network and thus the NMA effect estimates of each 'NOAC (all doses combined) versus placebo' comparison presented below were identical to those of the pairwise meta-analyses. We did not assess consistency owing to the absence of closed loops in all the networks of our predefined primary outcomes ([Primary outcomes](#)).

All-cause mortality

Network meta-analysis

Apixaban (all doses combined) compared with placebo probably has little or no effect on all-cause mortality (RR 1.09, 95% CI 0.88 to 1.35; NNTB 334; $I^2 = 0\%$, $\text{Tau}^2 = 0$; 2 studies, 8638 participants; moderate-certainty evidence; [Table 1](#)). See [Analysis 1.1](#) for the pairwise meta-analysis effect estimates.

Rivaroxaban (all doses combined) compared with placebo reduces the rate of all-cause mortality (RR 0.82, 95% CI 0.69 to 0.98; NNTB 250; $I^2 = 0\%$, $\text{Tau}^2 = 0$; 3 studies, 21,870 participants; high-certainty evidence; [Table 1](#)). See [Analysis 1.2](#) for the pairwise meta-analysis effect estimates.

Dabigatran (all doses combined) may reduce the rate of all-cause mortality compared with placebo (RR 0.57, 95% CI 0.31 to 1.06; NNTB 63; 1 study, 1861 participants; low-certainty evidence; [Table 1](#)). See [Analysis 1.3](#) for the pairwise meta-analysis effect estimates.

For the outcome all-cause mortality, apixaban may be inferior to rivaroxaban (RR 1.33, 95% CI 1.01 to 1.76; 5 studies; low-certainty evidence) and dabigatran (RR 1.92, 95% CI 1.00 to 3.70; 3 studies; low-certainty evidence). There may be little or no difference in the rate of all-cause mortality between rivaroxaban and dabigatran (RR 1.45, 95% CI 0.76 to 2.75; 4 studies; low-certainty evidence). See [Figure 1](#) and [Table 1](#).

Cardiovascular mortality

Network meta-analysis

Apixaban (all doses combined) compared with placebo probably has little or no effect on cardiovascular mortality (RR 0.99, 95% CI 0.77 to 1.27; NNT not applicable; $I^2 = 0\%$, $\text{Tau}^2 = 0$; 2 studies, 8638 participants; moderate-certainty evidence; [Table 2](#)). See [Analysis 2.1](#) for the pairwise meta-analysis effect estimates.

Rivaroxaban (all doses combined) compared with placebo probably reduces the rate of cardiovascular mortality (RR 0.83, 95% CI 0.69 to 1.01; NNTB 250; $I^2 = 0\%$, $\text{Tau}^2 = 0$; 3 studies, 21,870 participants; moderate-certainty evidence; [Table 2](#)). See [Analysis 2.2](#) for the pairwise meta-analysis effect estimates.

Dabigatran (all doses combined) compared with placebo may have little or no effect on cardiovascular mortality, although the point

estimate suggests a benefit (RR 0.72, 95% CI 0.34 to 1.52; NNTB 143; 1 study, 1861 participants; low-certainty evidence; [Table 2](#)). See [Analysis 2.3](#) for the pairwise meta-analysis effect estimates.

Low-certainty evidence suggests little or no difference in the rate of cardiovascular mortality between apixaban and rivaroxaban (RR 1.19, 95% CI 0.87 to 1.62; 5 studies), between apixaban and dabigatran (RR 1.38, 95% CI 0.63 to 3.03; 3 studies), and between rivaroxaban and dabigatran (RR 1.16, 95% CI 0.54 to 2.51; 4 studies). See [Figure 1](#) and [Table 2](#).

Major bleeding

Network meta-analysis

Apixaban (all doses combined) increases the rate of major bleeding compared with placebo (RR 2.41, 95% CI 1.44 to 4.06; NNTB 143; $I^2 = 0\%$, $\text{Tau}^2 = 0$; 2 studies, 8544 participants; high-certainty evidence; [Table 3](#)). See [Analysis 3.1](#) for the pairwise meta-analysis effect estimates.

Rivaroxaban (all doses combined) increases the rate of major bleeding compared with placebo (RR 3.31, 95% CI 1.12 to 9.77; NNTB 125; $I^2 = 73\%$, $\text{Tau}^2 = 0.61$; 3 studies, 21,870 participants; high-certainty evidence; [Table 3](#)). See [Analysis 3.2](#) for the pairwise meta-analysis effect estimates.

There may be little or no difference between dabigatran and placebo in the risk of major bleeding (RR 1.74, 95% CI 0.22 to 14.12; NNTB 500; 1 study, 1861 participants; low-certainty evidence; [Table 3](#)). See [Analysis 3.3](#) for the pairwise meta-analysis effect estimates.

Low-certainty evidence suggests little or no difference in the rate of major bleeding between apixaban and rivaroxaban (RR 0.67, 95% CI 0.15 to 2.94, 5 studies), between apixaban and dabigatran (RR 1.24, 95% CI 0.08 to 18.21, 3 studies), and between rivaroxaban and dabigatran (RR 1.84, 95% CI 0.14 to 24.75, 4 studies). See [Figure 2](#) and [Table 3](#).

Primary outcomes – secondary analyses (different doses of NOACs)

See [Appendix 2](#).

Secondary outcomes - secondary analyses (different doses of NOACs)

The results for the secondary outcomes are based on pairwise meta-analyses.

Myocardial infarction

NOACs versus placebo

The following investigated doses of apixaban probably have little or no effect on the rate of myocardial infarction compared with placebo (moderate-certainty evidence; [Analysis 4.4](#)).

- All doses combined (RR 0.88, 95% CI 0.67 to 1.16; $I^2 = 17\%$; 2 studies, 8638 participants)
- 10 mg (RR 0.90, 95% CI 0.71 to 1.14; $I^2 = 5\%$; 2 studies, 8321 participants)

Apixaban 5 mg may have little or no effect on the rate of myocardial infarction compared with placebo (RR 0.67, 95% CI 0.29 to 1.58; 1 study, 928 participants; low-certainty evidence; [Analysis 4.4](#)).

Rivaroxaban 10 mg reduces the rate of myocardial infarction compared with placebo (RR 0.77, 95% CI 0.65 to 0.92; $I^2 = 0\%$; 2 studies, 12,444 participants; high-certainty evidence; [Analysis 5.4](#)). The following investigated doses of rivaroxaban probably have little or no effect on the rate of myocardial infarction compared with placebo (moderate-certainty evidence; [Analysis 5.4](#)).

- All doses combined (RR 0.88, 95% CI 0.75 to 1.03; $I^2 = 15\%$; 3 studies, 21,870 participants)
- 5 mg (RR 0.95, 95% CI 0.81 to 1.11; $I^2 = 0\%$; 3 studies, 14,732 participants)

The following investigated doses of rivaroxaban may have little or no effect on the rate of myocardial infarction compared with placebo (low-certainty evidence; [Analysis 5.4](#)).

- 15 mg (RR 1.11, 95% CI 0.64 to 1.93; 1 study, 1516 participants)
- 20 mg (RR 0.69, 95% CI 0.40 to 1.19; 1 study, 1771 participants)

The following investigated doses of dabigatran may have little or no effect on the rate of myocardial infarction compared with placebo (low-certainty evidence; [Analysis 6.4](#)).

- All doses combined (RR 1.99, 95% CI 0.71 to 5.60; 1 study, 1861 participants)
- 50 mg BD (RR 2.26, 95% CI 0.70 to 7.28; 1 study, 740 participants)
- 75 mg BD (RR 2.02, 95% CI 0.61 to 6.64; 1 study, 739 participants)
- 110 mg BD (RR 1.60, 95% CI 0.47 to 5.42; 1 study, 777 participants)
- 150 mg BD (RR 2.14, 95% CI 0.65 to 7.04; 1 study, 718 participants)

Different doses of NOACs

There may be little or no difference in the rate of myocardial infarction between apixaban 5 mg and apixaban 10 mg (RR 1.17, 95% CI 0.40 to 3.44; 1 study, 635 participants; low-certainty evidence; [Analysis 7.4](#)).

There is probably little or no difference in the rate of myocardial infarction between rivaroxaban 5 mg and rivaroxaban 10 mg (RR 1.17, 95% CI 0.97 to 1.41; $I^2 = 0\%$; 2 studies, 11,593 participants; moderate-certainty evidence; [Analysis 8.4](#)).

There may be little or no difference in the rate of myocardial infarction between the following doses of rivaroxaban (low-certainty evidence).

- 5 mg versus 15 mg (RR 0.94, 95% CI 0.46 to 1.92; 1 study, 664 participants; [Analysis 9.4](#))
- 5 mg versus 20 mg (RR 1.52, 95% CI 0.75 to 3.08; 1 study, 919 participants; [Analysis 10.4](#))
- 10 mg versus 15 mg (RR 0.65, 95% CI 0.36 to 1.18; 1 study, 1412 participants; [Analysis 11.4](#))
- 10 mg versus 20 mg (RR 1.06, 95% CI 0.59 to 1.89; 1 study, 1667 participants; [Analysis 12.4](#))
- 15 mg versus 20 mg (RR 1.62, 95% CI 0.83 to 3.16; 1 study, 967 participants; [Analysis 13.4](#))

There may be little or no difference in the rate of myocardial infarction between the following doses of dabigatran (low-certainty evidence).

- 50 mg BD versus 75 mg BD (RR 1.12, 95% CI 0.44 to 2.88; 1 study, 737 participants; [Analysis 14.4](#))

- 50 mg BD versus 110 mg BD (RR 1.41, 95% CI 0.53 to 3.76; 1 study, 775 participants; [Analysis 15.4](#))
- 50 mg BD versus 150 mg BD (RR 1.06, 95% CI 0.41 to 2.71; 1 study, 716 participants; [Analysis 16.4](#))
- 75 mg BD versus 110 mg BD (RR 1.26, 95% CI 0.46 to 3.44; 1 study, 774 participants; [Analysis 17.4](#))
- 75 mg BD versus 150 mg BD (RR 0.94, 95% CI 0.36 to 2.48; 1 study, 715 participants; [Analysis 18.4](#))
- 110 mg BD versus 150 mg BD (RR 0.75, 95% CI 0.27 to 2.04; 1 study, 753 participants; [Analysis 19.4](#))

Stroke

NOACs versus placebo

The following investigated doses of apixaban probably have little or no effect on the rate of stroke compared with placebo (moderate-certainty evidence; [Analysis 4.5](#)).

- All doses combined (RR 0.66, 95% CI 0.40 to 1.11; $I^2 = 0\%$; 2 studies, 8638 participants)
- 10 mg (RR 0.68, 95% CI 0.41 to 1.15; $I^2 = 0\%$; 2 studies, 8321 participants)

Apixaban 5 mg may have little or no effect on the rate of stroke compared with placebo (RR 0.38, 95% CI 0.02 to 7.99; 1 study, 928 participants; low-certainty evidence; [Analysis 4.5](#)).

The following investigated doses of rivaroxaban probably have little or no effect on the rate of stroke compared with placebo (moderate-certainty evidence; [Analysis 5.5](#)).

- All doses combined (RR 0.84, 95% CI 0.45 to 1.55; $I^2 = 48\%$; 3 studies, 21,870 participants)
- 5 mg (RR 0.99, 95% CI 0.68 to 1.44; $I^2 = 0\%$; 3 studies, 14,732 participants)
- 10 mg (RR 1.25, 95% CI 0.85 to 1.83; $I^2 = 0\%$; 2 studies, 12,444 participants)

The following investigated doses of rivaroxaban may have little or no effect on the rate of stroke compared with placebo (low-certainty evidence; [Analysis 5.5](#)).

- 15 mg (RR 0.25, 95% CI 0.01 to 4.43; 1 study, 1516 participants)
- 20 mg (RR 0.32, 95% CI 0.04 to 2.62; 1 study, 1771 participants)

Dabigatran (all doses combined) may reduce the rate of stroke compared with placebo (RR 0.08, 95% CI 0.01 to 0.80; 1 study, 1861 participants; low-certainty evidence; [Analysis 6.5](#)). The following investigated doses of dabigatran may have little or no effect on the rate of stroke compared with placebo (low-certainty evidence; [Analysis 6.5](#)).

- 50 mg BD (RR 0.14, 95% CI 0.01 to 2.77; 1 study, 740 participants)
- 75 mg BD (RR 0.34, 95% CI 0.04 to 3.22; 1 study, 739 participants)
- 110 mg (RR 0.13, 95% CI 0.01 to 2.52; 1 study, 777 participants)
- 150 mg BD (RR 0.15, 95% CI 0.01 to 2.95; 1 study, 718 participants)

Different doses of NOACs

There may be little or no difference in the rate of stroke between apixaban 5 mg and apixaban 10 mg (RR 0.33, 95% CI 0.01 to 8.18; 1 study, 635 participants; low-certainty evidence; [Analysis 7.5](#)).

There is probably little or no difference in the rate of stroke between rivaroxaban 5 mg and rivaroxaban 10 mg (RR 0.85, 95% CI 0.58 to 1.25; $I^2 = 0\%$; 2 studies, 11,593 participants; moderate-certainty evidence; [Analysis 8.5](#)).

There may be little or no difference in the rate of stroke between the following doses of rivaroxaban (low-certainty evidence).

- 5 mg versus 15 mg (RR 3.47, 95% CI 0.14 to 84.77; 1 study, 664 participants; [Analysis 9.5](#))
- 5 mg versus 20 mg (RR 1.98, 95% CI 0.12 to 31.61; 1 study, 919 participants; [Analysis 10.5](#))
- 10 mg versus 15 mg (RR 3.04, 95% CI 0.16 to 56.32; 1 study, 1412 participants; [Analysis 11.5](#))
- Rivaroxaban 10 mg versus 20 mg (RR 2.31, 95% CI 0.26 to 20.66; 1 study, 1667 participants; [Analysis 12.5](#))
- Rivaroxaban 15 mg versus 20 mg (RR 0.57, 95% CI 0.02 to 13.99; 1 study, 967 participants; [Analysis 13.5](#))

There may be little or no difference in the rate of stroke between the following doses of dabigatran (low-certainty evidence).

- 50 mg BD versus 75 mg BD (RR 0.33, 95% CI 0.01 to 8.13; 1 study, 737 participants; [Analysis 14.5](#))
- 75 mg BD versus 110 mg BD (RR 3.31, 95% CI 0.14 to 80.97; 1 study, 774 participants; [Analysis 17.5](#))
- 75 mg versus 150 mg BD (RR 2.83, 95% CI 0.12 to 69.22; 1 study, 715 participants; [Analysis 18.5](#))

Stent thrombosis

NOACs versus placebo

One RCT compared stent thrombosis between apixaban and placebo ([APPRAISE 2](#)). Apixaban 10 mg compared with placebo probably has little or no effect on the rate of stent thrombosis (RR 0.73, 95% CI 0.47 to 1.12; 1 study, 7392 participants; moderate-certainty evidence; [Analysis 4.6](#)).

Two RCTs compared stent thrombosis between rivaroxaban and placebo ([ATLAS ACS 2](#), [GEMINI-ACS](#)). The following investigated doses of rivaroxaban probably have little or no effect on the rate of stent thrombosis compared with placebo (moderate-certainty evidence; [Analysis 5.6](#)).

- All doses combined (RR 0.76, 95% CI 0.52 to 1.12; $I^2 = 27\%$; 1 study, 18,379 participants)
- 5 mg (RR 0.76, 95% CI 0.49 to 1.19; $I^2 = 35\%$; 2 studies, 13,264 participants)
- 10 mg (RR 0.71, 95% CI 0.50 to 1.01; 1 study, 10,228 participants)

Different doses of NOACs

There is probably little or no difference in the rate of stent thrombosis between rivaroxaban 5 mg and rivaroxaban 10 mg (RR 0.92, 95% CI 0.62 to 1.37; 1 study, 10,229 participants; moderate-certainty evidence; [Analysis 8.6](#)).

Non-major bleeding

NOACs versus placebo

The following investigated doses of apixaban increase the rate of non-major bleeding compared with placebo (high-certainty evidence; [Analysis 4.7](#)).

- All doses combined (RR 2.71, 95% CI 1.47 to 5.01; $I^2 = 0\%$; 2 studies, 8544 participants)
- 10 mg (RR 2.74, 95% CI 1.45 to 5.17; $I^2 = 0\%$; 2 studies, 8229 participants)

Apixaban 5 mg may have little or no effect on the rate of non-major bleeding compared with placebo (RR 1.90, 95% CI 0.39 to 9.37; 1 study, 914 participants; low-certainty evidence; [Analysis 4.7](#)).

The following investigated doses of rivaroxaban increase the rate of non-major bleeding compared with placebo (high-certainty evidence; [Analysis 5.7](#)).

- All doses combined (RR 2.18, 95% CI 1.41 to 3.35; $I^2 = 0\%$; 3 studies, 21,870 participants)
- 5 mg (RR 1.71, 95% CI 1.04 to 2.80; $I^2 = 0\%$; 3 studies, 14,732 participants)
- 10 mg (RR 2.52, 95% CI 1.54 to 4.13; $I^2 = 0\%$; 2 studies, 12,444 participants)

The following investigated doses of rivaroxaban probably increase the rate of non-major bleeding compared with placebo (moderate-certainty evidence; [Analysis 5.7](#)).

- 15 mg (RR 6.52, 95% CI 1.20 to 35.43; 1 study, 1516 participants)
- 20 mg (RR 4.75, 95% CI 0.92 to 24.39; 1 study, 1771 participants)

Different doses of NOACs

There may be little or no difference in the rate of non-major bleeding between apixaban 5 mg and apixaban 10 mg (RR 1.50, 95% CI 0.25 to 8.92; 1 study, 630 participants; low-certainty evidence; [Analysis 7.6](#)).

There is probably little or no difference in the rate of non-major bleeding between rivaroxaban 5 mg and rivaroxaban 10 mg (RR 0.65, 95% CI 0.42 to 1.00; $I^2 = 0\%$; 2 studies, 11,593 participants; moderate-certainty evidence; [Analysis 8.7](#)).

There may be little or no difference in the rate of non-major bleeding between the following doses of rivaroxaban (low-certainty evidence).

- 5 mg versus 15 mg (RR 0.29, 95% CI 0.03 to 2.57; 1 study, 664 participants; [Analysis 9.6](#))
- 5 mg versus 20 mg (RR 0.40, 95% CI 0.05 to 3.38; 1 study, 919 participants; [Analysis 10.6](#))
- 10 mg versus 15 mg (RR 0.51, 95% CI 0.14 to 1.78; 1 study, 1412 participants; [Analysis 11.6](#))
- 10 mg versus 20 mg (RR 0.69, 95% CI 0.21 to 2.27; 1 study, 1667 participants; [Analysis 12.6](#))
- 15 mg versus 20 mg (RR 1.37, 95% CI 0.37 to 5.08; 1 study, 967 participants; [Analysis 13.6](#))

Recurrent hospitalisation

No studies reported recurrent hospitalisation.

Systemic embolism

One RCT assessed systemic embolism between rivaroxaban (5 mg to 20 mg QD) versus placebo ([ATLAS ACS](#)). The following investigated doses of rivaroxaban probably have little or no

effect on the rate of systemic embolism compared with placebo (moderate-certainty evidence; [Analysis 5.8](#)).

- All doses combined (RR 0.07, 95% CI 0.00 to 1.38; 1 study, 3491 participants)
- 10 mg (RR 0.16, 95% CI 0.01 to 3.03; 1 study, 2216 participants)

The following investigated doses of rivaroxaban may have little or no effect on the rate of systemic embolism compared with placebo (low-certainty evidence; [Analysis 5.8](#)).

- 5 mg (RR 0.54, 95% CI 0.03 to 10.36; 1 study, 1468 participants)
- 15 mg (RR 0.46, 95% CI 0.02 to 8.97; 1 study, 1516 participants)
- 20 mg (RR 0.27, 95% CI 0.01 to 5.24; 1 study, 1771 participants)

Health-related quality of life

No studies reported health-related quality of life.

Subgroup analysis

We found insufficient data to pursue our intended subgroup analyses.

Ranking

We ranked competing treatments for the primary outcomes by P scores, which are derived from the P values of all pairwise comparisons, and enable ranking of treatments on a continuous 0-to-1 scale. P scores were based solely on the point estimates and standard errors of the frequentist NMA estimates under the normality assumption. P scores measure the mean extent of certainty that a treatment is better than the competing treatments. However, P scores are not a conclusive indicator of treatment performance; they do not reveal the size of treatment effects or the statistical significance of treatment differences. Consequently, it is important to consider other elements when evaluating these outcomes, such as the certainty of evidence and the clinical context.

Ranking of treatments (NOACs, all doses combined)

All-cause mortality

The P scores suggest that dabigatran is associated with the lowest risk of all-cause mortality, followed by rivaroxaban, placebo, and apixaban ([Table 5](#)).

Cardiovascular mortality

The P scores suggest that dabigatran is associated with the lowest risk of cardiovascular mortality, followed by rivaroxaban, apixaban, and placebo ([Table 5](#)).

Major bleeding

The P scores suggest that placebo is associated with the lowest risk of major bleeding, followed by dabigatran, apixaban, and rivaroxaban ([Table 5](#)).

DISCUSSION

Summary of main results

Our review aimed to assess the efficacy and safety of NOACs after AMI in people without an indication for anticoagulation. We included six trials, with 33,039 participants, comparing NOACs plus antiplatelet therapy with placebo plus antiplatelet therapy after

AMI. To assess the efficacy of these agents, we evaluated all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, stent thrombosis, recurrent hospitalisation, systemic embolism, and health-related quality of life. To assess the safety of NOACs, we assessed major TIMI bleeding and any non-major TIMI bleeding.

Efficacy

High-certainty evidence suggests that rivaroxaban (combined dose) reduces the risk of all-cause mortality, and moderate-certainty evidence suggests that rivaroxaban probably reduces the risk of cardiovascular mortality after AMI. Low-certainty evidence suggests that dabigatran may reduce the rate of all-cause mortality compared with placebo. Moderate-certainty evidence suggests no meaningful difference in the rate of all-cause mortality and cardiovascular mortality between apixaban and placebo. There is uncertainty about the rate of cardiovascular mortality with dabigatran compared with placebo.

There are inconclusive results regarding the efficacy of different doses of NOACs (specifically apixaban, rivaroxaban, and dabigatran) versus placebo for the rate of all-cause mortality, cardiovascular mortality, stroke, and stent thrombosis. Dabigatran (combined dose) may reduce the risk of stroke compared with placebo. Rivaroxaban (10 mg daily) may reduce the rate of myocardial infarction compared with placebo. Only one trial reported the outcome systemic embolism ([ATLAS ACS](#)). No trials assessed recurrent hospitalisation or health-related quality of life. No trials assessed edoxaban after AMI in people without an indication for oral anticoagulation.

Safety

High-certainty evidence suggests that apixaban and rivaroxaban increase the risk of major bleeding compared with placebo, while moderate-certainty evidence suggests these drugs probably increase the risk of non-major bleeding. The evidence is very uncertain about the risk of major bleeding with dabigatran compared with placebo after AMI.

Indirect comparisons of different NOACs

We found no head-to-head trials of different NOACs. Our NMA compared NOACs agents indirectly against each other, finding that no NOAC was superior to any other at any individual investigated dose for any of the primary outcomes. However, moderate-certainty evidence suggests that apixaban (combined dose) is probably less effective than rivaroxaban or dabigatran in preventing all-cause mortality after AMI in people without an indication for anticoagulation.

Overall completeness and applicability of evidence

We aimed to evaluate the efficacy and safety of NOACs after AMI in people without an indication for anticoagulation. Given the complexity of the condition, and in the absence of RCTs comparing different types of NOACs against each other, we conducted an NMA. This provided a comprehensive, coherent, and methodologically robust comparison of all available treatment options across efficacy and safety outcomes. We combined both direct and indirect evidence, thus increasing the statistical power and confidence in the results.

The conclusions of this review are based on a limited number of RCTs. The included studies reported all of our primary outcomes

(all-cause mortality, cardiovascular mortality, and major bleeding), but not all of our secondary outcomes. Three trials provided rates of stent thrombosis ([APPRAISE 2](#), [ATLAS ACS 2](#), [GEMINI-ACS](#)). All trials except [REDEEM](#) reported TIMI minor bleeding. No trials assessed recurrent hospitalisation or health-related quality of life. Only [ATLAS ACS](#) reported systemic embolism. No trials assessed the role of edoxaban in secondary prevention after AMI in people without an indication for anticoagulation.

Quality of the evidence

The overall certainty of the evidence ranged from low to high. The main reason for downgrading the certainty of the evidence was imprecision of results with wide CIs. Two trials did not meet the optimal information size ([APPRAISE 1](#) and [REDEEM](#)).

Potential biases in the review process

We conducted a comprehensive search for studies and used rigorous methods to minimise bias in the review process. Two review authors independently screened the results of the literature search to identify relevant studies, assessed each included study, extracted data, and assessed the risk of bias using the Cochrane risk of bias tool RoB 1. Any discrepancies between the two review authors were resolved through discussion, and a third reviewer was consulted if necessary.

One strength of our review is that we not only included all published phase II and III RCTs of NOACs, but also retrieved unpublished data related to all individual doses for the phase II study of rivaroxaban. We conducted the review according to a previously published protocol as far as possible; we documented all deviations from the protocol in the [Differences between protocol and review](#) section.

However, we acknowledge that our review has some limitations. First, we assessed the outcomes at the latest point of follow-up for each trial, which ranged from six to 13 months. We identified heterogeneity across the included trials with respect to type of concomitant antiplatelet therapy; follow-up time; and type, dose, and duration of antithrombotic therapy. This heterogeneity could affect the interpretation of our results. We also acknowledge that most of the participants included in our analysis were part of rivaroxaban trials, and there is less evidence on apixaban and dabigatran. Additionally, the lack of data for the small proportion of people who receive SAPT is a limitation of our review.

Finally, we note that individual participant data were not publicly available. An individual participant-level data analysis could help us to determine which people would benefit most from a given treatment combination.

Despite these limitations, our review provides valuable insights into the efficacy and safety of NOACs in combination with antiplatelet therapy for secondary prevention after AMI.

Agreements and disagreements with other studies or reviews

Our findings agree with and extend the findings of three previous systematic reviews.

[Oldgren 2013](#) performed a meta-analysis of RCTs to evaluate the efficacy and safety of adding NOACs (apixaban, dabigatran, dorexaban, rivaroxaban, and ximelagatran) to single (aspirin) or

dual (aspirin and clopidogrel) antiplatelet therapy after ACS. The findings suggested that adding NOACs to antiplatelet therapy resulted in a modest reduction in cardiovascular events but a substantial increase in bleeding. However, [Oldgren 2013](#) included RCTs of NOACs that were not approved by the FDA (ximelagatran and darexaban).

[Khan 2017](#) conducted a meta-analysis to assess the safety and efficacy of adding NOACs (apixaban, rivaroxaban, and dabigatran) to SAPT or DAPT in people with ACS, and concluded that the addition of NOACs to DAPT was associated with an increase in the risk of clinically significant bleeding and only a modest reduction in major adverse cardiovascular events. The addition of NOACs to SAPT did not result in a significant reduction in major adverse cardiovascular events or an increase in clinically significant bleeding. However, [Khan 2017](#) included RCTs assessing NOACs in people with an indication for anticoagulation due to atrial fibrillation.

[Chiarito 2018](#) suggested a favourable net clinical benefit when adding NOACs to antiplatelet therapy for secondary prevention after ACS, particularly in people presenting with STEMI; the findings showed that administration of NOACs in addition to antiplatelet therapy after STEMI appeared to improve ischaemic events at the cost of a marginally increased risk of major bleeding.

In contrast to these previous meta-analyses, we used individual efficacy outcomes rather than composite outcomes, which might explain why we found no meaningful difference in efficacy for all individual doses. We analysed the safety results using the TIMI criteria to avoid the limitation of the variability in definitions of bleeding events across included studies. Furthermore, our review provided a comprehensive and comparative evaluation of all available treatment options within an NMA framework, thus increasing the statistical power and confidence in the results.

AUTHORS' CONCLUSIONS

Implications for practice

Compared with placebo, non-vitamin K antagonist oral anticoagulants (NOACs; specifically apixaban and rivaroxaban) in addition to antiplatelet therapy after acute myocardial infarction (AMI) in people without an indication for oral anticoagulation are associated with increased risk of major bleeding. Rivaroxaban compared to placebo reduces the risk of all-cause mortality and probably reduces the risk of cardiovascular mortality. However, we detected no meaningful difference in efficacy outcomes for any of the NOACs at specific doses compared to placebo.

Implications for research

Although the evidence suggests that NOACs reduce mortality, the effect size/impact is small and associated with increased bleeding. Our data show that clinicians should exercise caution when considering NOACs as a therapeutic option for people who have had an AMI, particularly in view of the widespread use of potent P2Y12 inhibitors. More research is required to better understand the appropriate use of NOACs in this population. The available evidence does not support the hypothesis that higher NOAC doses result in a greater reduction of ischaemic events. This finding could affect future trial design and dosage selection. Lower NOAC doses paired with a single antiplatelet therapy might be a safe strategy after AMI. However, more research is needed to determine the

benefits of this regimen in terms of efficacy outcomes compared with antiplatelet therapy alone. In addition, future studies should aim to determine which people would benefit from the addition of a NOAC to antiplatelets. The results of this review suggest that an appropriate target population may be people with higher atherothrombotic risk who are not at increased risk for bleeding. Identifying this subpopulation represents a challenge for future research.

Outcomes of future studies should include risk of recurrent hospitalisation and health-related quality of life. Almost all included trials were conducted while clopidogrel was the sole P2Y12 inhibitor available. Therefore, researchers should compare NOACs with potent P2Y12 inhibitors (prasugrel and ticagrelor) to establish a regimen with an improved efficacy/safety profile for people at high ischaemic risk. In addition, there is a need for head-to-head trials of different NOACs to determine the preferred NOAC agent in antithrombotic therapy that combines platelet inhibition and anticoagulation after AMI.

ACKNOWLEDGEMENTS

Cochrane Heart supported the authors in the development of this review prior to its closure in March 2023. The following people conducted the editorial process for this review.

- Co-ordinating Editor/ Sign-off Editor (final editorial decision): Professor Rui Providencia, University College London, UK.
- Managing Editor (selected peer reviewers, collated peer-reviewer comments, provided editorial guidance to authors, edited the article): Ghazaleh Aali, University College London, UK.
- Copy Editor (copy-editing and production): Julia Turner, Cochrane Central Production Service.
- Information Specialist: Dr Farhad Shokraneh, Cochrane Heart, University College London, and Charlene Bridges, Cochrane Heart, University College London.
- Peer-reviewers (provided comments and recommended an editorial decision): Cinzia Del Giovane (statistical review); Silvia Minozzi (methods review); Dr Francisco Marín, MD, PhD, Cardiology Department, Hospital Clínico Universitario Virgen de la Arrixaca, University of Murcia, Murcia, Spain (clinical review); Dr Ferruccio Pelone, University College London, UK (methods review).
- Cochrane Evidence Production & Methods Directorate (Liz Bickerdike, Joey Kwong, Lindsay Robertson, Sofia Tsokani) provided further input prior to publication.

The authors would also like to acknowledge the substantial and generous contributions made by the following people, who helped inform the Background and Methods of the original protocol: Nicole Martin, University College London, UK (Managing Editor of Cochrane Heart); Andrea Takeda, University College London, UK (Systematic Review Specialist of Cochrane Heart); Sarah Hodgkinson (Associate Editor of the Cochrane Circulation and Breathing Network); Mahmood Ahmad, Royal Free Hospital, Royal Free London NHS Foundation Trust London (Contact Editor of Cochrane Heart); and the peer reviewers Mehul Srivastava, Craig Williams and Lenny Vasanthan.

This review was funded by the National Institute for Health and Care Research (NIHR) Cochrane Infrastructure funding to Cochrane Heart (closed in March 2023) and Evidence Synthesis Programme

(NIHR150853) Incentive Award Scheme 2021. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

REFERENCES

References to studies included in this review

APPRAISE 1 {published data only}

* APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. *Circulation* 2009;**119**(22):2877-85.

NCT00313300. Safety study of apixaban in recent acute coronary syndrome [A phase 2, placebo-controlled, randomized, double blind, parallel arm, dose ranging study to evaluate safety and efficacy of apixaban in patients with a recent acute coronary syndrome]. clinicaltrials.gov/show/NCT00313300 (first received 12 April 2006).

APPRAISE 2 {published data only}

* Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. *New England Journal of Medicine* 2011;**365**(8):699-708.

Cornel J, James S, Wallentin L, Lopes RD, Neely M, Alexander JH, et al. Apixaban after acute coronary syndrome in patients with heart failure: insights from the APPRAISE-2 trial. *European Heart Journal* 2012;**33**(Suppl 1):335-6.

Cornel JH, Lopes RD, James S, Stevens SR, Neely ML, Liaw D, et al. Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. *American Heart Journal* 2015;**169**(4):531-8.

Guimaraes PO, Lopes RD, Stevens SR, Zimmerman A, Wruck L, James SK, et al. Reporting clinical end points and safety events in an acute coronary syndrome trial: results with integrated collection. *Journal of the American Heart Association* 2017;**6**:4.

Hagstrom E, Wallentin L, Wojdyla D, Neely ML, Stevens SR, Alexander JH, et al. Management and clinical consequences of major bleeding in high-risk patients following an acute coronary syndrome. Is aspirin the problem? Insights from the APPRAISE-2 trial. *European Heart Journal* 2015;**36** Suppl 1:861-2.

Hess CN, James S, Lopes RD, Wojdyla DM, Neely ML, Liaw D, et al. Apixaban plus mono versus dual antiplatelet therapy in acute coronary syndromes: insights from the APPRAISE-2 trial. *Journal of the American College of Cardiology* 2015;**66**(7):777-87.

James SK, Wallentin L, Alexander JH, Harrington RA, Mohan P. Apixaban for prevention of acute ischemic events in patients with acute coronary syndromes. *Journal of Thrombosis and Haemostasis* 2011;**9** Suppl 2:20.

Khan R, Lopes RD, Neely ML, Stevens SR, Harrington RA, Diaz R, et al. Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. *Heart (British Cardiac Society)* 2015;**101**(18):1475-84.

NCT00831441. Phase III acute coronary syndrome (APPRAISE-2) [Apixaban for prevention of acute ischemic events – 2 A phase 3, randomized, double-blind, evaluation of the safety and efficacy of apixaban in subjects with a recent acute coronary syndrome]. clinicaltrials.gov/show/NCT00831441 (first received 29 January 2009).

Sharma A, Hagstrom E, Wojdyla DM, Neely ML, Harrington RA, Wallentin L, et al. Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: insights from the APPRAISE-2 trial. *American Heart Journal* 2019;**215**:106-13.

Sherwood M, Lopes R, Sun J-L, Harrington R, Wallentin L, Laskowitz DT, et al. Apixaban following acute coronary syndromes among patients with prior stroke: insights from the app raise-2 trial. *Journal of the American College of Cardiology* 2015;**65**(10 Suppl 1):A195.

Sherwood MW, Lopes RD, Sun JL, Liaw D, Harrington RA, Wallentin L, et al. Apixaban following acute coronary syndromes in patients with prior stroke: insights from the APPRAISE-2 trial. *American Heart Journal* 2018;**197**:1-8.

ATLAS ACS {published data only}

Alkhalafan F, Kerneis M, Nafee T, Yee Megan K, Chi G, Plotnikov A, et al. D-Dimer levels and effect of rivaroxaban on those levels and outcomes in patients with acute coronary syndrome (An ATLAS ACS-TIMI 46 Trial Substudy). *American Journal of Cardiology* 2018;**122**(9):1459-64.

Alkhalafan F, Kerneis M, Nafee T, Yee Megan K, Chi G, Plotnikov A, et al. D-dimer levels and clinical outcomes in acute coronary syndrome patients: an ATLAS ACS TIMI 46 trial substudy. *Circulation* 2018;**138**.

Geller BJ, Mega JL, Morrow DA, Guo J, Hoffman EB, Gibson MC, et al. Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial. *Journal of Thrombosis and Thrombolysis* 2014;**37**(3):310-6.

* Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. *Lancet* 2009;**374**(9683):29-38.

NCT00402597. Rivaroxaban in combination with aspirin alone or with aspirin and a thienopyridine in patients with acute coronary syndromes (The ATLAS ACS TIMI 46 Trial) [A randomized, double-blind, placebo-controlled, multicenter, dose-escalation and dose-confirmation study to evaluate the safety and efficacy of rivaroxaban in combination with aspirin alone or with aspirin and a thienopyridine in subjects with acute coronary syndromes]. clinicaltrials.gov/show/NCT00402597 (first received 22 November 2006).

NCT00809965. An efficacy and safety study for rivaroxaban in patients with acute coronary syndrome [A randomized, double-blind, placebo-controlled, event-driven multicenter study to evaluate the efficacy and safety of rivaroxaban in subjects with

a recent acute coronary syndrome]. clinicaltrials.gov/show/NCT00809965 (first received 17 December 2008).

ATLAS ACS 2 {published data only}

Alkhalafan F, Nafee T, Yee M, Chi GC, Kalayci A, Plotnikov A, et al. The association of white blood cell count and bleeding in acute coronary syndrome: an insight into the ATLAS ACS-TIMI 51 trial. *Circulation* 2019;**140** Suppl 1.

Alkhalafan F, Nafee T, Yee MK, Chi G, Kalayci A, Plotnikov A, et al. Relation of white blood cell count to bleeding and ischemic events in patients with acute coronary syndrome (from the ATLAS ACS 2-TIMI 51 Trial). *American Journal of Cardiology* 2020;**125**(5):661-9.

Arora R, Lang C, Quddus A. Bayesian net-clinical benefit analysis of rivaroxaban in patients with acute coronary syndromes. *Journal of the American College of Cardiology* 2013;**61**(10 Suppl 1):E1534.

Cavender M, Braunwald E, Gibson CM, Wiviott S, Murphy S, Amuchastegui M, et al. Rivaroxaban reduces spontaneous and large myocardial infarctions: findings from the ATLAS ACS 2 – TIMI 51 trial. *Journal of the American College of Cardiology* 2013;**61**(10 Suppl 1):E3.

Cavender MA, Gibson CM, Braunwald E, Wiviott SD, Murphy SA, Toda KE, et al. The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 – TIMI 51 trial. *European Heart Journal* 2015;**4**(5):468-74.

EUCTR2008-002708-25-CZ. A randomized, double-blind, placebo-controlled, event-driven multicenter study to evaluate the efficacy and safety of rivaroxaban in subjects with a recent acute coronary syndrome. The ATLAS ACS 2 TIMI 51 Trial. www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002708-25 2009.

Gibson CM, Chakrabarti A, Levitan B, Yuan Z, Murphy SA, Mega J, et al. A net clinical outcome analysis comparing fatal or irreversible ischemic and bleeding events in ATLAS ACS 2 – TIMI 51, abstract 13152. *Circulation* 2018;**2012**(126):A13152.

Gibson CM, Chakrabarti AK, Mega J, Bode C, Bassand J-P, Verheugt FW, et al. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. *Journal of the American College of Cardiology* 2013;**62**(4):286-90.

Gibson CM, Levitan B, Gibson William J, Yee Megan K, Murphy Sabina A, Yuan Z, et al. Fatal or irreversible bleeding and ischemic events with rivaroxaban in acute coronary syndrome. *Journal of the American College of Cardiology* 2018;**72**(2):129-36.

Gibson CM, Mega JL, Braunwald E. Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS ACS 2-TIMI 51) trial: a randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. *Circulation* 2011;**124**(21):2367.

Gibson CM, Mega JL, Burton P, Goto S, Verheugt F, Bode C, et al. Rationale and design of the Anti-Xa therapy to lower

cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. *American Heart Journal* 2011;**161**(5):815-21.e6.

Gibson CM, Yee MK, Korjian S, Daaboul Y, Gibson WJ, Plotnikov AN, et al. Safety and efficacy of rivaroxaban when added to aspirin monotherapy among stabilized post-acute coronary syndrome patients: a pooled analysis study of ATLAS ACS-TIMI 46 and ATLAS ACS 2-TIMI 51. *Journal of the American Heart Association* 2019;**8**(5):e009451.

Gibson CM. Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate. *European Heart Journal* 2012;**33**(1):140.

Korjian S, Braunwald E, Daaboul Y, Mi M, Bhatt DL, Verheugt FW, et al. Usefulness of rivaroxaban for secondary prevention of acute coronary syndrome in patients with history of congestive heart failure (from the ATLAS-ACS-2 TIMI-51 Trial). *American Journal of Cardiology* 2018;**122**(11):1896-901.

Korjian S, Braunwald E, Daaboul Y, Verheugt F, Bode C, Tendera M, et al. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: insights from the ATLAS ACS 2-TIMI 51 trial. *European Heart Journal. Acute Cardiovascular Care* 2019;**8**(2):186-93.

Krantz MJ, Kaul S. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome ACS 2-Thrombolysis In Myocardial Infarction 51). *Journal of the American College of Cardiology* 2013;**62**(9):777-81.

Mega J, Braunwald E, Murphy S, Fox K, Ruda M, Verheugt F, et al. Rivaroxaban in patients after an acute coronary syndrome with cardiac biomarker elevation: insights from the ATLAS ACS 2-TIMI 51 trial. *European Heart Journal* 2014;**35**(Suppl 1):992.

Mega JL, Braunwald E, Murphy S, Plotnikov A, Nancy C-B, Aylward P, et al. Rivaroxaban in the setting of continued dual antiplatelet therapy: findings from the atlas ACS 2-TIMI 51 trial. *Journal of the American College of Cardiology* 2013;**61**(10 Suppl 1):E4.

Mega JL, Braunwald E, Murphy SA, Plotnikov AN, Burton P, Kiss RG, et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction. Results from the ATLAS-ACS-2-TIMI-51 trial. *Rational Pharmacotherapy in Cardiology* 2014;**10**(2):245-52.

Mega JL, Braunwald E, Murphy SA, Plotnikov AN, Burton P, Kiss RG, et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In

Myocardial Infarction-51). *Journal of the American College of Cardiology* 2013;**61**(18):1853-9.

Mega JL, Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. *New England Journal of Medicine* 2012;**366**(1):9-19.

Mega JL, Braunwald E, Wiviott SD, Murphy S, Plotnikov A, Gotcheva N, et al. Evaluation of cardiac events in ATLAS ACS 2-TIMI 51. *Circulation* 2012;**126**(21 Suppl 1):A16014.

Mega JL, Braunwald E, Wiviott SD, Murphy SA, Plotnikov A, Gotcheva N, et al. Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51). *American Journal of Cardiology* 2013;**112**(4):472-8.

Mega JL. Low-Dose rivaroxaban reduced mortality in patients with a recent acute coronary syndrome. *Annals of Internal Medicine* 2012;**156**(10):JC5-3.

O'Donoghue ML, Mega JL, Braunwald E, Bhatt DL, Murphy SA, Nicolau JC, et al. The efficacy and safety of low-dose rivaroxaban with or without a proton pump inhibitor: insights from the atlas ACS 2-TIMI 51 trial. *Circulation* 2013;**128**:22 Suppl 1.

Ogden K, Quock TP, Patel AA, Mody SH, Veerman M, Crivera C. Economic burden of mortality and cardiovascular events among patients with acute coronary syndromes in a commercial health plan. *Circulation: Cardiovascular Quality and Outcomes* 2013;**6**:3 Suppl 1.

Zhang L, Yan X, Nandy P, Willmann S, Fox KA, Berkowitz SD, et al. Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome. *Therapeutic Advances in Cardiovascular Disease* 2019;**13**:1753944719863641.

GEMINI-ACS {published data only}

NCT02293395. A study to compare the safety of rivaroxaban versus acetylsalicylic acid in addition to either clopidogrel or ticagrelor therapy in participants with acute coronary syndrome [A randomized, double-blind, double-dummy, active-controlled, parallel-group, multicenter study to compare the safety of rivaroxaban versus acetylsalicylic acid in addition to either clopidogrel or ticagrelor therapy in subjects with acute coronary syndrome]. clinicaltrials.gov/show/NCT02293395 (first received 18 November 2014).

Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. *Lancet* 2017;**389**(10081):1799-808.

Povsic TJ, Roe MT, Ohman EM, Steg PG, James S, Plotnikov A, et al. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: the design of the GEMINI-ACS-1 phase II study. *American Heart Journal* 2016;**174**:120-8.

REDEEM {published data only}

NCT00621855. RE-DEEM dose finding study for dabigatran etexilate in patients with acute coronary syndrome [Randomised dabigatran etexilate dose finding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel: multi-centre, prospective, placebo controlled, group dose escalation trial (RE-DEEM study)]. clinicaltrials.gov/show/NCT00621855 (first received 22 February 2008).

Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. *European Heart Journal* 2011;**32**(22):2781-9.

Oldgren J, Wallentin L, Budaj A, Granger CB, Harper R, Khder Y, et al. Randomised dabigatran etexilate dose finding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel (RE-DEEM). *Circulation* 2010;**120**(21):2160-1.

References to studies excluded from this review

Alizadeh 2019 {published data only}

Alizadeh M, Antoniou S, Fhadil S, Rathod R, Guttmann O, Knight C, et al. The use of direct oral anti-coagulations (DOACs) compared to vitamin K antagonist in patients with left ventricular thrombus after acute myocardial infarction. *European Heart Journal* 2019;**40**(Suppl 1):4026.

Borst 2018 {published data only}

Borst O, Munzer P, Alnaggar N, Geue S, Tegtmeyer R, Rath D, et al. Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction. *Blood Advances* 2018;**2**(6):715-30.

Devereaux 2018 {published data only}

Devereaux PJ, Duceppe E, Guyatt G, Tandon V, Rodseth R, Biccard BM, et al. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. *Lancet* 2018;**391**(10137):2325-34.

Duceppe 2018 {published data only}

Duceppe E, Yusuf S, Tandon V, Rodseth R, Biccard BM, Xavier D, et al. Design of a randomized placebo-controlled trial to assess dabigatran and omeprazole in patients with myocardial injury after noncardiac surgery (MANAGE). *Canadian Journal of Cardiology* 2018;**34**(3):295-302.

Euctr 2013a {published data only}

EUCTR2012-004180-43-CZ. Rivaroxaban for the prevention of major cardiovascular events in coronary or peripheral artery disease. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012-004180-43-CZ 2013.

Euctr 2013b {published data only}

EUCTR2013-000046-19-BG. A study to assess the effectiveness and safety of rivaroxaban in reducing the risk of death,

myocardial infarction or stroke in participants with heart failure and coronary artery disease following an episode of decompensated heart failure. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-000046-19-BG 2013.

Gao 2015 {published data only}

Gao F, Shen H, Wang Z, Yang S, Liu X, Zhou Y. Risk of hemorrhagic and ischemic stroke for dual antiplatelet therapy and new generation oral anticoagulants in patients with acute coronary syndrome. *Journal of the American College of Cardiology* 2015;**66**(16 Suppl 1):C158.

Greenberg 2018a {published data only}

Greenberg BH, Anker SD, Byra WM, Nessel CC, Cleland JG, Fu M, et al. Effects of rivaroxaban on thrombotic events in heart failure patients with coronary disease and sinus rhythm. *Circulation* 2018;**138**(25):e761-2.

Greenberg 2018b {published data only}

Greenberg B, Anker S, Byra WM, Fu M, Nessel CC, Cleland JG, et al. A randomized study comparing rivaroxaban with placebo in subjects with heart failure and significant coronary artery disease following an episode of decompensated heart failure: the COMMANDER HF study. *Journal of Cardiac Failure* 2018;**24**(11):811.

Kopin 2016 {published data only}

Kopin D, Sherwood MW, Jones WS, Granger CB, Lopes RD, Alexander JH, et al. Percutaneous coronary intervention and antiplatelet therapy on apixaban or warfarin: insights from the ARISTOTLE trial. *Circulation* 2016;**134**:Suppl 1.

Lee 2018 {published data only}

Lee J, Nakanishi R, Li D, Shaikh K, Shekar C, Osawa K, et al. Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis. *American Heart Journal* 2018;**206**:127-30.

NCT04333407 {published data only}

NCT04333407. Preventing cardiac complication of COVID-19 disease with early acute coronary syndrome therapy: a randomised controlled trial. clinicaltrials.gov/show/NCT04333407 (first received 3 April 2020).

NCT04688723 {published data only}

NCT04688723. Dual therapy with dabigatran/ticagrelor versus dual therapy with dabigatran/clopidogrel in ACS patients with indication for NOAC undergoing PCI. clinicaltrials.gov/show/NCT04688723 (first received 30 December 2020).

NCT04805710 {published data only}

NCT04805710. Rivaroxaban or aspirin in patients with CHD & GD undergoing PCI. clinicaltrials.gov/show/NCT04805710 (first received 18 March 2021).

NCT04838808 {published data only}

NCT04838808. Rivaroxaban in type 2 myocardial infarctions. clinicaltrials.gov/show/NCT04838808 (first received 9 April 2021).

Nct 2012 {published data only}

NCT01661101. Management of myocardial injury after noncardiac surgery trial. clinicaltrials.gov/show/NCT01661101 (first received 9 August 2012).

Schiele 2018 {published data only}

Schiele F, Puymirat E, Ferrieres J, Simon T, Danchin N. Do randomized clinical trial selection criteria reflect real-life levels of risk in acute myocardial infarction survivors? the compass trial in light of the FAST-MI 2005-2010-2015 registries. *Circulation* 2018;**138**:Suppl 1.

Zannad 2015 {published data only}

Zannad F, Greenberg B, Cleland JG, Gheorghiadu M, van Veldhuisen DJ, Mehra MR, et al. Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial. *European Journal of Heart Failure* 2015;**17**(7):735-42.

Zannad 2018 {published data only}

Zannad F, Anker SD, Byra WM, Cleland JG, Fu M, Gheorghiadu M, et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. *New England Journal of Medicine* 2018;**379**(14):1332-42.

References to ongoing studies

NCT03775746 {published data only}

NCT03775746. Can very low dose rivaroxaban in addition to dual antiplatelet therapy (DAPT) improve thrombotic status in acute coronary syndrome (ACS) ACS (VaLiDate-R). clinicaltrials.gov/show/NCT03775746 (first received 14 December 2018).

Additional references

Al Said 2018

Al Said S, Bode C, Duerschmied D. Anticoagulation in Atherosclerotic Disease. *Hamostaseologie* 2018;**38**(4):240-6.

Al Said 2021

Al Said S, Alabed S, Sumaya W, Alsaid D, Kaier K, Duerschmied D, et al. Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis. *Cochrane Database of Systematic Reviews* 2021, Issue 5. Art. No: CD014678. [DOI: [10.1002/14651858.CD014678](https://doi.org/10.1002/14651858.CD014678)]

Alexander 2009

Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. *Circulation* 2009;**119**(22):2877-85.

Alexander 2011

Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. *New England Journal of Medicine* 2011;**365**(8):699-708.

Amsterdam 2014

Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology* 2014;**64**(24):e139-e228.

Anand 2003

Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. *Journal of the American College of Cardiology* 2003;**41**:62S-69S.

Andreotti 2006

Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. *European Heart Journal* 2006;**27**:519-26.

Bauer 2013

Bauer KA. Pros and cons of new oral anticoagulants. *Hematology* 2013;**2013**:464-70.

Bonaca 2015

Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. *New England Journal of Medicine* 2015;**372**(19):1791-800.

Brignardello-Petersen 2020

Brignardello-Petersen R, Izcovich A, Rochwerf B, Florez ID, Hazlewood G, Alhazanni W, et al, GRADE working group. GRADE approach to drawing conclusions from a network meta-analysis using a partially contextualised framework. *BMJ* 2020;**371**:m3907. [DOI: [10.1136/bmj.m3907](https://doi.org/10.1136/bmj.m3907)]

Chaimani 2022

Chaimani A, Caldwell DM, Li T, Higgins JP, Salanti G. Chapter 11: Undertaking network meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v.6.3.

Chesebro 1987

Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. *Circulation* 1987;**76**(1):142-54.

Chiarito 2018

Chiarito M, Cao D, Cannata F, Godino C, Lodigiani C, Ferrante G, et al. Direct oral anticoagulants in addition to antiplatelet therapy for secondary prevention after acute coronary

syndromes: a systematic review and meta-analysis. *JAMA Cardiology* 2018;**3**(3):234-41.

Cohen 1998

Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. 2nd edition. Hillsdale (NJ): L. Erlbaum Associates, 1998.

Collet 2020

Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *European Heart Journal* 2021;**42**(14):1289-367. [DOI: [10.1093/eurheartj/ehaa575](https://doi.org/10.1093/eurheartj/ehaa575)]

Connolly 2009

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *New England Journal of Medicine* 2009;**361**(12):1139-51.

Cuker 2019

Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, et al. Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum. *American Journal of Hematology* 2019;**94**:697.

Cutlip 2007

Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es G-A, et al. Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation* 2007;**115**:2344-51.

Deeks 2022

Deeks JJ, Higgins JPT, Altman DG, editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v.6.3.

Eriksson 2011

Eriksson B, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. *Annual Review of Medicine* 2011;**62**:41-57.

Farang 2019

Farang M, Spinhakis N, Gue YX, Srinivasan M, Sullivan K, Wellsted D, et al. Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study. *European Heart Journal* 2019;**40**(3):295-305. [DOI: [10.1093/eurheartj/ehy656](https://doi.org/10.1093/eurheartj/ehy656)]

Garg 2015

Garg P, Galper BZ, Cohen DJ, Yeh RW, Mauri L. Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents. *American Heart Journal* 2015;**169**(2):222-33.e5. [DOI: [10.1016/j.ahj.2014.11.002](https://doi.org/10.1016/j.ahj.2014.11.002)] [PMID: 25641531]

Gibson 2011

Gibson CM, Mega JL, Burton P, Goto S, Verheugt F, Bode C, et al. Rationale and design of the anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. *American Heart Journal* 2011;**161**(5):815-21.

Giugliano 2013

Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. *New England Journal of Medicine* 2013;**369**(22):2093-104.

Glund 2015

Glund S, Moschetti V, Norris S, Stangier J, Schmohl M, van Ryn J, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. *Thrombosis and Haemostasis* 2015;**113**(5):943-51.

GRADEpro GDT 2015 [Computer program]

GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepr.org.

Granger 2011

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. *New England Journal of Medicine* 2011;**365**(11):981-92.

Higgins 2017

Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.

Hurlen 2002

Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. *New England Journal of Medicine* 2002;**347**:969-74.

Ibanez 2018

Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *European Heart Journal* 2018;**39**(2):119-77.

Jackson 2012

Jackson D, White IR and Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. *Statistics in Medicine* 2012;**31**:3805-20.

James 2018

James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;**392**(10159):1789-858.

Jan 2018

Jan S, Lee SW, Sawhney JP, Ong TK, Chin CT, Kim HS, et al. Predictors of high-cost hospitalization in the treatment of acute coronary syndrome in Asia: findings from EPICOR Asia. *BMC Cardiovascular Disorders* 2018;**18**(1):139.

Jernberg 2015

Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. *European Heart Journal* 2015;**36**(19):1163-70.

Khan 2017

Khan SU, Arshad A, Riaz IB, Talluri S, Nasir F, Kaluski E. Meta-analysis of the safety and efficacy of the oral anticoagulant agents (apixaban, rivaroxaban, dabigatran) in patients with acute coronary syndrome. *American Journal of Cardiology* 2018;**121**(3):301-7.

Kikkert 2018

Kikkert WJ, Damman P. Optimal duration of dual antiplatelet therapy for coronary artery disease. *Netherlands Heart Journal* 2018;**26**(6):321-33. [DOI: [10.1007/s12471-018-1113-5](https://doi.org/10.1007/s12471-018-1113-5)]

Krahn 2013

Krahn U, Binder H, König J. A graphical tool for locating inconsistency in network meta-analyses. *BMC Medical Research Methodology* 2013;**13**:35.

Lefebvre 2022

Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Marshall C, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v.6.3.

Leon 1998

Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. *New England Journal of Medicine* 1998;**339**(23):1665-71.

Liang 2020

Liang L, Moore B, Soni A. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2017: Statistical Brief #261; July 2020. www.hcup-us.ahrq.gov/reports/statbriefs/sb261-Most-Expensive-Hospital-Conditions-2017.jsp (accessed 4 May 2021).

Mega 2012

Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt D, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. *New England Journal of Medicine* 2012;**366**(1):9-19.

Merlini 1994

Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. *Circulation* 1994;**90**(1):61-8.

NICE 2015

NICE. Rivaroxaban for prevention adverse outcomes after acute management of acute coronary syndrome. www.nice.org.uk/guidance/ta335/resources/rivaroxaban-for-preventing-adverse-outcomes-after-acute-management-of-acute-coronary-syndrome-82602549055429 (accessed 28 April 2021).

O'Gara 2013

O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013;**127**(4):e362-425. [DOI: [10.1161/CIR.0b013e3182742cf6](https://doi.org/10.1161/CIR.0b013e3182742cf6)]

Oldgren 2011

Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. *European Heart Journal* 2011;**32**(22):2781-9.

Oldgren 2013

Oldgren J, Wallentin L, Alexander JH, James S, Jönelid B, Steg G, et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. *European Heart Journal* 2013;**34**(22):1670-80.

Page 2021

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;**372**:n71. [DOI: [10.1136/bmj.n71](https://doi.org/10.1136/bmj.n71)]

Patel 2011

Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *New England Journal of Medicine* 2011;**365**(10):883-91.

Pollack 2015

Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. *New England Journal of Medicine* 2015;**373**(6):511-20.

Review Manager 2020 [Computer program]

Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.

Roffi 2016

Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *European Heart Journal* 2016;**37**(3):267-315.

Rothberg 2005

Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. *Annals of Internal Medicine* 2005;**143**:241-50.

Rücker 2012

Rücker G. Network meta-analysis, electrical networks and graph theory. *Research Synthesis Methods* 2012;**3**(4):312-24.

Rücker 2014

Rücker G, Schwarzer G. Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis. *Statistics in Medicine* 2014;**33**(25):4353-69.

Rücker 2015

Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. *BMC Medical Research Methodology* 2015;**15**:58.

Rücker 2017

Rücker G, Schwarzer G, Krahn U, König J. netmeta: Network Meta-Analysis using Frequentist Methods. cran.r-project.org/web/packages/netmeta (accessed 6 May 2021).

Saraf 2010

Saraf S, Christopoulos C, Salha IB, Stott DJ, Gorog DA. Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction. *Journal of the American College of Cardiology* 2010;**55**:2107-15.

Schünemann 2022

Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v.6.3.

Sumaya 2018a

Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Bertilsson M, et al. Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. *European Heart Journal* 2018;**39**:1078-85.

Sumaya 2018b

Sumaya W, Parker WA, Fretwell R, Hall IR, Barmby DS, Richardson JD, et al. Pharmacodynamic effects of a 6-hour regimen of enoxaparin in patients undergoing primary

percutaneous coronary intervention (PENNY PCI Study). *Thrombosis and Haemostasis* 2018;**118**:1250-6.

Sumaya 2020

Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Himmelmann A, et al. Impaired fibrinolysis predicts adverse outcome in acute coronary syndrome patients with diabetes: a PLATO sub-study. *Thrombosis and Haemostasis* 2020;**120**(3):412-22.

Valgimigli 2017

Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). *European Heart Journal* 2017;**39**(3):213-60.

van Es 2002

van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) research group. Aspirin

and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. *Lancet* 2002;**360**:109-13.

Varin 2013

Varin R, Mirshahi S, Mirshahi P, Klein C, Jamshedov J, Chidiac J, et al. Whole blood clots are more resistant to lysis than plasma clots – greater efficacy of rivaroxaban. *Thrombosis Research* 2013;**131**:e100-9.

Vos 2016

Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016;**388**(10053):1545-602.

Wilkins 2017

Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Leal J, Luengo-Fernandez R, et al. European Cardiovascular Disease Statistics 2017. European Heart Network, Brussels.

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

APPRAISE 1

Study characteristics

Methods	Randomised, double-blind, placebo-controlled trial Study dates: May 2006–October 2007
Participants	Setting: 151 sites in 14 countries in Europe, the Middle East, and North America Number randomised/analysed: 1715/1715 Age: median 61 years Sex (male/female): 77%/23%
Interventions	Experimental group 1 (n = 315): apixaban 2.5 mg twice daily Experimental group 2 (n= 315): apixaban 10mg once daily Control group (n = 599): placebo Cointerventions: all participants received aspirin, and 76% received additional clopidogrel. Inclusion criteria <ul style="list-style-type: none"> • Age 18–90 years • Recent (within 7 days) STE-ACS or NSTEMI-ACS • Clinical stability with evidence-based care • ≥ 1 additional risk factor for recurrent ischaemic events Exclusion criteria <ul style="list-style-type: none"> • Aspirin allergy

APPRAISE 1 (Continued)

- Planned catheterisation, percutaneous coronary intervention, coronary bypass surgery, or other invasive procedure
- Persistent severe hypertension
- Severe renal insufficiency
- Active bleeding or a high risk for bleeding
- Coagulopathy
- Acute pericarditis or pericardial effusion
- Stroke within 3 months
- New York Heart Association class IV heart failure
- Thrombocytopenia
- Anaemia
- Indication for ongoing anticoagulation
- Long-term nonsteroidal anti-inflammatory drug or high-dose aspirin use
- Ongoing treatment with strong CYP3A4 inhibitors
- Participation in an investigational drug or device trial within 30 days
- Women of childbearing potential

Outcomes	<p>Primary outcomes</p> <ul style="list-style-type: none"> • ISTH major or clinically relevant non-major bleeding (event rate was number of participants with events divided by the number of participants treated, measured as a percentage) <p>Secondary outcomes</p> <ul style="list-style-type: none"> • Cardiovascular death • Myocardial infarction • Severe recurrent ischaemia • Ischaemic stroke
Notes	Sponsor: Bristol-Myers Squibb

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised via a centralised interactive voice response system.
Allocation concealment (selection bias)	Low risk	Randomised via a centralised interactive voice response system.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind study.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcomes were reviewed by a blinded independent clinical events committee.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Clearly described in Figure 1. Loss to follow-up ~10%.
Selective reporting (reporting bias)	Low risk	All outcomes in the trial registration reported. Registered in ClinicalTrials.gov (NCT00313300).

APPRAISE 1 (Continued)

Other bias	Low risk	The clinical trial data were managed at Bristol-Myers Squibb, but the locked database was transferred in full to the Duke Clinical Research Institute for analysis. All analyses were performed independently by statisticians at the Duke Clinical Research Institute. The sponsors reviewed and commented on the manuscript, but their approval was not required.
------------	----------	---

APPRAISE 2
Study characteristics

Methods	Randomised, double-blind, placebo-controlled trial Study dates: March 2009–November 2010
Participants	Setting: 858 sites in 39 countries Number randomised/analysed: 7392/7392 Age: median 67 years Sex (male/female): 67%/33%
Interventions	Experimental group (n = 3705): apixaban 5 mg twice daily Control group (n = 3687): placebo, twice daily Cointerventions: all participants received aspirin, and 81% received additional clopidogrel. Inclusion criteria <ul style="list-style-type: none"> • ACS (myocardial infarction, with or without ST-segment elevation, or unstable angina) within the previous 7 days • Symptoms of myocardial ischaemia lasting ≥ 10 minutes with the person at rest • Either elevated levels of cardiac biomarkers or dynamic ST-segment depression or elevation of ≥ 0.1 mV • Clinical stability with standard treatment (e.g. aspirin or aspirin plus any P2Y12-receptor antagonist) • ≥ 2 of the following high-risk characteristics: age ≥ 65 years, diabetes mellitus, myocardial infarction within the previous 5 years, cerebrovascular disease, peripheral vascular disease, clinical heart failure or a LVEF $< 40\%$ in association with the index event, impaired renal function with a calculated creatinine clearance < 60 mL/minute, and no revascularisation after the index event Exclusion criteria <ul style="list-style-type: none"> • Severe hypertension • Active bleeding or high risk for major bleeding • Haemoglobin < 9 g/day
Outcomes	Primary Outcomes <ul style="list-style-type: none"> • Efficacy: cardiovascular death/myocardial infarction/ischaemic stroke • Safety: major bleeding using TIMI criteria Secondary Outcomes <ul style="list-style-type: none"> • Efficacy <ul style="list-style-type: none"> ◦ Cardiovascular death/myocardial infarction/ischaemic stroke/unstable angina ◦ Cardiovascular death/myocardial infarction/ischaemic or haemorrhagic stroke/fatal bleeding ◦ Cardiovascular death/myocardial infarction/ischaemic stroke or haemorrhagic stroke

APPRAISE 2 (Continued)

- Cardiovascular death
- Myocardial infarction
- Stroke
- Stent thrombosis
- Safety
 - Major or minor bleeding using TIMI criteria
 - ISTH bleeding
 - GUSTO bleeding

Notes Supported by Bristol-Myers Squibb and Pfizer.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Participants were randomly assigned, in a 1:1 ratio, to receive apixaban, at a dose of 5 mg BD, or matching placebo".
Allocation concealment (selection bias)	Low risk	Quote: "Randomisation was performed in a blinded fashion with the use of an interactive voice-response system, in permuted blocks of two, stratified according to site and according to planned long-term use of aspirin or aspirin plus a P2Y12-receptor antagonist".
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind study.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The primary and secondary outcomes were adjudicated with the use of pre-specified criteria by an independent clinical events committee.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Among the participants who underwent randomisation, 81 (1.1%) withdrew consent and 50 (0.7%) were lost to follow-up for the primary outcome during the intended treatment period.
Selective reporting (reporting bias)	Low risk	All outcomes were defined a priori in the published protocol. The trial protocol and statistical analysis plan are available at NEJM.org.
Other bias	Low risk	Sponsors (Bristol-Myers Squibb and Pfizer). Sponsor approval not required.

ATLAS ACS
Study characteristics

Methods	Randomised, double-blind, placebo-controlled trial Study dates: November 2006–October 2008
Participants	Setting: 297 sites in 27 countries Number randomised/analysed: 3491/3491 Age: median 57 years Sex (male/female): 78%/22%

Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis (Review)

ATLAS ACS (Continued)

Interventions	<p>Experimental group (n = 2331): rivaroxaban 5 mg once daily, 10 mg once daily, 15 mg once daily, 20 mg once daily</p> <p>Control group (n = 1160): placebo</p> <p>Cointerventions: all participants received aspirin and 80% received additional clopidogrel.</p> <p>Inclusion Criteria</p> <ul style="list-style-type: none"> • Symptoms suggestive of ACS lasting \geq 10 minutes at rest occurring within 7 days of randomisation • Have a diagnosis of STEMI or NSTEMI/unstable angina (i.e. chest pain or discomfort) with \geq 1 protocol-defined high risk feature <p>Exclusion Criteria</p> <ul style="list-style-type: none"> • Active bleeding or high risk of bleeding or intracranial haemorrhage (bleeding within the skull enclosing the brain) • Need for continued anticoagulant therapy • Significantly impaired renal or hepatic function • Severe concomitant diseases (e.g. cardiogenic shock (heart damage that results in insufficient blood supply to other parts or organs of the body), refractory ventricular arrhythmias (irregular contractions of the heart unresponsive to treatment), or any severe condition that would limit life expectancy of the patient to $<$ 6 months) 	
Outcomes	<p>Primary outcomes</p> <ul style="list-style-type: none"> • TIMI clinically significant bleeding events • Composite endpoint of all-cause death, myocardial infarction, stroke (ischaemic, haemorrhagic or unknown), or severe recurrent ischaemia requiring revascularisation) <p>Secondary outcomes</p> <ul style="list-style-type: none"> • Composite endpoint of all-cause death, myocardial infarction, or stroke • Number of deaths (all-cause) • Composite endpoint of all-cause death, myocardial infarction, stroke, severe recurrent ischemia requiring revascularisation, and TIMI major or minor bleeding, to assess the net clinical benefit 	
Notes	Funding: Johnson & Johnson Pharmaceutical Research & Development and Bayer Healthcare AG	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomised with a block randomisation method at 1:1:1.
Allocation concealment (selection bias)	Low risk	Block randomisation.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Investigators and participants were blinded to treatment.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	A blinded clinical events committee adjudicated all the components of the main safety and efficacy outcomes.

ATLAS ACS (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	The primary analysis was based on the ITT population, including all participants who were randomly assigned to a treatment group, irrespective of administration. "Figure 2 Trial profile" shows causes of drug discontinuation and details of ITT analysis.
Selective reporting (reporting bias)	Low risk	All prespecified outcomes were reported. This study is registered at ClinicalTrials.gov (NCT00402597).
Other bias	Low risk	This study was designed as a collaboration between the TIMI Study Group, the sponsors, and a steering committee of investigators. All analyses were undertaken by the TIMI Study Group, with an independent copy of the complete database.

ATLAS ACS 2
Study characteristics

Methods	Randomised, double-blind, placebo-controlled trial Study dates: November 2008–September 2011
Participants	Setting: 766 sites in 44 countries Number randomised/analysed: 15526/15526 Age: median 62 years Sex (male/female): 75%/25%
Interventions	Experimental group 1 (n = 5174): rivaroxaban 2.5 mg, 1 tablet twice daily Experimental group 2 (n = 5176): rivaroxaban 5 mg, 1 tablet twice daily Control group (n = 5176): placebo, 1 tablet twice daily Cointerventions: all participants received aspirin, and 93% received additional clopidogrel. Inclusion criteria <ul style="list-style-type: none"> • Current aspirin therapy alone or in combination with a thienopyridine as per national or local dosing recommendation • Hospitalisation for symptoms suggestive of ACS that lasted ≥ 10 minutes at rest and occurred ≤ 48 hours before going to the hospital Exclusion criteria <ul style="list-style-type: none"> • Any condition that, in the opinion of the investigator, contraindicates anticoagulant therapy or would have an unacceptable risk of bleeding • Need for continued anticoagulant therapy • Significant renal impairment or known significant liver disease
Outcomes	Primary outcomes <ul style="list-style-type: none"> • Percentage of participants with the composite endpoint of cardiovascular death, myocardial infarction, or stroke Secondary outcomes

ATLAS ACS 2 (Continued)

- Percentage of participants with the composite endpoint of all-cause death, myocardial infarction, or stroke
- Percentage of participants with the composite endpoint of cardiovascular death, myocardial infarction, ischemic stroke, or TIMI major bleeding event not associated with coronary artery bypass graft surgery
- Percentage of participants with the composite endpoint of cardiovascular death, myocardial infarction, stroke, or severe recurrent ischaemia requiring revascularisation
- Percentage of participants with the composite endpoint of cardiovascular death, myocardial infarction, stroke, or severe recurrent ischaemia leading to hospitalisation

Notes Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C and Bayer

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Participants were randomly assigned in a 1:1:1 fashion to twice-daily administration of either 2.5 mg or 5.0 mg of rivaroxaban or placebo".
Allocation concealment (selection bias)	Low risk	Described in trial design.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind study.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Clinical-events committee whose members were unaware of study-group assignments adjudicated outcomes.
Incomplete outcome data (attrition bias) All outcomes	Low risk	The rates of loss to follow-up were 0.2% for low-dose rivaroxaban, 0.3% for normal-dose rivaroxaban, and 0.3% for placebo.
Selective reporting (reporting bias)	Low risk	All outcomes in the trial registration reported.
Other bias	Low risk	An independent data and safety monitoring committee monitored the trial and reviewed unblinded data.

GEMINI-ACS
Study characteristics

Methods	Randomised, double-blind, placebo-controlled trial Study dates: April 2015–October 2016
Participants	Setting: 371 clinical centres in 21 countries Number randomised/analysed: 3037/3037 Age: median 62 years Sex (male/female): 75%/25%

Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis (Review)

Copyright © 2024 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

GEMINI-ACS (Continued)

Interventions

Experimental group 1 (n = 1519): rivaroxaban 2.5 mg twice daily plus ASA placebo once daily (along with either clopidogrel 75 mg once daily or ticagrelor 90 mg twice daily) for 180–360 days of treatment

Experimental group 2 (n = 1518): ASA 100 mg once daily plus rivaroxaban placebo twice daily (along with either clopidogrel 75 mg once daily or ticagrelor 90 mg twice daily) for 180–360 days of treatment

Cointerventions: all participants received single antiplatelet therapy with either clopidogrel (43.9%) or ticagrelor (56.1%).

Inclusion criteria

- Age ≥ 18 years
- Symptoms suggestive of ACS (angina, or symptoms thought to be equivalent) within 48 hours of hospital presentation, or developed ACS while being hospitalised
- Diagnosis of STEMI or NSTEMI-ACS, plus diabetes mellitus or a history of a prior myocardial infarction in participant ≤ 54 years
- Randomisation within the screening window of 10 days after hospital admission for the index ACS event
- Acute-phase treatment for the index ACS, such as intravenous anticoagulant or antiplatelet
- Maintenance dual antiplatelet therapy with either clopidogrel plus ASA or ticagrelor plus ASA, with the intent to continue the treatment with a platelet adenosine diphosphate P2Y12 receptor antagonist (P2Y12 inhibitor) after randomisation
- Willingness to provide a pharmacogenomics DNA sample

Exclusion criteria

- Any condition that, in the opinion of the investigator, contraindicates anticoagulant therapy or would have an unacceptable risk
- Prior stroke of any aetiology or transient ischaemic attack
- Participant who received thrombolytic therapy as treatment for the index ACS event could not be enrolled in the ticagrelor stratum
- Anticipated need for chronic administration of omeprazole or esomeprazole concomitantly with clopidogrel
- Known allergy or intolerance to ASA or rivaroxaban

Outcomes

Primary outcomes

- TIMI non-coronary artery bypass graft (CABG) surgery
- Clinically significant bleeding (non-CABG major, minor, or requiring medical attention) up to day 390

Secondary outcomes

- Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO), Bleeding Academic Research Consortium (BARC), and International Society on Thrombosis and Haemostasis (ISTH) bleeding criteria
- Composite of cardiovascular death, myocardial infarction, stroke, or definite stent thrombosis
- All-cause death
- Individual component ischaemic endpoints measured throughout the entire study period (ITT population)

Notes

Funding: Janssen Research & Development and Bayer AG

Risk of bias

Bias	Authors' judgement	Support for judgement
-------------	---------------------------	------------------------------

Random sequence generation (selection bias)	Low risk	Quote: "Participants were randomly assigned (1:1) to either aspirin or rivaroxaban based on a randomisation schedule. Randomisation was balanced by using randomly permuted blocks with size of four and was stratified based on
---	----------	--

GEMINI-ACS (Continued)

		the background P2Y12 inhibitor (clopidogrel or ticagrelor) intended to be used at the time of randomisation".
Allocation concealment (selection bias)	Low risk	Quote: "The interactive web response system assigned a unique treatment code, which dictated treatment assignment for the participant".
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Investigators and participants were masked to treatment assignment. The study drugs (i.e. rivaroxaban and rivaroxaban placebo, aspirin and aspirin placebo) were identical in appearance and were packaged in identical containers.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	All bleeding and ischaemic events were independently adjudicated by a clinical events committee blinded to treatment assignment using previously published criteria.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Participants were analysed according to randomised treatment group, regardless of actual treatment received. A modified ITT analysis was used for bleeding events and included from time of randomisation to 2 days after last dose of study drug. For participants who did not have events, censoring was done at the date of last dose of study drug plus 2 days or the last clinical evaluation date (whichever came first). Only 1 participant was lost to follow-up during the study period.
Selective reporting (reporting bias)	Low risk	All prespecified outcomes were reported. This study is registered with ClinicalTrials.gov (NCT02293395).
Other bias	Low risk	A data safety monitoring committee reviewed unblinded data throughout the trial. The Duke Clinical Research Institute co-ordinated the trial, managed the database, and did the secondary and post-hoc analyses for this report, independent of the sponsors. An international executive committee designed the trial and was responsible for oversight of study conduct and reporting of all results and takes responsibility for the accuracy and completeness of data analyses. The study authors are fully responsible for the study design, data collection, analysis, and interpretation of the results.

REDEEM
Study characteristics

Methods	Randomised, double-blind, placebo-controlled trial Study dates: March 2008–October 2009
Participants	Setting: 161 clinical centres in 24 countries Number randomised/analysed: 1878/1878 Age: median 62 years Sex (male/female): 75%/25%
Interventions	Experimental group 1 (n = 369): dabigatran 50 mg twice daily Experimental group 2 (n = 368): dabigatran 75 mg twice daily Experimental group 3 (n = 406): dabigatran 110 mg twice daily

Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis (Review)

REDEEM (Continued)

Experimental group 4 (n =347): dabigatran 150 mg twice daily

Control group (n = 371): placebo

Cointerventions: all participants received aspirin, and 93% received additional clopidogrel.

Inclusion criteria

- ACS with ≥ 1 additional risk factor for cardiovascular complications

Exclusion criteria

- Long-term treatment with any other oral anticoagulant
- Severe/disabling stroke within last 6 months
- Conditions associated with increased bleeding risk
- Anaemia or thrombocytopenia
- Severe renal impairment
- Liver disease
- Positive pregnancy test

Outcomes

Primary outcomes

- Number of participants displaying the composite of major and clinically relevant minor bleeding events (ISTH definition) during total observation time

Secondary outcomes

- Composite of cardiovascular death, non-fatal myocardial infarction, and non-haemorrhagic stroke during 6 months of treatment
- Composite of all-cause death, non-fatal myocardial infarction, severe recurrent ischaemia, and non haemorrhagic stroke during 6 months of treatment
- Individual occurrence of death (cardiovascular and all-cause), non-fatal myocardial infarction, severe recurrent ischaemia, and non-haemorrhagic stroke during 6 months of treatment
- Number of participants with any reduction of D-dimer concentration
- Change from baseline in log₁₀ D-dimer after 1 and 4 weeks
- Number of participants with bleeding events during total observation time (ISTH definition of a major bleed and clinically relevant minor bleed).
- Laboratory analyses: number of participants with possible clinically significant abnormalities (increase or decrease from baseline)

Notes

Sponsor: Boehringer Ingelheim, Collaborator: Uppsala University

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised via a centralised interactive voice response system (IVRS).
Allocation concealment (selection bias)	Low risk	Randomised via a centralised interactive voice response system (IVRS). The IVRS was re-programmed to achieve balance between the five groups.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind study.

REDEEM (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	All bleeds, deaths, and suspected cases of myocardial infarction, severe recurrent ischaemia, and stroke were evaluated independently by two experienced physicians blinded to study drug assignment.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All bleeds, deaths, and suspected cases of myocardial infarction, severe recurrent ischaemia, and stroke were evaluated independently by two experienced physicians blinded to study drug assignment.
Selective reporting (reporting bias)	Low risk	Outcomes are the same as on the trial registration website (clinicaltrials.gov/ct2/show/NCT00621855).
Other bias	Low risk	Industry-funded study. Source of funding and conflicts of interests documented. No other sources of bias identified.

ACS: acute coronary syndrome; ASA: acetylsalicylic acid; BAR Bleeding Academic Research Consortium; CABG: coronary artery bypass graft; GUSTO: Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries; ISTH: International Society of Thrombosis and Hemostasis; ITT: intention-to-treat; LVEF: left ventricular ejection fraction; NSTEMI: non-ST-segment elevation acute coronary syndrome; NSTEMI: non-ST elevation myocardial infarction; STEMI: ST segment elevation myocardial infarction; TIMI: Thrombolysis In Myocardial Infarction.

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Alizadeh 2019	Ineligible study design.
Borst 2018	Ineligible setting.
Devereaux 2018	Ineligible population (surgery).
Duceppe 2018	Ineligible population (surgery).
Euctr 2013a	Ineligible indication.
Euctr 2013b	Ineligible setting.
Gao 2015	Ineligible study design.
Greenberg 2018a	Ineligible indication.
Greenberg 2018b	Ineligible indication.
Kopin 2016	Ineligible indication for anticoagulation (atrial fibrillation).
Lee 2018	Ineligible indication for anticoagulation (atrial fibrillation).
Nct 2012	Ineligible setting.
NCT04333407	Ineligible population.
NCT04688723	Ineligible comparator.
NCT04805710	Ineligible indication for anticoagulation (atrial fibrillation).
NCT04838808	Ineligible population.

Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis (Review)

Copyright © 2024 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

Study	Reason for exclusion
Schiele 2018	Ineligible population.
Zannad 2015	Ineligible indication.
Zannad 2018	Ineligible indication.

Characteristics of ongoing studies [ordered by study ID]

NCT03775746

Study name	Can very low dose rivaroxaban in addition to dual antiplatelet therapy (DAPT) Improve thrombotic status in acute coronary syndrome (ACS) ACS (VaLiDate-R)
Methods	Randomised, parallel assignment, open label
Participants	150 participants
Interventions	Clopidogrel 75 mg tablet Rivaroxaban 2.5 mg tablet Ticagrelor 90 mg tablet
Outcomes	Primary outcomes <ul style="list-style-type: none"> Change in lysis time (LT) in the 3 treatment groups assessed using the GTT from admission to follow-up at 30 days, to investigate, in people with recent ACS and who have impaired endogenous fibrinolysis, whether the addition of low dose rivaroxaban to DAPT can improve endogenous thrombotic and fibrinolytic status Secondary outcomes <ul style="list-style-type: none"> Frequency of further angioplasty (Time frame: 6 months) Clinical events including reintervention Frequency of further heart attack, stroke, or death (Time frame: 6 months) Incidence of further major adverse cardiac events
Starting date	8 January 2019
Contact information	East and North Hertfordshire NHS Trust
Notes	Registered at ClinicalTrials.gov (NCT03775746)


ACS: acute coronary syndrome; DAPT: dual antiplatelet therapy; GTT: global thrombosis test.

DATA AND ANALYSES


Comparison 1. NOACs (all doses combined) versus placebo: all-cause mortality

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 All-cause mortality (apixaban versus placebo)	2	8638	Risk Ratio (M-H, Random, 95% CI)	1.09 [0.88, 1.35]
1.2 All-cause mortality (rivaroxaban versus placebo)	3	21870	Risk Ratio (M-H, Random, 95% CI)	0.82 [0.69, 0.98]
1.3 All-cause mortality (dabigatran versus placebo)	1	1861	Risk Ratio (M-H, Random, 95% CI)	0.57 [0.31, 1.06]

Analysis 1.1. Comparison 1: NOACs (all doses combined) versus placebo: all-cause mortality, Outcome 1: All-cause mortality (apixaban versus placebo)



Analysis 1.2. Comparison 1: NOACs (all doses combined) versus placebo: all-cause mortality, Outcome 2: All-cause mortality (rivaroxaban versus placebo)



Analysis 1.3. Comparison 1: NOACs (all doses combined) versus placebo: all-cause mortality, Outcome 3: All-cause mortality (dabigatran versus placebo)

Study or Subgroup	Dabigatran		Placebo		Weight	Risk Ratio	Risk Ratio
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI
REDEEM	32	1490	14	371	100.0%	0.57 [0.31, 1.06]	
Total (95% CI)		1490		371	100.0%	0.57 [0.31, 1.06]	
Total events:	32		14				
Heterogeneity: Not applicable							
Test for overall effect: Z = 1.79 (P = 0.07)							
Test for subgroup differences: Not applicable							

Comparison 2. NOACs (all doses combined) versus placebo: cardiovascular mortality

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.1 Cardiovascular mortality (apixaban versus placebo)	2	8638	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.77, 1.27]
2.2 Cardiovascular mortality (rivaroxaban versus placebo)	3	21870	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.69, 1.01]
2.3 Cardiovascular mortality (dabigatran versus placebo)	1	1861	Risk Ratio (M-H, Random, 95% CI)	0.72 [0.34, 1.52]

Analysis 2.1. Comparison 2: NOACs (all doses combined) versus placebo: cardiovascular mortality, Outcome 1: Cardiovascular mortality (apixaban versus placebo)

Study or Subgroup	Apixaban		Placebo		Weight	Risk Ratio	Risk Ratio
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI
APPRAISE 1	15	635	11	611	10.5%	1.31 [0.61, 2.83]	
APPRAISE 2	105	3705	109	3687	89.5%	0.96 [0.74, 1.25]	
Total (95% CI)		4340		4298	100.0%	0.99 [0.77, 1.27]	
Total events:	120		120				
Heterogeneity: Tau ² = 0.00; Chi ² = 0.57, df = 1 (P = 0.45); I ² = 0%							
Test for overall effect: Z = 0.07 (P = 0.94)							
Test for subgroup differences: Not applicable							

Analysis 2.2. Comparison 2: NOACs (all doses combined) versus placebo: cardiovascular mortality, Outcome 2: Cardiovascular mortality (rivaroxaban versus placebo)

Study or Subgroup	Rivaroxaban		Placebo		Weight	Risk Ratio	Risk Ratio
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI
ATLAS ACS	28	2331	13	1160	8.3%	1.07 [0.56, 2.06]	
ATLAS ACS 2	226	10229	143	5113	83.3%	0.79 [0.64, 0.97]	
GEMINI-ACS	19	1519	17	1518	8.4%	1.12 [0.58, 2.14]	
Total (95% CI)		14079		7791	100.0%	0.83 [0.69, 1.01]	
Total events:		273	173				
Heterogeneity: Tau ² = 0.00; Chi ² = 1.61, df = 2 (P = 0.45); I ² = 0%							
Test for overall effect: Z = 1.88 (P = 0.06)							
Test for subgroup differences: Not applicable							


Analysis 2.3. Comparison 2: NOACs (all doses combined) versus placebo: cardiovascular mortality, Outcome 3: Cardiovascular mortality (dabigatran versus placebo)

Study or Subgroup	Dabigatran		Placebo		Weight	Risk Ratio	Risk Ratio
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI
REDEEM	26	1490	9	371	100.0%	0.72 [0.34, 1.52]	
Total (95% CI)		1490		371	100.0%	0.72 [0.34, 1.52]	
Total events:		26	9				
Heterogeneity: Not applicable							
Test for overall effect: Z = 0.86 (P = 0.39)							
Test for subgroup differences: Not applicable							


Comparison 3. NOACs (all doses combined) versus placebo: major bleeding

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.1 Major bleeding (apixaban versus placebo)	2	8544	Risk Ratio (M-H, Random, 95% CI)	2.41 [1.44, 4.06]
3.2 Major bleeding (rivaroxaban versus placebo)	3	21870	Risk Ratio (M-H, Random, 95% CI)	3.31 [1.12, 9.77]
3.3 Major bleeding (dabigatran versus placebo)	1	1861	Risk Ratio (M-H, Random, 95% CI)	1.74 [0.22, 14.12]


Analysis 3.1. Comparison 3: NOACs (all doses combined) versus placebo: major bleeding, Outcome 1: Major bleeding (apixaban versus placebo)



Analysis 3.2. Comparison 3: NOACs (all doses combined) versus placebo: major bleeding, Outcome 2: Major bleeding (rivaroxaban versus placebo)



Analysis 3.3. Comparison 3: NOACs (all doses combined) versus placebo: major bleeding, Outcome 3: Major bleeding (dabigatran versus placebo)




Comparison 4. Apixaban (different doses) versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.1 All-cause mortality	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.1.1 Apixaban 5 mg versus placebo	1	928	Risk Ratio (M-H, Random, 95% CI)	1.77 [0.79, 3.96]
4.1.2 Apixaban 10 mg versus placebo	2	8321	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.86, 1.32]
4.1.3 Apixaban total versus placebo	2	8638	Risk Ratio (M-H, Random, 95% CI)	1.09 [0.88, 1.35]
4.2 Cardiovascular mortality	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
4.2.1 Apixaban 5 mg versus placebo	1	928	Risk Ratio (M-H, Random, 95% CI)	1.93 [0.84, 4.40]
4.2.2 Apixaban 10 mg versus placebo	2	8321	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.73, 1.22]
4.2.3 Apixaban total versus placebo	2	8638	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.77, 1.27]
4.3 Major bleeding	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
4.3.1 Apixaban 5 mg versus placebo	1	914	Risk Ratio (M-H, Random, 95% CI)	0.38 [0.02, 7.89]
4.3.2 Apixaban 10 mg versus placebo	2	8229	Risk Ratio (M-H, Random, 95% CI)	2.56 [1.52, 4.30]
4.3.3 Apixaban total versus placebo	2	8544	Risk Ratio (M-H, Random, 95% CI)	2.41 [1.44, 4.06]
4.4 Myocardial infarction	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
4.4.1 Apixaban 5 mg versus placebo	1	928	Risk Ratio (M-H, Random, 95% CI)	0.67 [0.29, 1.58]
4.4.2 Apixaban 10 mg versus placebo	2	8321	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.71, 1.14]
4.4.3 Apixaban total versus placebo	2	8638	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.67, 1.16]
4.5 Stroke	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
4.5.1 Apixaban 5 mg versus placebo	1	928	Risk Ratio (M-H, Random, 95% CI)	0.38 [0.02, 7.99]
4.5.2 Apixaban 10 mg versus placebo	2	8321	Risk Ratio (M-H, Random, 95% CI)	0.68 [0.41, 1.15]
4.5.3 Apixaban total versus placebo	2	8638	Risk Ratio (M-H, Random, 95% CI)	0.66 [0.40, 1.11]
4.6 Stent thrombosis	1	7392	Risk Ratio (M-H, Random, 95% CI)	0.73 [0.47, 1.12]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.6.1 Apixaban 10 mg versus placebo	1	7392	Risk Ratio (M-H, Random, 95% CI)	0.73 [0.47, 1.12]
4.7 Non-major bleeding	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
4.7.1 Apixaban 5 mg versus placebo	1	914	Risk Ratio (M-H, Random, 95% CI)	1.90 [0.39, 9.37]
4.7.2 apixaban 10mg versus placebo	2	8229	Risk Ratio (M-H, Random, 95% CI)	2.74 [1.45, 5.17]
4.7.3 apixaban total versus placebo	2	8544	Risk Ratio (M-H, Random, 95% CI)	2.71 [1.47, 5.01]

Analysis 4.1. Comparison 4: Apixaban (different doses) versus placebo, Outcome 1: All-cause mortality




Analysis 4.2. Comparison 4: Apixaban (different doses) versus placebo, Outcome 2: Cardiovascular mortality




0.01 0.1 1 10 100
Favours apixaban Favours placebo


Analysis 4.3. Comparison 4: Apixaban (different doses) versus placebo, Outcome 3: Major bleeding




Analysis 4.4. Comparison 4: Apixaban (different doses) versus placebo, Outcome 4: Myocardial infarction




Analysis 4.5. Comparison 4: Apixaban (different doses) versus placebo, Outcome 5: Stroke



Analysis 4.6. Comparison 4: Apixaban (different doses) versus placebo, Outcome 6: Stent thrombosis



Analysis 4.7. Comparison 4: Apixaban (different doses) versus placebo, Outcome 7: Non-major bleeding



Comparison 5. Rivaroxaban (different doses) versus placebo


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5.1 All-cause mortality	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
5.1.1 Rivaroxaban 5 mg versus placebo	3	14732	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.55, 1.82]
5.1.2 Rivaroxaban 10 mg versus placebo	2	12444	Risk Ratio (M-H, Random, 95% CI)	0.84 [0.56, 1.26]
5.1.3 Rivaroxaban 15 mg versus placebo	1	1516	Risk Ratio (M-H, Random, 95% CI)	0.61 [0.18, 2.08]
5.1.4 Rivaroxaban 20 mg versus placebo	1	1771	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.47, 2.40]
5.1.5 Rivaroxaban total versus placebo	3	21870	Risk Ratio (M-H, Random, 95% CI)	0.82 [0.69, 0.98]
5.2 Cardiovascular mortality	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5.2.1 Rivaroxaban 5 mg versus placebo	3	14732	Risk Ratio (M-H, Random, 95% CI)	1.14 [0.53, 2.44]
5.2.2 Rivaroxaban 10 mg versus placebo	2	12444	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.72, 1.13]
5.2.3 Rivaroxaban 15 mg versus placebo	1	1516	Risk Ratio (M-H, Random, 95% CI)	0.75 [0.22, 2.62]
5.2.4 Rivaroxaban 20 mg versus placebo	1	1771	Risk Ratio (M-H, Random, 95% CI)	1.17 [0.49, 2.80]
5.2.5 Rivaroxaban total versus placebo	3	21870	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.69, 1.01]
5.3 Major bleeding	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
5.3.1 Rivaroxaban 5 mg versus placebo	3	14732	Risk Ratio (M-H, Random, 95% CI)	2.39 [1.11, 5.16]
5.3.2 Rivaroxaban 10 mg versus placebo	2	12444	Risk Ratio (M-H, Random, 95% CI)	6.17 [1.83, 20.85]
5.3.3 Rivaroxaban 15 mg versus placebo	1	1516	Risk Ratio (M-H, Random, 95% CI)	19.55 [2.36, 161.85]
5.3.4 Rivaroxaban 20 mg versus placebo	1	1771	Risk Ratio (M-H, Random, 95% CI)	15.19 [1.90, 121.15]
5.3.5 Rivaroxaban total versus placebo	3	21870	Risk Ratio (M-H, Random, 95% CI)	3.31 [1.12, 9.77]
5.4 Myocardial infarction	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
5.4.1 Rivaroxaban 5 mg versus placebo	3	14732	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.81, 1.11]
5.4.2 Rivaroxaban 10 mg versus placebo	2	12444	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.65, 0.92]
5.4.3 Rivaroxaban 15 mg versus placebo	1	1516	Risk Ratio (M-H, Random, 95% CI)	1.11 [0.64, 1.93]
5.4.4 Rivaroxaban 20 mg versus placebo	1	1771	Risk Ratio (M-H, Random, 95% CI)	0.69 [0.40, 1.19]
5.4.5 Rivaroxaban total versus placebo	3	21870	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.75, 1.03]
5.5 Stroke	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5.5.1 Rivaroxaban 5 mg versus placebo	3	14732	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.68, 1.44]
5.5.2 Rivaroxaban 10 mg versus placebo	2	12444	Risk Ratio (M-H, Random, 95% CI)	1.25 [0.85, 1.83]
5.5.3 Rivaroxaban 15 mg versus placebo	1	1516	Risk Ratio (M-H, Random, 95% CI)	0.25 [0.01, 4.43]
5.5.4 Rivaroxaban 20 mg versus placebo	1	1771	Risk Ratio (M-H, Random, 95% CI)	0.32 [0.04, 2.62]
5.5.5 Rivaroxaban total versus placebo	3	21870	Risk Ratio (M-H, Random, 95% CI)	0.84 [0.45, 1.55]
5.6 Stent thrombosis	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
5.6.1 Rivaroxaban 5 mg versus placebo	2	13264	Risk Ratio (M-H, Random, 95% CI)	0.76 [0.49, 1.19]
5.6.2 Rivaroxaban 10 mg versus placebo	1	10228	Risk Ratio (M-H, Random, 95% CI)	0.71 [0.50, 1.01]
5.6.3 Rivaroxaban total versus placebo	2	18379	Risk Ratio (M-H, Random, 95% CI)	0.76 [0.52, 1.12]
5.7 Non-major bleeding	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
5.7.1 Rivaroxaban 5 mg versus placebo	3	14732	Risk Ratio (M-H, Random, 95% CI)	1.71 [1.04, 2.80]
5.7.2 Rivaroxaban 10 mg versus placebo	2	12444	Risk Ratio (M-H, Random, 95% CI)	2.52 [1.54, 4.13]
5.7.3 Rivaroxaban 15 mg versus placebo	1	1516	Risk Ratio (M-H, Random, 95% CI)	6.52 [1.20, 35.43]
5.7.4 Rivaroxaban 20 mg versus placebo	1	1771	Risk Ratio (M-H, Random, 95% CI)	4.75 [0.92, 24.39]
5.7.5 Rivaroxaban total versus placebo	3	21870	Risk Ratio (M-H, Random, 95% CI)	2.18 [1.41, 3.35]
5.8 Systemic embolism	1		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
5.8.1 Rivaroxaban 5 mg versus placebo	1	1468	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.03, 10.36]
5.8.2 Rivaroxaban 10 mg versus placebo	1	2216	Risk Ratio (M-H, Random, 95% CI)	0.16 [0.01, 3.03]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5.8.3 Rivaroxaban 15 mg versus placebo	1	1516	Risk Ratio (M-H, Random, 95% CI)	0.46 [0.02, 8.97]
5.8.4 Rivaroxaban 20 mg versus placebo	1	1771	Risk Ratio (M-H, Random, 95% CI)	0.27 [0.01, 5.24]
5.8.5 Rivaroxaban total versus placebo	1	3491	Risk Ratio (M-H, Random, 95% CI)	0.07 [0.00, 1.38]


Analysis 5.1. Comparison 5: Rivaroxaban (different doses) versus placebo, Outcome 1: All-cause mortality




Analysis 5.2. Comparison 5: Rivaroxaban (different doses) versus placebo, Outcome 2: Cardiovascular mortality



Analysis 5.3. Comparison 5: Rivaroxaban (different doses) versus placebo, Outcome 3: Major bleeding




Analysis 5.4. Comparison 5: Rivaroxaban (different doses) versus placebo, Outcome 4: Myocardial infarction




0.01 0.1 1 10 100
Favours rivaroxaban Favours placebo


Analysis 5.5. Comparison 5: Rivaroxaban (different doses) versus placebo, Outcome 5: Stroke




Analysis 5.6. Comparison 5: Rivaroxaban (different doses) versus placebo, Outcome 6: Stent thrombosis



Analysis 5.7. Comparison 5: Rivaroxaban (different doses) versus placebo, Outcome 7: Non-major bleeding



Analysis 5.8. Comparison 5: Rivaroxaban (different doses) versus placebo, Outcome 8: Systemic embolism



0.01 0.1 1 10 100
Favours rivaroxaban Favours placebo


Comparison 6. Dabigatran (different doses) versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
6.1 All-cause mortality	1		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
6.1.1 Dabigatran 50 mg BD versus placebo	1	740	Risk Ratio (M-H, Random, 95% CI)	0.57 [0.24, 1.35]
6.1.2 Dabigatran 75 mg BD versus placebo	1	739	Risk Ratio (M-H, Random, 95% CI)	0.72 [0.32, 1.60]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
6.1.3 Dabigatran 110 mg BD versus placebo	1	777	Risk Ratio (M-H, Random, 95% CI)	0.46 [0.19, 1.12]
6.1.4 Dabigatran 150 mg BD versus placebo	1	718	Risk Ratio (M-H, Random, 95% CI)	0.53 [0.22, 1.31]
6.1.5 Dabigatran total versus placebo	1	1861	Risk Ratio (M-H, Random, 95% CI)	0.57 [0.31, 1.06]
6.2 Cardiovascular mortality	1		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
6.2.1 Dabigatran 50 mg BD versus placebo	1	740	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.35, 2.29]
6.2.2 Dabigatran 75 mg BD versus placebo	1	739	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.40, 2.51]
6.2.3 Dabigatran 110 mg BD versus placebo	1	777	Risk Ratio (M-H, Random, 95% CI)	0.51 [0.17, 1.50]
6.2.4 Dabigatran 150 mg BD versus placebo	1	718	Risk Ratio (M-H, Random, 95% CI)	0.48 [0.15, 1.53]
6.2.5 Dabigatran total versus placebo	1	1861	Risk Ratio (M-H, Random, 95% CI)	0.72 [0.34, 1.52]
6.3 Major bleeding	1		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
6.3.1 Dabigatran 50 mg BD versus placebo	1	740	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.06, 16.01]
6.3.2 Dabigatran 75 mg BD versus placebo	1	739	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.01, 8.22]
6.3.3 Dabigatran 110 mg BD versus placebo	1	777	Risk Ratio (M-H, Random, 95% CI)	4.57 [0.54, 38.93]
6.3.4 Dabigatran 150 mg BD versus placebo	1	718	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.07, 17.03]
6.3.5 Dabigatran total versus placebo	1	1861	Risk Ratio (M-H, Random, 95% CI)	1.74 [0.22, 14.12]
6.4 Myocardial infarction	1		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
6.4.1 Dabigatran 50 mg BD versus placebo	1	740	Risk Ratio (M-H, Random, 95% CI)	2.26 [0.70, 7.28]
6.4.2 Dabigatran 75 mg BD versus placebo	1	739	Risk Ratio (M-H, Random, 95% CI)	2.02 [0.61, 6.64]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
6.4.3 Dabigatran 110 mg BD versus placebo	1	777	Risk Ratio (M-H, Random, 95% CI)	1.60 [0.47, 5.42]
6.4.4 Dabigatran 150 mg BD versus placebo	1	718	Risk Ratio (M-H, Random, 95% CI)	2.14 [0.65, 7.04]
6.4.5 Dabigatran total versus placebo	1	1861	Risk Ratio (M-H, Random, 95% CI)	1.99 [0.71, 5.60]
6.5 Stroke	1		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
6.5.1 Dabigatran 50 mg BD versus placebo	1	740	Risk Ratio (M-H, Random, 95% CI)	0.14 [0.01, 2.77]
6.5.2 Dabigatran 75 mg BD versus placebo	1	739	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.04, 3.22]
6.5.3 Dabigatran 110 mg BD versus placebo	1	777	Risk Ratio (M-H, Random, 95% CI)	0.13 [0.01, 2.52]
6.5.4 Dabigatran 150 mg BD versus placebo	1	718	Risk Ratio (M-H, Random, 95% CI)	0.15 [0.01, 2.95]
6.5.5 Dabigatran versus placebo	1	1861	Risk Ratio (M-H, Random, 95% CI)	0.08 [0.01, 0.80]


Analysis 6.1. Comparison 6: Dabigatran (different doses) versus placebo, Outcome 1: All-cause mortality




Analysis 6.2. Comparison 6: Dabigatran (different doses) versus placebo, Outcome 2: Cardiovascular mortality




Analysis 6.3. Comparison 6: Dabigatran (different doses) versus placebo, Outcome 3: Major bleeding



Analysis 6.4. Comparison 6: Dabigatran (different doses) versus placebo, Outcome 4: Myocardial infarction



Analysis 6.5. Comparison 6: Dabigatran (different doses) versus placebo, Outcome 5: Stroke




Comparison 7. Apixaban 5 mg versus apixaban 10 mg


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
7.1 All-cause mortality	1	635	Risk Ratio (M-H, Random, 95% CI)	2.21 [0.78, 6.28]
7.2 Cardiovascular mortality	1	635	Risk Ratio (M-H, Random, 95% CI)	2.76 [0.89, 8.57]
7.3 Major bleeding	1	630	Risk Ratio (M-H, Random, 95% CI)	0.14 [0.01, 2.75]
7.4 Myocardial infarction	1	635	Risk Ratio (M-H, Random, 95% CI)	1.17 [0.40, 3.44]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
7.5 Stroke	1	635	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.01, 8.18]
7.6 Non-major bleeding	1	630	Risk Ratio (M-H, Random, 95% CI)	1.50 [0.25, 8.92]


Analysis 7.1. Comparison 7: Apixaban 5 mg versus apixaban 10 mg, Outcome 1: All-cause mortality




Analysis 7.2. Comparison 7: Apixaban 5 mg versus apixaban 10 mg, Outcome 2: Cardiovascular mortality




Analysis 7.3. Comparison 7: Apixaban 5 mg versus apixaban 10 mg, Outcome 3: Major bleeding




Analysis 7.4. Comparison 7: Apixaban 5 mg versus apixaban 10 mg, Outcome 4: Myocardial infarction



Analysis 7.5. Comparison 7: Apixaban 5 mg versus apixaban 10 mg, Outcome 5: Stroke



Analysis 7.6. Comparison 7: Apixaban 5 mg versus apixaban 10 mg, Outcome 6: Non-major bleeding




Comparison 8. Rivaroxaban 5 mg versus rivaroxaban 10 mg


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
8.1 All-cause mortality	2	11593	Risk Ratio (M-H, Random, 95% CI)	1.57 [0.31, 8.03]
8.2 Cardiovascular mortality	2	11593	Risk Ratio (M-H, Random, 95% CI)	1.56 [0.30, 8.11]
8.3 Major bleeding	2	11593	Risk Ratio (M-H, Random, 95% CI)	0.61 [0.21, 1.72]
8.4 Myocardial infarction	2	11593	Risk Ratio (M-H, Random, 95% CI)	1.17 [0.97, 1.41]
8.5 Stroke	2	11593	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.58, 1.25]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
8.6 Stent thrombosis	1	10229	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.62, 1.37]
8.7 Non-major bleeding	2	11593	Risk Ratio (M-H, Random, 95% CI)	0.65 [0.42, 1.00]


Analysis 8.1. Comparison 8: Rivaroxaban 5 mg versus rivaroxaban 10 mg, Outcome 1: All-cause mortality




Analysis 8.2. Comparison 8: Rivaroxaban 5 mg versus rivaroxaban 10 mg, Outcome 2: Cardiovascular mortality




Analysis 8.3. Comparison 8: Rivaroxaban 5 mg versus rivaroxaban 10 mg, Outcome 3: Major bleeding




Analysis 8.4. Comparison 8: Rivaroxaban 5 mg versus rivaroxaban 10 mg, Outcome 4: Myocardial infarction




Analysis 8.5. Comparison 8: Rivaroxaban 5 mg versus rivaroxaban 10 mg, Outcome 5: Stroke



Analysis 8.6. Comparison 8: Rivaroxaban 5 mg versus rivaroxaban 10 mg, Outcome 6: Stent thrombosis




Analysis 8.7. Comparison 8: Rivaroxaban 5 mg versus rivaroxaban 10 mg, Outcome 7: Non-major bleeding




Comparison 9. Rivaroxaban 5 mg versus rivaroxaban 15 mg

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
9.1 All-cause mortality	1	664	Risk Ratio (M-H, Random, 95% CI)	3.47 [0.95, 12.69]
9.2 Cardiovascular mortality	1	664	Risk Ratio (M-H, Random, 95% CI)	3.47 [0.95, 12.69]
9.3 Major bleeding	1	664	Risk Ratio (M-H, Random, 95% CI)	0.19 [0.02, 1.59]
9.4 Myocardial infarction	1	664	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.46, 1.92]
9.5 Stroke	1	664	Risk Ratio (M-H, Random, 95% CI)	3.47 [0.14, 84.77]
9.6 Non-major bleeding	1	664	Risk Ratio (M-H, Random, 95% CI)	0.29 [0.03, 2.57]


Analysis 9.1. Comparison 9: Rivaroxaban 5 mg versus rivaroxaban 15 mg, Outcome 1: All-cause mortality




Analysis 9.2. Comparison 9: Rivaroxaban 5 mg versus rivaroxaban 15 mg, Outcome 2: Cardiovascular mortality




Analysis 9.3. Comparison 9: Rivaroxaban 5 mg versus rivaroxaban 15 mg, Outcome 3: Major bleeding




Analysis 9.4. Comparison 9: Rivaroxaban 5 mg versus rivaroxaban 15 mg, Outcome 4: Myocardial infarction



Analysis 9.5. Comparison 9: Rivaroxaban 5 mg versus rivaroxaban 15 mg, Outcome 5: Stroke



Analysis 9.6. Comparison 9: Rivaroxaban 5 mg versus rivaroxaban 15 mg, Outcome 6: Non-major bleeding




Comparison 10. Rivaroxaban 5 mg versus rivaroxaban 20 mg


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
10.1 All-cause mortality	1	919	Risk Ratio (M-H, Random, 95% CI)	1.98 [0.80, 4.95]
10.2 Cardiovascular mortality	1	919	Risk Ratio (M-H, Random, 95% CI)	2.23 [0.87, 5.73]
10.3 Major bleeding	1	919	Risk Ratio (M-H, Random, 95% CI)	0.25 [0.03, 1.97]
10.4 Myocardial infarction	1	919	Risk Ratio (M-H, Random, 95% CI)	1.52 [0.75, 3.08]
10.5 Stroke	1	919	Risk Ratio (M-H, Random, 95% CI)	1.98 [0.12, 31.61]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
10.6 Non-major bleeding	1	919	Risk Ratio (M-H, Random, 95% CI)	0.40 [0.05, 3.38]


Analysis 10.1. Comparison 10: Rivaroxaban 5 mg versus rivaroxaban 20 mg, Outcome 1: All-cause mortality




Analysis 10.2. Comparison 10: Rivaroxaban 5 mg versus rivaroxaban 20 mg, Outcome 2: Cardiovascular mortality




Analysis 10.3. Comparison 10: Rivaroxaban 5 mg versus rivaroxaban 20 mg, Outcome 3: Major bleeding




Analysis 10.4. Comparison 10: Rivaroxaban 5 mg versus rivaroxaban 20 mg, Outcome 4: Myocardial infarction



Analysis 10.5. Comparison 10: Rivaroxaban 5 mg versus rivaroxaban 20 mg, Outcome 5: Stroke




Analysis 10.6. Comparison 10: Rivaroxaban 5 mg versus rivaroxaban 20 mg, Outcome 6: Non-major bleeding




Comparison 11. Rivaroxaban 10 mg versus rivaroxaban 15 mg

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
11.1 All-cause mortality	1	1412	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.24, 3.37]
11.2 Cardiovascular mortality	1	1412	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.24, 3.37]
11.3 Major bleeding	1	1412	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.35, 2.28]
11.4 Myocardial infarction	1	1412	Risk Ratio (M-H, Random, 95% CI)	0.65 [0.36, 1.18]
11.5 Stroke	1	1412	Risk Ratio (M-H, Random, 95% CI)	3.04 [0.16, 56.32]
11.6 Non-major bleeding	1	1412	Risk Ratio (M-H, Random, 95% CI)	0.51 [0.14, 1.78]


Analysis 11.1. Comparison 11: Rivaroxaban 10 mg versus rivaroxaban 15 mg, Outcome 1: All-cause mortality




Analysis 11.2. Comparison 11: Rivaroxaban 10 mg versus rivaroxaban 15 mg, Outcome 2: Cardiovascular mortality




Analysis 11.3. Comparison 11: Rivaroxaban 10 mg versus rivaroxaban 15 mg, Outcome 3: Major bleeding




Analysis 11.4. Comparison 11: Rivaroxaban 10 mg versus rivaroxaban 15 mg, Outcome 4: Myocardial infarction



Analysis 11.5. Comparison 11: Rivaroxaban 10 mg versus rivaroxaban 15 mg, Outcome 5: Stroke




Analysis 11.6. Comparison 11: Rivaroxaban 10 mg versus rivaroxaban 15 mg, Outcome 6: Non-major bleeding




Comparison 12. Rivaroxaban 10 mg versus rivaroxaban 20 mg

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
12.1 All-cause mortality	1	1667	Risk Ratio (M-H, Random, 95% CI)	0.51 [0.20, 1.33]
12.2 Cardiovascular mortality	1	1667	Risk Ratio (M-H, Random, 95% CI)	0.58 [0.22, 1.53]
12.3 Major bleeding	1	1667	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.50, 2.69]
12.4 Myocardial infarction	1	1667	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.59, 1.89]
12.5 Stroke	1	1667	Risk Ratio (M-H, Random, 95% CI)	2.31 [0.26, 20.66]
12.6 Non-major bleeding	1	1667	Risk Ratio (M-H, Random, 95% CI)	0.69 [0.21, 2.27]


Analysis 12.1. Comparison 12: Rivaroxaban 10 mg versus rivaroxaban 20 mg, Outcome 1: All-cause mortality




Analysis 12.2. Comparison 12: Rivaroxaban 10 mg versus rivaroxaban 20 mg, Outcome 2: Cardiovascular mortality




Analysis 12.3. Comparison 12: Rivaroxaban 10 mg versus rivaroxaban 20 mg, Outcome 3: Major bleeding




Analysis 12.4. Comparison 12: Rivaroxaban 10 mg versus rivaroxaban 20 mg, Outcome 4: Myocardial infarction



Analysis 12.5. Comparison 12: Rivaroxaban 10 mg versus rivaroxaban 20 mg, Outcome 5: Stroke




Analysis 12.6. Comparison 12: Rivaroxaban 10 mg versus rivaroxaban 20 mg, Outcome 6: Non-major bleeding




Comparison 13. Rivaroxaban 15 mg versus rivaroxaban 20 mg

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
13.1 All-cause mortality	1	967	Risk Ratio (M-H, Random, 95% CI)	0.57 [0.16, 2.10]
13.2 Cardiovascular mortality	1	967	Risk Ratio (M-H, Random, 95% CI)	0.64 [0.17, 2.41]
13.3 Major bleeding	1	967	Risk Ratio (M-H, Random, 95% CI)	1.29 [0.45, 3.68]
13.4 Myocardial infarction	1	967	Risk Ratio (M-H, Random, 95% CI)	1.62 [0.83, 3.16]
13.5 Stroke	1	967	Risk Ratio (M-H, Random, 95% CI)	0.57 [0.02, 13.99]
13.6 Non-major bleeding	1	967	Risk Ratio (M-H, Random, 95% CI)	1.37 [0.37, 5.08]


Analysis 13.1. Comparison 13: Rivaroxaban 15 mg versus rivaroxaban 20 mg, Outcome 1: All-cause mortality




Analysis 13.2. Comparison 13: Rivaroxaban 15 mg versus rivaroxaban 20 mg, Outcome 2: Cardiovascular mortality




Analysis 13.3. Comparison 13: Rivaroxaban 15 mg versus rivaroxaban 20 mg, Outcome 3: Major bleeding




Analysis 13.4. Comparison 13: Rivaroxaban 15 mg versus rivaroxaban 20 mg, Outcome 4: Myocardial infarction



Analysis 13.5. Comparison 13: Rivaroxaban 15 mg versus rivaroxaban 20 mg, Outcome 5: Stroke




Analysis 13.6. Comparison 13: Rivaroxaban 15 mg versus rivaroxaban 20 mg, Outcome 6: Non-major bleeding




Comparison 14. Dabigatran 50 mg BD versus dabigatran 75 mg BD

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
14.1 All-cause mortality	1	737	Risk Ratio (M-H, Random, 95% CI)	0.80 [0.32, 2.00]
14.2 Cardiovascular mortality	1	737	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.35, 2.27]
14.3 Major bleeding	1	737	Risk Ratio (M-H, Random, 95% CI)	2.99 [0.12, 73.21]
14.4 Myocardial infarction	1	737	Risk Ratio (M-H, Random, 95% CI)	1.12 [0.44, 2.88]
14.5 Stroke	1	737	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.01, 8.13]


Analysis 14.1. Comparison 14: Dabigatran 50 mg BD versus dabigatran 75 mg BD, Outcome 1: All-cause mortality




Analysis 14.2. Comparison 14: Dabigatran 50 mg BD versus dabigatran 75 mg BD, Outcome 2: Cardiovascular mortality




Analysis 14.3. Comparison 14: Dabigatran 50 mg BD versus dabigatran 75 mg BD, Outcome 3: Major bleeding



Analysis 14.4. Comparison 14: Dabigatran 50 mg BD versus dabigatran 75 mg BD, Outcome 4: Myocardial infarction




Analysis 14.5. Comparison 14: Dabigatran 50 mg BD versus dabigatran 75 mg BD, Outcome 5: Stroke




Comparison 15. Dabigatran 50 mg BD versus dabigatran 110 mg BD

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
15.1 All-cause mortality	1	775	Risk Ratio (M-H, Random, 95% CI)	1.26 [0.46, 3.43]
15.2 Cardiovascular mortality	1	775	Risk Ratio (M-H, Random, 95% CI)	1.76 [0.58, 5.33]
15.3 Major bleeding	1	775	Risk Ratio (M-H, Random, 95% CI)	0.22 [0.03, 1.87]
15.4 Myocardial infarction	1	775	Risk Ratio (M-H, Random, 95% CI)	1.41 [0.53, 3.76]
15.5 Stroke	1	775	Risk Ratio (M-H, Random, 95% CI)	Not estimable


Analysis 15.1. Comparison 15: Dabigatran 50 mg BD versus dabigatran 110 mg BD, Outcome 1: All-cause mortality




Analysis 15.2. Comparison 15: Dabigatran 50 mg BD versus dabigatran 110 mg BD, Outcome 2: Cardiovascular mortality




Analysis 15.3. Comparison 15: Dabigatran 50 mg BD versus dabigatran 110 mg BD, Outcome 3: Major bleeding



Analysis 15.4. Comparison 15: Dabigatran 50 mg BD versus dabigatran 110 mg BD, Outcome 4: Myocardial infarction



Analysis 15.5. Comparison 15: Dabigatran 50 mg BD versus dabigatran 110 mg BD, Outcome 5: Stroke




Comparison 16. Dabigatran 50 mg BD versus dabigatran 150 mg BD


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
16.1 All-cause mortality	1	716	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.39, 2.93]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
16.2 Cardiovascular mortality	1	716	Risk Ratio (M-H, Random, 95% CI)	1.88 [0.57, 6.19]
16.3 Major bleeding	1	716	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.06, 14.98]
16.4 Myocardial infarction	1	716	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.41, 2.71]
16.5 Stroke	1	716	Risk Ratio (M-H, Random, 95% CI)	Not estimable


Analysis 16.1. Comparison 16: Dabigatran 50 mg BD versus dabigatran 150 mg BD, Outcome 1: All-cause mortality




Analysis 16.2. Comparison 16: Dabigatran 50 mg BD versus dabigatran 150 mg BD, Outcome 2: Cardiovascular mortality




Analysis 16.3. Comparison 16: Dabigatran 50 mg BD versus dabigatran 150 mg BD, Outcome 3: Major bleeding



Analysis 16.4. Comparison 16: Dabigatran 50 mg BD versus dabigatran 150 mg BD, Outcome 4: Myocardial infarction




Analysis 16.5. Comparison 16: Dabigatran 50 mg BD versus dabigatran 150 mg BD, Outcome 5: Stroke




Comparison 17. Dabigatran 75 mg BD versus dabigatran 110 mg BD

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
17.1 All-cause mortality	1	774	Risk Ratio (M-H, Random, 95% CI)	1.58 [0.61, 4.10]
17.2 Cardiovascular mortality	1	774	Risk Ratio (M-H, Random, 95% CI)	1.99 [0.67, 5.87]
17.3 Major bleeding	1	774	Risk Ratio (M-H, Random, 95% CI)	0.10 [0.01, 1.81]
17.4 Myocardial infarction	1	774	Risk Ratio (M-H, Random, 95% CI)	1.26 [0.46, 3.44]
17.5 Stroke	1	774	Risk Ratio (M-H, Random, 95% CI)	3.31 [0.14, 80.97]


Analysis 17.1. Comparison 17: Dabigatran 75 mg BD versus dabigatran 110 mg BD, Outcome 1: All-cause mortality




Analysis 17.2. Comparison 17: Dabigatran 75 mg BD versus dabigatran 110 mg BD, Outcome 2: Cardiovascular mortality




Analysis 17.3. Comparison 17: Dabigatran 75 mg BD versus dabigatran 110 mg BD, Outcome 3: Major bleeding



Analysis 17.4. Comparison 17: Dabigatran 75 mg BD versus dabigatran 110 mg BD, Outcome 4: Myocardial infarction



Analysis 17.5. Comparison 17: Dabigatran 75 mg BD versus dabigatran 110 mg BD, Outcome 5: Stroke




Comparison 18. Dabigatran 75 mg BD versus dabigatran 150 mg BD


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
18.1 All-cause mortality	1	715	Risk Ratio (M-H, Random, 95% CI)	1.35 [0.52, 3.50]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
18.2 Cardiovascular mortality	1	715	Risk Ratio (M-H, Random, 95% CI)	2.12 [0.66, 6.83]
18.3 Major bleeding	1	715	Risk Ratio (M-H, Random, 95% CI)	0.31 [0.01, 7.69]
18.4 Myocardial infarction	1	715	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.36, 2.48]
18.5 Stroke	1	715	Risk Ratio (M-H, Random, 95% CI)	2.83 [0.12, 69.22]


Analysis 18.1. Comparison 18: Dabigatran 75 mg BD versus dabigatran 150 mg BD, Outcome 1: All-cause mortality




Analysis 18.2. Comparison 18: Dabigatran 75 mg BD versus dabigatran 150 mg BD, Outcome 2: Cardiovascular mortality




Analysis 18.3. Comparison 18: Dabigatran 75 mg BD versus dabigatran 150 mg BD, Outcome 3: Major bleeding



Analysis 18.4. Comparison 18: Dabigatran 75 mg BD versus dabigatran 150 mg BD, Outcome 4: Myocardial infarction




Analysis 18.5. Comparison 18: Dabigatran 75 mg BD versus dabigatran 150 mg BD, Outcome 5: Stroke




Comparison 19. Dabigatran 110 mg BD versus dabigatran 150 mg BD

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
19.1 All-cause mortality	1	753	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.30, 2.41]
19.2 Cardiovascular mortality	1	753	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.29, 3.95]
19.3 Major bleeding	1	753	Risk Ratio (M-H, Random, 95% CI)	4.27 [0.50, 36.40]
19.4 Myocardial infarction	1	753	Risk Ratio (M-H, Random, 95% CI)	0.75 [0.27, 2.04]
19.5 Stroke	1	753	Risk Ratio (M-H, Random, 95% CI)	Not estimable


Analysis 19.1. Comparison 19: Dabigatran 110 mg BD versus dabigatran 150 mg BD, Outcome 1: All-cause mortality




Analysis 19.2. Comparison 19: Dabigatran 110 mg BD versus dabigatran 150 mg BD, Outcome 2: Cardiovascular mortality




Analysis 19.3. Comparison 19: Dabigatran 110 mg BD versus dabigatran 150 mg BD, Outcome 3: Major bleeding



Analysis 19.4. Comparison 19: Dabigatran 110 mg BD versus dabigatran 150 mg BD, Outcome 4: Myocardial infarction



Analysis 19.5. Comparison 19: Dabigatran 110 mg BD versus dabigatran 150 mg BD, Outcome 5: Stroke



ADDITIONAL TABLES

Table 1. League table – all-cause mortality

Pairwise meta-analysis

Table 1. League table – all-cause mortality (Continued)

Placebo	1.09 (0.88 to 1.35)	0.82 (0.69 to 0.98)	0.57 (0.31 to 1.06)
1.09 (0.88 to 1.35)	Apixaban	—	—
0.82 (0.69 to 0.98)	1.33 (1.01 to 1.76)	Rivaroxaban	—
0.57 (0.31 to 1.06)	1.92 (1.00 to 3.70)	1.45 (0.76 to 2.75)	Dabigatran
Network meta-analysis			

Comparisons between treatments should be read from left to right, and the estimate is in the cell in common between the column-defining treatment and the row-defining treatment. The upper triangle presents the results from direct (pairwise) meta-analyses, and the lower triangle presents the results from the NMA. The lower triangle contains the RRs of the NMA (mixed) effect estimates comparing the treatment in the row versus the treatment in the column, whereas cells in the upper triangle refer to the RR direct effect estimates comparing the treatment in the column versus the treatment in the row. If the (mixed or direct) RR for A versus B is available, the B versus A comparison can be easily calculated as 1/RR (the inverse of the estimated effect). Results are presented as RR (95% CI), where an RR < 1 favours the row-defining treatment. The order of treatments in the diagonal is arbitrary and does not reflect ranking. CI: confidence interval; NMA: network meta-analysis; RR: risk ratio.

Table 2. League table – cardiovascular mortality

Pairwise meta-analysis			
Placebo	0.99 (0.77 to 1.27)	0.83 (0.69 to 1.01)	0.72 (0.34 to 1.52)
0.99 (0.77 to 1.27)	Apixaban	—	—
0.83 (0.69 to 1.01)	1.19 (0.87 to 1.62)	Rivaroxaban	—
0.72 (0.34 to 1.52)	1.38 (0.63 to 3.03)	1.16 (0.54 to 2.51)	Dabigatran
Network meta-analysis			

Comparisons between treatments should be read from left to right, and the estimate is in the cell in common between the column-defining treatment and the row-defining treatment. The upper triangle presents the results from direct (pairwise) meta-analyses, and the lower triangle presents the results from the NMA. The lower triangle contains the RRs of the NMA (mixed) effect estimates comparing the treatment in the row versus the treatment in the column, whereas cells in the upper triangle refer to the RR direct effect estimates comparing the treatment in the column versus the treatment in the row. If the (mixed or direct) RR for A versus B is available, the B versus A comparison can be easily calculated as 1/RR (the inverse of the estimated effect). Results are presented as RR (95% CI), where an RR < 1 favours the row-defining treatment. The order of treatments in the diagonal is arbitrary and does not reflect ranking. CI: confidence interval; NMA: network meta-analysis; RR: risk ratio.

Table 3. League table – major bleeding

Pairwise meta-analysis			
Placebo	2.41 (1.44 to 4.06)	3.31 (1.12 to 9.77)	1.74 (0.22 to 14.12)
2.41 (1.44 to 4.06)	Apixaban	—	—
3.31 (1.12 to 9.77)	0.67 (0.15 to 2.94)	Rivaroxaban	—
1.74 (0.22 to 14.12)	1.24 (0.08 to 18.21)	1.84 (0.14 to 24.75)	Dabigatran

Table 3. League table – major bleeding (Continued)

Network meta-analysis

Comparisons between treatments should be read from left to right, and the estimate is in the cell in common between the column-defining treatment and the row-defining treatment. The upper triangle presents the results from direct (pairwise) meta-analyses, and the lower triangle presents the results from the NMA. The lower triangle contains the RRs of the NMA (mixed) effect estimates comparing the treatment in the row versus the treatment in the column, whereas cells in the upper triangle refer to the RR direct effect estimates comparing the treatment in the column versus the treatment in the row. If the (mixed or direct) RR for A versus B is available, the B versus A comparison can be easily calculated as 1/RR (the inverse of the estimated effect). Results are presented as RR (95% CI), where an RR < 1 favours the row-defining treatment. The order of treatments in the diagonal is arbitrary and does not reflect ranking. CI: confidence interval; NMA: network meta-analysis; RR: risk ratio.

Table 4. Baseline characteristics of included trials

Variable	APPRAISE 1	APPRAISE 2	ATLAS ACS	ATLAS ACS 2	GEMINI-ACS	REDEEM
Design	RCT (phase II)	RCT (phase III)	RCT (phase II)	RCT (phase III)	RCT (phase II)	RCT (phase II)
Overall study population	1715	7392	3491	15526	3037	1878
NOAC type	Apixaban	Apixaban	Rivaroxaban	Rivaroxaban	Rivaroxaban	Dabigatran
NOAC dosages	2.5 mg BD, 10 mg QD	5 mg BD	5 mg QD, 10 mg QD, 15 mg QD, 20 mg QD	2.5 mg BD, 5 mg BD	2.5 mg BD	50 mg BD, 75 mg BD, 110 mg BD, 150 mg BD
Concomitant antiplatelet therapy	All participants received aspirin, and 76% received additional clopidogrel.	All participants received aspirin, and 81% received additional clopidogrel.	All participants received aspirin and 80% received additional clopidogrel.	All participants received aspirin, and 93% received additional clopidogrel.	All participants received SAPT with either clopidogrel (43.9%) or ticagrelor (56.1%).	All participants received aspirin, and 93% received additional clopidogrel.
Date of study	May 2006–Oct 2007	Mar 2009–Nov 2010	Nov 2006–Oct 2008	Nov 2008–Sep 2011	Apr 2015–Oct 2016	Mar 2008–Oct 2009
Follow-up (months)	6	8	6	13	11	6
Centres/countries	151/14	858/39	297/27	766/44	371/21	161/24
N randomised	1715	7392	3491	15,526	3037	1878
Days to randomisation	4	6	4	5	5	7
Median age (years)	61	67	57	62	62	62
Age (> 65 years), %	NR	59	24	37	42	45
Sex (male), %	77	67	78	75	75	75
STEMI, %	63	40	52	50	49	60

Table 4. Baseline characteristics of included trials (Continued)

NSTEMI, %	28	41	30	26	40	40
Unstable angina, %	9	18	18	24	11	NR
PCI for MI, %	66	44	61	63	87	55
Previous MI, %	6	25	21	27	21	29
Diabetes, %	22	48	19	32	29	32
Hypertension, %	NR	NR	57	68	71	67
Dyslipidaemia, %	NR	NR	44	49	56	NR
Smoker, %	NR	12	62	NR	32	61
Heart failure, %	13	28	NR	NR	10	11
Peripheral artery disease, %	6	18	NR	NR	4	7
Cerebrovascular disease, %	4	10	NR	3	NR	NR
Renal insufficiency, %	29	28	NR	NR	NR	NR

BD: twice daily; MI: myocardial infarction; N: number; NOAC: non-vitamin K antagonist oral anticoagulant; NR: not reported; NSTEMI: non-ST-segment elevation myocardial infarction; PCI: percutaneous coronary intervention; QD: once daily; RCT: randomised controlled trial; SAPT: single antiplatelet therapy; STEMI: ST-segment elevation myocardial infarction.

Table 5. Ranking of treatments according to P values of all pairwise comparisons (non-vitamin-K-antagonist oral anticoagulants, all doses combined versus placebo)

Intervention	Rank (P value)		
	All-cause mortality	Cardiovascular death	Major bleeding
Placebo	3 (0.2833)	4 (0.2318)	1 (0.8572)
Apixaban	4 (0.0838)	3 (0.2943)	3 (0.4108)
Rivaroxaban	2 (0.6971)	2 (0.7276)	4 (0.2101)
Dabigatran	1 (0.9358)	1 (0.7462)	2 (0.5219)

Table 6. Ranking of treatments according to P values of all pairwise comparisons (different doses of non-vitamin-K-antagonist oral anticoagulants versus placebo)

Intervention	Rank (P value)		
	All-cause mortality	Cardiovascular death	Major bleeding
Placebo	10 (0.3509)	9 (0.4104)	3 (0.737)
Apixaban 5 mg	11 (0.1103)	11 (0.1405)	2 (0.8104)

Table 6. Ranking of treatments according to P values of all pairwise comparisons (different doses of non-vitamin-K-antagonist oral anticoagulants versus placebo) *(Continued)*

Apixaban 10 mg	8 (0.3861)	7 (0.4696)	7 (0.4306)
Rivaroxaban 5 mg	9 (0.3623)	10 (0.3677)	6 (0.4671)
Rivaroxaban 10 mg	6 (0.5289)	4 (0.5551)	9 (0.2273)
Rivaroxaban 15 mg	3 (0.683)	3 (0.6854)	11 (0.1438)
Rivaroxaban 20 mg	7 (0.4168)	5 (0.4935)	10 (0.2135)
Dabigatran 50 mg BD	4 (0.6601)	6 (0.4757)	4 (0.6634)
Dabigatran 75 mg BD	5 (0.5423)	8 (0.4147)	1 (0.8241)
Dabigatran 110 mg BD	1 (0.7655)	2 (0.734)	8 (0.3341)
Dabigatran 150 mg BD	2 (0.6936)	1 (0.7535)	5 (0.6485)

APPENDICES

Appendix 1. Search strategies

CENTRAL

#1 MeSH descriptor: [Myocardial Infarction] explode all trees

#2 Myocardial infarction

#3 (MI or AMI)

#4 ST-segment elevation myocardial infarction

#5 non-ST segment elevation myocardial infarction

#6 (NSTEMI or STEMI)

#7 heart attack*

#8 {OR #1-#7}

#9 ((novel or new) NEAR/5 anticoagulant*)

#10 ((non-vitamin K or direct) NEAR/5 oral anticoagulant*)

#11 NOACS

#12 DOACS

#13 Apixaban

#14 MeSH descriptor: [Dabigatran] this term only

#15 Dabigatran

#16 Edoxaban

#17 MeSH descriptor: [Rivaroxaban] this term only

#18 Rivaroxaban

Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis (Review)

Copyright © 2024 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

#19 {OR #9-#18}

#20 #8 AND #19

MEDLINE Ovid

1 exp Myocardial Infarction/ (180783)

2 Myocardial infarction.tw. (187199)

3 (MI or AMI).tw. (69445)

4 ST-segment elevation myocardial infarction.tw. (9027)

5 non-ST segment elevation myocardial infarction.tw. (1688)

6 (NSTEMI or STEMI).tw. (13276)

7 heart attack*.tw. (5811)

8 1 or 2 or 3 or 4 or 5 or 6 or 7 (284530)

9 ((novel or new) adj5 anticoagulant*).tw. (5210)

10 ((non-vitamin K or direct) adj5 oral anticoagulant*).tw. (5682)

11 NOACS.tw. (1852)

12 DOACS.tw. (2124)

13 Apixaban.tw. (3629)

14 Dabigatran/ (3365)

15 dabigatran.tw. (4991)

16 Edoxaban.tw. (1516)

17 Rivaroxaban/ (3720)

18 rivaroxaban.tw. (5636)

19 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 (17181)

20 8 and 19 (947)

21 randomized controlled trial.pt. (534678)

22 controlled clinical trial.pt. (94229)

23 randomized.ab. (524225)

24 placebo.ab. (219053)

25 drug therapy.fs. (2336544)

26 randomly.ab. (360014)

27 trial.ab. (556623)

28 groups.ab. (2209947)

29 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 (5037851)

30 exp animals/ not humans.sh. (4849891)

31 29 not 30 (4380044)

32 20 and 31 (718)

Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis (Review)

Copyright © 2024 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

Embase Ovid

- 1 exp heart infarction/ (381377)
- 2 Myocardial infarction.tw. (267719)
- 3 (MI or AMI).tw. (121925)
- 4 ST-segment elevation myocardial infarction.tw. (14379)
- 5 non-ST segment elevation myocardial infarction.tw. (2547)
- 6 (NSTEMI or STEMI).tw. (33786)
- 7 heart attack*.tw. (8223)
- 8 1 or 2 or 3 or 4 or 5 or 6 or 7 (463386)
- 9 ((novel or new) adj5 anticoagulant*).tw. (8835)
- 10 ((non-vitamin K or direct) adj5 oral anticoagulant*).tw. (9600)
- 11 NOACS.tw. (3855)
- 12 DOACS.tw. (4130)
- 13 apixaban/ (14352)
- 14 Apixaban.tw. (7833)
- 15 dabigatran/ (15298)
- 16 Dabigatran.tw. (10162)
- 17 edoxaban/ (5405)
- 18 Edoxaban.tw. (2744)
- 19 rivaroxaban/ (20404)
- 20 Rivaroxaban.tw. (11776)
- 21 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 (39822)
- 22 8 and 21 (4020)
- 23 random\$.tw. (1662380)
- 24 factorial\$.tw. (40743)
- 25 crossover\$.tw. (79103)
- 26 cross over\$.tw. (33121)
- 27 cross-over\$.tw. (33121)
- 28 placebo\$.tw. (321543)
- 29 (doubl\$ adj blind\$).tw. (214008)
- 30 (singl\$ adj blind\$).tw. (26845)
- 31 assign\$.tw. (420769)
- 32 allocat\$.tw. (167033)
- 33 volunteer\$.tw. (262761)
- 34 crossover procedure/ (67244)

35 double blind procedure/ (182224)

36 randomized controlled trial/ (658353)

37 single blind procedure/ (42924)

38 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 (2479777)

39 (animal/ or nonhuman/) not human/ (5815400)

40 38 not 39 (2198481)

41 22 and 40 (1035)

CPCI-S

16 #15 AND #14

15 TS=(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*)

14 #13 AND #7

13 #12 OR #11 OR #10 OR #9 OR #8

12 TS=(Apixaban or Dabigatran or Edoxaban or Rivaroxaban)

11 TS=DOACS

10 TS=NOACS

9 TS=(("non-vitamin K" or direct) NEAR/5 "oral anticoagulant*")

8 TS=((novel or new) NEAR/5 anticoagulant*)

7 #6 OR #5 OR #4 OR #3 OR #2 OR #1

6 TS=heart attack*

5 TS=(NSTEMI or STEMI)

4 TS=non-ST segment elevation myocardial infarction

3 TS=ST-segment elevation myocardial infarction

2 TS=(MI or AMI)

1 TS=Myocardial infarction

ClinicalTrials.gov

Advanced search

Condition or disease: Acute Myocardial Infarction

AND

Study type: Interventional Studies (Clinical Trials)

AND

Intervention/treatment: Anticoagulant

WHO ICTRP

Advanced search

Condition: Acute Myocardial Infarction (with synonyms)

AND

Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis (Review)

Copyright © 2024 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

Intervention: Anticoagulants (with synonyms)

Appendix 2. Primary outcomes – secondary analyses (different doses of NOACs)

All-cause mortality

Non-vitamin-K-antagonist oral anticoagulants (NOACs) at different doses versus placebo

Direct evidence

There may be little or no difference in the rate of all-cause mortality between apixaban 5 mg and placebo (RR 1.77, 95% CI 0.79 to 3.96; 1 study, 928 participants; low-certainty evidence; [Analysis 4.1](#)), and there is probably little or no difference in the rate of all-cause mortality between apixaban 10 mg and placebo (RR 1.06, 95% CI 0.86 to 1.32; $I^2 = 0\%$; 2 studies, 8321 participants; moderate-certainty evidence; [Analysis 4.1](#)).

The following doses of rivaroxaban probably have little or no effect on the rate of all-cause mortality compared with placebo (moderate-certainty evidence; [Analysis 5.1](#)).

- 5 mg (RR 1.00, 95% CI 0.55 to 1.82; $I^2 = 74\%$; 3 studies, 14,732 participants)
- 10 mg (RR 0.84, 95% CI 0.56 to 1.26; $I^2 = 28\%$; 2 studies, 12,444 participants)

The following doses of rivaroxaban may have little or no effect on the rate of all-cause mortality compared with placebo (low-certainty evidence; [Analysis 5.1](#)).

- 15 mg (RR 0.61, 95% CI 0.18 to 2.08; $I^2 = 0\%$; 1 study, 1516 participants)
- 20 mg (RR 1.07, 95% CI 0.47 to 2.40; 1 study, 1771 participants)

The following doses of dabigatran may have little or no effect on the rate of all-cause mortality compared with placebo (low-certainty evidence; [Analysis 6.1](#)).

- 50 mg BD (RR 0.57, 95% CI 0.24 to 1.35; 1 study, 740 participants)
- 75 mg BD (RR 0.72, 95% CI 0.32 to 1.60; 1 study, 739 participants)
- 110 mg BD (RR 0.46, 95% CI 0.19 to 1.12; 1 study, 777 participants)
- Dabigatran 150 mg BD (RR 0.53, 95% CI 0.22 to 1.31; 1 study, 718 participants)

Network meta-analysis

The following doses of apixaban may have little or no effect on the rate of all-cause mortality compared with placebo (low-certainty evidence).

- 5 mg (RR 1.91, 95% CI 0.62 to 5.86)
- 10 mg (RR 0.98, 95% CI 0.46 to 2.10)

The following doses of rivaroxaban may have little or no effect on the rate of all-cause mortality compared with placebo (low-certainty evidence).

- 5 mg (RR 0.99, 95% CI 0.54 to 1.82)
- 10 mg (RR 0.79, 95% CI 0.39 to 1.60)
- 15 mg (RR 0.54, 95% CI 0.13 to 2.22)
- 20 mg (RR 0.94, 95% CI 0.32 to 2.77)

The following doses of dabigatran may have little or no effect on the rate of all-cause mortality compared with placebo (low-certainty evidence).

- 50 mg BD (RR 0.57, 95% CI 0.17 to 1.98)
- 75 mg BD (RR 0.72, 95% CI 0.22 to 2.38)
- 110 mg BD (RR 0.46, 95% CI 0.13 to 1.62)
- 150 mg BD (RR 0.53, 95% CI 0.15 to 1.89)

NOACs at different doses compared to each other

Network meta-analysis

There may be little or no difference in the rate of all-cause mortality between apixaban 5 mg and apixaban 10 mg (RR 2.21, 95% CI 0.78 to 6.28; 1 study, 635 participants; low-certainty evidence; [Analysis 7.1](#)).

There is probably little or no difference in the rate of all-cause mortality between rivaroxaban 5 mg and rivaroxaban 10 mg (RR 1.57, 95% CI 0.31 to 8.03; $I^2 = 91\%$; 2 studies, 11,593 participants; moderate-certainty evidence; [Analysis 8.1](#)). There may be little or no difference in the rate of all-cause mortality between the following doses of rivaroxaban (low-certainty evidence).

- 5 mg versus 15 mg (RR 3.47, 95% CI 0.95 to 12.69; 1 study, 664 participants; [Analysis 9.1](#))
- 5 mg versus 20 mg (RR 1.98, 95% CI 0.80 to 4.95; 1 study, 919 participants; [Analysis 10.1](#))
- 10 mg versus 15 mg (RR 0.90, 95% CI 0.24 to 3.37; 1 study, 1412 participants; [Analysis 11.1](#))
- 10 mg versus 20 mg (RR 0.51, 95% CI 0.20 to 1.33; 1 study, 1667 participants; [Analysis 12.1](#))
- 15 mg versus 20 mg (RR 0.57, 95% CI 0.16 to 2.10; 1 study, 967 participants; [Analysis 13.1](#))

There may be little or no difference in the rate of all-cause mortality between the following doses of dabigatran (low-certainty evidence)

- 50 mg BD versus 75 mg BD (RR 0.80, 95% CI 0.32 to 2.00; 1 study, 737 participants; [Analysis 14.1](#))
- 50 mg BD versus 110 mg BD (RR 1.26, 95% CI 0.46 to 3.43; 1 study, 775 participants; [Analysis 15.1](#))
- 50 mg BD versus 150 mg BD (RR 1.07, 95% CI 0.39 to 2.93; 1 study, 715 participants; [Analysis 16.1](#))
- 75 mg BD versus 110 mg BD (RR 1.58, 95% CI 0.61 to 4.10; 1 study, 774 participants; [Analysis 17.1](#))
- 75 mg BD versus 150 mg BD (RR 1.35, 95% CI 0.52 to 3.50; 1 study, 715 participants; [Analysis 18.1](#))
- 110 mg BD versus 150 mg BD (RR 0.85, 95% CI 0.30 to 2.41; 1 study, 753 participants; [Analysis 19.1](#)).

There may be little or no difference in the rate of all-cause mortality between apixaban 5 mg and the following interventions (low-certainty evidence; [Figure 3](#)).

- Rivaroxaban 5 mg (RR 1.92, 95% CI 0.54 to 6.86)
- Rivaroxaban 10 mg (RR 2.43, 95% CI 0.65 to 9.14)
- Rivaroxaban 15 mg (RR 3.57, 95% CI 0.58 to 21.83)
- Rivaroxaban 20 mg (RR 2.04, 95% CI 0.43 to 9.71)
- Dabigatran 50 mg BD (RR 3.33, 95% CI 0.63 to 17.62)
- Dabigatran 75 mg BD (RR 2.65, 95% CI 0.52 to 13.66)
- Dabigatran 110 mg BD (RR 4.18, 95% CI 0.77 to 22.62)
- Dabigatran 150 mg BD (RR 3.57, 95% CI 0.66 to 19.33)

There may be little or no difference in the rate of all-cause mortality between apixaban 10 mg and the following interventions (low-certainty evidence; [Figure 3](#)).

- Rivaroxaban 5 mg (RR 0.99, 95% CI 0.37 to 2.61)
- Rivaroxaban 10 mg (RR 1.25, 95% CI 0.44 to 3.53)
- Rivaroxaban 15 mg (RR 1.84, 95% CI 0.37 to 9.22)
- Rivaroxaban 20 mg (RR 1.05, 95% CI 0.28 to 3.95)
- Dabigatran 50 mg BD (RR 1.71, 95% CI 0.40 to 7.30)
- Dabigatran 75 mg BD (RR 1.37, 95% CI 0.33 to 5.63)
- Dabigatran 110 mg BD (RR 2.15, 95% CI 0.49 to 9.40)
- Dabigatran 150 mg BD (RR 1.84, 95% CI 0.42 to 8.03)

There may be little or no difference in the rate of all-cause mortality between rivaroxaban 5 mg and the following interventions (low-certainty evidence; [Figure 3](#)).

- Dabigatran 50 mg BD (RR 1.73, 95% CI 0.44 to 6.84)
- Dabigatran 75 mg BD (RR 1.38, 95% CI 0.36 to 5.27)
- Dabigatran 110 mg BD (RR 2.18, 95% CI 0.54 to 8.82)
- Dabigatran 150 mg BD (RR 1.86, 95% CI 0.46 to 7.53)

There may be little or no difference in the rate of all-cause mortality between rivaroxaban 10 mg and the following interventions (low-certainty evidence; [Figure 3](#)).

- Dabigatran 50 mg BD (RR 1.37, 95% CI 0.33 to 5.68)
- Dabigatran 75 mg BD (RR 1.09, 95% CI 0.27 to 4.38)
- Dabigatran 110 mg BD (RR 1.72, 95% CI 0.41 to 7.32)
- Dabigatran 150 mg BD (RR 1.47, 95% CI 0.35 to 6.25)

There may be little or no difference in the rate of all-cause mortality between rivaroxaban 15 mg and the following interventions (low-certainty evidence; [Figure 3](#)).

- Dabigatran 50 mg BD (RR 0.93, 95% CI 0.14 to 6.14)
- Dabigatran 75 mg BD (RR 0.74, 95% CI 0.12 to 4.77)
- Dabigatran 110 mg BD (RR 1.17, 95% CI 0.17 to 7.86)
- Dabigatran 150 mg BD (RR 1.00, 95% CI 0.15 to 6.71)

There may be little or no difference in the rate of all-cause mortality between rivaroxaban 20 mg and the following interventions (low-certainty evidence; [Figure 3](#)).

- Dabigatran 50 mg BD (RR 1.63, 95% CI 0.31 to 8.43)
- Dabigatran 75 mg BD (RR 1.30, 95% CI 0.26 to 6.53)
- Dabigatran 110 mg BD (RR 2.05, 95% CI 0.39 to 10.83)
- Dabigatran 150 mg BD (RR 1.75, 95% CI 0.33 to 9.25)

Cardiovascular mortality

NOACs at different doses versus placebo

Direct evidence

There may be little or no difference in the rate of cardiovascular mortality between apixaban 5 mg and placebo (RR 1.93, 95% CI 0.84 to 4.40; 1 study, 928 participants; low-certainty evidence; [Analysis 4.2](#)). There is probably little or no difference in the rate of cardiovascular mortality between apixaban 10 mg and placebo (RR 0.94, 95% CI 0.73 to 1.22; $I^2 = 0\%$; 2 studies, 8321 participants; moderate-certainty evidence; [Analysis 4.2](#)).

The following doses of rivaroxaban probably have little or no effect on the rate of cardiovascular mortality compared with placebo (moderate-certainty evidence; [Analysis 5.2](#)).

- 5 mg (RR 1.14, 95% CI 0.53 to 2.44; $I^2 = 81\%$; 3 studies, 14,732 participants)
- 10 mg (RR 0.90, 95% CI 0.72 to 1.13; $I^2 = 0\%$; 2 studies, 12,444 participants)

The following doses of rivaroxaban may have little or no effect on the rate of cardiovascular mortality compared with placebo (low-certainty evidence; [Analysis 5.2](#)).

- 15 mg (RR 0.75, 95% CI 0.22 to 2.62; 1 study, 1516 participants)
- 20 mg (RR 1.17, 95% CI 0.49 to 2.80; 1 study, 1771 participants)

The following doses of dabigatran may have little or no effect on the rate of cardiovascular mortality compared with placebo (low-certainty evidence; [Analysis 6.2](#)).

- 50 mg BD (RR 0.89, 95% CI 0.35 to 2.29; 1 study, 740 participants)
- 75 mg BD (RR 1.01, 95% CI 0.40 to 2.51; 1 study, 739 participants)
- 110 mg BD (RR 0.51, 95% CI 0.17 to 1.50; 1 study, 777 participants)
- 150 mg BD (RR 0.48, 95% CI 0.15 to 1.53; 1 study, 718 participants)

Network meta-analysis

The following doses of apixaban may have little or no effect on the rate of cardiovascular mortality compared with placebo (low-certainty evidence).

- 5 mg (RR 1.98, 95% CI 0.60 to 6.55)
- 10 mg (RR 0.93, 95% CI 0.40 to 2.14)

The following doses of rivaroxaban may have little or no effect on the rate of cardiovascular mortality compared with placebo (low-certainty evidence).

- 5 mg (RR 1.07, 95% CI 0.55 to 2.07)
- 10 mg (RR 0.81, 95% CI 0.37 to 1.75)
- 15 mg (RR 0.57, 95% CI 0.13 to 2.48)
- 20 mg (RR 0.88, 95% CI 0.27 to 2.85)

The following doses of dabigatran may have little or no effect on the rate of cardiovascular mortality compared with placebo (low-certainty evidence).

- 50 mg BD (RR 0.89, 95% CI 0.23 to 3.50)
- 75 mg BD (RR 1.01, 95% CI 0.26 to 3.87)
- 110 mg BD (RR 0.51, 95% CI 0.12 to 2.20)
- 150 mg BD (RR 0.48, 95% CI 0.10 to 2.20)

NOACs compared to each other

Network meta-analysis

There may be little or no difference in the rate of cardiovascular mortality between apixaban 5 mg and apixaban 10 mg (RR 2.76, 95% CI 0.89 to 8.57; 1 study, 635 participants; low-certainty evidence; [Analysis 7.2](#)).

There is probably little or no difference in the rate of cardiovascular mortality between rivaroxaban 5 mg and rivaroxaban 10 mg (RR 1.56, 95% CI 0.30 to 8.11; $I^2 = 91%$; 2 studies, 11,593 participants; moderate-certainty evidence; [Analysis 8.2](#)) There may be little or no difference in the rate of cardiovascular mortality between the following doses of rivaroxaban (low-certainty evidence).

- 5 mg versus 15 mg (RR 3.47, 95% CI 0.95 to 12.69; 1 study, 664 participants; [Analysis 9.2](#))
- 5 mg versus 20 mg (RR 2.23, 95% CI 0.87 to 5.73; 1 study, 919 participants; low-certainty evidence; [Analysis 10.2](#))
- 10 mg versus 15 mg (RR 0.90, 95% CI 0.24 to 3.37; 1 study, 1412 participants; low-certainty evidence; [Analysis 11.2](#))
- 10 mg versus 20 mg (RR 0.58, 95% CI 0.22 to 1.53; 1 study 1667 participants; low-certainty evidence; [Analysis 12.2](#))
- 15 mg versus 20 mg (RR 0.64, 95% CI 0.17 to 2.41; 1 study, 967 participants; low-certainty evidence; [Analysis 13.2](#))

There may be little or no difference in the rate of cardiovascular mortality between the following doses of dabigatran (low-certainty evidence).

- 50 mg BD versus 75 mg BD (RR 0.89, 95% CI 0.35 to 2.27; 1 study, 737 participants; low-certainty evidence; [Analysis 14.2](#))
- 50 mg BD versus 110 mg BD (RR 1.76, 95% CI 0.58 to 5.33; 1 study, 775 participants; low-certainty evidence; [Analysis 15.2](#))
- 50 mg BD versus 150 mg BD (RR 1.88, 95% CI 0.57 to 6.19; 1 study, 716 participants; low-certainty evidence; [Analysis 16.2](#))
- 75 mg BD versus 110 mg BD (RR 1.99, 95% CI 0.67 to 5.87; 1 study, 774 participants; low-certainty evidence; [Analysis 17.2](#))
- 75 mg BD versus 150 mg BD (RR 2.12, 95% CI 0.66 to 6.83; 1 study, 715 participants; low-certainty evidence; [Analysis 18.2](#))
- 110 mg BD versus 150 mg BD (RR 1.07, 95% CI 0.29 to 3.95; 1 study, 753 participants; low-certainty evidence; [Analysis 19.2](#))

There may be little or no difference in the rate of cardiovascular mortality between apixaban 5 mg and the following interventions (low-certainty evidence; [Figure 3](#)).

- Rivaroxaban 5 mg (RR 1.85, 95% CI 0.47 to 7.27)
- Rivaroxaban 10 mg (RR 2.45, 95% CI 0.59 to 10.18)
- Rivaroxaban 15 mg (RR 3.49, 95% CI 0.52 to 23.41)
- Rivaroxaban 20 mg (RR 2.25, 95% CI 0.42 to 12.07)
- Dabigatran 50 mg BD (RR 2.21, 95% CI 0.36 to 13.60)
- Dabigatran 75 mg BD (RR 1.96, 95% CI 0.32 to 11.88)
- Dabigatran 110 mg BD (RR 3.89, 95% CI 0.59 to 25.88)
- Dabigatran 150 mg BD (RR 4.16, 95% CI 0.60 to 29.06)

There may be little or no difference in the rate of cardiovascular mortality between apixaban 10 mg and the following interventions (low-certainty evidence; [Figure 3](#)).

- Rivaroxaban 5 mg (RR 0.87, 95% CI 0.30 to 2.52)
- Rivaroxaban 10 mg (RR 1.15, 95% CI 0.37 to 3.59)
- Rivaroxaban 15 mg (RR 1.64, 95% CI 0.30 to 8.96)
- Rivaroxaban 20 mg (RR 1.06, 95% CI 0.25 to 4.48)
- Dabigatran 50 mg BD (RR 1.04, 95% CI 0.21 to 5.15)
- Dabigatran 75 mg BD (RR 0.92, 95% CI 0.19 to 4.49)
- Dabigatran 110 mg BD (RR 1.83, 95% CI 0.34 to 9.90)
- Dabigatran 150 mg BD (RR 1.96, 95% CI 0.34 to 11.18)

There may be little or no difference in the rate of cardiovascular mortality between rivaroxaban 5 mg and the following interventions (low-certainty evidence; [Figure 3](#)).

- Dabigatran 50 mg BD (RR 1.20, 95% CI 0.26 to 5.46)
- Dabigatran 75 mg BD (RR 1.06, 95% CI 0.24 to 4.75)
- Dabigatran 110 mg BD (RR 2.11, 95% CI 0.42 to 10.53)
- Dabigatran 150 mg BD (RR 2.25, 95% CI 0.42 to 11.93)

There may be little or no difference in the rate of cardiovascular mortality between rivaroxaban 10 mg and the following interventions (low-certainty evidence; [Figure 3](#)).

- Dabigatran 50 mg BD (RR 0.90, 95% CI 0.19 to 4.34)
- Dabigatran 75 mg BD (RR 0.80, 95% CI 0.17 to 3.78)
- Dabigatran 110 mg BD (RR 1.59, 95% CI 0.30 to 8.35)
- Dabigatran 150 mg BD (RR 1.70, 95% CI 0.31 to 9.44)

There may be little or no difference in the rate of cardiovascular mortality between rivaroxaban 15 mg and the following interventions (low-certainty evidence; [Figure 3](#)).

- Dabigatran 50 mg BD (RR 0.63, 95% CI 0.08 to 4.73)
- Dabigatran 75 mg BD (RR 0.56, 95% CI 0.08 to 4.14)
- Dabigatran 110 mg BD (RR 1.11, 95% CI 0.14 to 8.93)
- Dabigatran 150 mg BD (RR 1.19, 95% CI 0.14 to 9.98)

There may be little or no difference in the rate of cardiovascular mortality between rivaroxaban 20 mg and the following interventions (low-certainty evidence; [Figure 3](#)).

- Dabigatran 50 mg BD (RR 0.98, 95% CI 0.16 to 5.96)
- Dabigatran 75 mg BD (RR 0.87, 95% CI 0.15 to 5.21)
- Dabigatran 110 mg BD (RR 1.73, 95% CI 0.26 to 11.35)
- Dabigatran 150 mg BD (RR 1.85, 95% CI 0.27 to 12.75)

Major bleeding

NOACs at different doses versus placebo

Direct evidence

Apixaban 10 mg increases the rate of major bleeding compared with placebo (RR 2.56, 95% CI 1.52 to 4.30; $I^2 = 0\%$; 2 studies, 8229 participants; high-certainty evidence; [Analysis 4.3](#)). There may be little or no difference between apixaban 5 mg and placebo in risk of major bleeding (RR 0.38, 95% CI 0.02 to 7.89; 1 study, 914 participants; low-certainty evidence; [Analysis 4.3](#)).

Rivaroxaban at the following investigated doses increases the rate of major bleeding compared with placebo (high-certainty evidence; [Analysis 5.3](#)).

- 5 mg (RR 2.39, 95% CI 1.11 to 5.16; $I^2 = 44\%$; 3 studies, 14,732 participants)
- 10 mg (RR 6.17, 95% CI 1.83 to 20.85; $I^2 = 45\%$; 2 studies, 12,444 participants)

Rivaroxaban at the following investigated doses probably increases the rate of major bleeding compared with placebo (moderate-certainty evidence; [Analysis 5.3](#)).

- 15 mg (RR 19.55, 95% CI 2.36 to 161.85; 1 study, 1516 participants)
- 20 mg (RR 15.19, 95% CI 1.90 to 121.15; 1 study, 1771 participants)

There may be little or no difference in major bleeding between the following doses of dabigatran and placebo (low-certainty evidence; [Analysis 6.3](#)).

- 50 mg BD (RR 1.01, 95% CI 0.06 to 16.01; 1 study, 740 participants)
- 75 mg BD (RR 0.34, 95% CI 0.01 to 8.22; 1 study, 739 participants)
- 110 mg BD (RR 4.57, 95% CI 0.54 to 38.93; 1 study, 777 participants)
- 150 mg BD (RR 1.07, 95% CI 0.07 to 17.03; 1 study, 718 participants).

Network meta-analysis

Apixaban 10 mg probably increases the rate of major bleeding compared with placebo (RR 2.57, 95% CI 1.00 to 6.56; moderate-certainty evidence). We are uncertain about the effect of apixaban 5 mg on major bleeding (RR 0.37, 95% CI 0.02 to 7.80; very low-certainty evidence).

Rivaroxaban at the following investigated doses probably increases the rate of major bleeding compared with placebo (moderate-certainty evidence).

- 5 mg (RR 2.42, 95% CI 1.09 to 5.38)
- 10 mg (RR 4.77, 95% CI 1.95 to 11.65)
- 15 mg (RR 6.89, 95% CI 1.61 to 29.52)
- 20 mg (RR 5.35, 95% CI 1.32 to 21.72)

We are uncertain about the effect of the following investigated doses of dabigatran on major bleeding compared with placebo (very low-certainty evidence).

- 50 mg BD (RR 1.01, 95% CI 0.09 to 11.61)
- 75 mg BD (RR 0.34, 95% CI 0.01 to 9.41)
- 110 mg BD (RR 3.35, 95% CI 0.44 to 25.53)
- 150 mg BD (RR 1.07, 95% CI 0.09 to 12.34)

NOACs at different doses compared to each other

Network meta-analysis

There may be little or no difference in the rate of major bleeding between apixaban 5 mg and apixaban 10 mg (RR 0.14, 95% CI 0.01 to 2.75; 1 study, 630 participants; low-certainty evidence; [Analysis 7.3](#)).

There is probably little or no difference in the rate of major bleeding between rivaroxaban 5 mg and rivaroxaban 10 mg (RR 0.61, 95% CI 0.21 to 1.72; $I^2 = 38%$; 2 studies, 11,593 participants; moderate-certainty evidence; [Analysis 8.3](#)). There may be little or no difference in the rate of major bleeding between the following doses of rivaroxaban and placebo (low-certainty evidence).

- 5 mg versus 15 mg (RR 0.19, 95% CI 0.02 to 1.59; 1 study, 664 participants; [Analysis 9.3](#))
- 5 mg versus 20 mg (RR 0.25, 95% CI 0.03 to 1.97; 1 study, 919 participants; [Analysis 10.3](#))
- 10 mg versus 15 mg (RR 0.90, 95% CI 0.35 to 2.28; 1 study, 1412 participants; [Analysis 11.3](#))
- 10 mg versus 20 mg (RR 1.16, 95% CI 0.50 to 2.69; 1 study, 1667 participants; [Analysis 12.3](#))
- 15 mg versus 20 mg (RR 1.29, 95% CI 0.45 to 3.68; 1 study, 967 participants; [Analysis 13.3](#))

There may be little or no difference in the rate of major bleeding between the following doses of dabigatran (low-certainty evidence).

- 50 mg BD versus 75 mg BD (RR 2.99, 95% CI 0.12 to 73.21; 1 study, 737 participants; low-certainty evidence; [Analysis 14.3](#))
- 50 mg BD versus 110 mg BD (RR 0.22, 95% CI 0.03 to 1.87; 1 study, 775 participants; low-certainty evidence; [Analysis 15.3](#))
- 50 mg BD versus 150 mg BD (RR 0.94, 95% CI 0.06 to 14.98; 1 study, 716 participants; low-certainty evidence; [Analysis 16.3](#))
- 75 mg BD versus 110 mg BD (RR 0.10, 95% CI 0.01 to 1.81; 1 study, 774 participants; low-certainty evidence; [Analysis 17.3](#))
- 75 mg BD versus 150 mg BD (RR 0.31, 95% CI 0.01 to 7.69; 1 study, 715 participants; low-certainty evidence; [Analysis 18.3](#))
- 110 mg BD versus 150 mg BD (RR 4.27, 95% CI 0.50 to 36.40; 1 study, 753 participants; low-certainty evidence; [Analysis 19.3](#))

There may be little or no difference in the rate of major bleeding between apixaban 5 mg and the following interventions (low-certainty evidence; [Figure 3](#)).

- Rivaroxaban 5 mg (RR 0.15, 95% CI 0.01 to 3.58)
- Rivaroxaban 10 mg (RR 0.08, 95% CI 0.00 to 1.86)
- Rivaroxaban 15 mg (RR 0.05, 95% CI 0.00 to 1.58)
- Rivaroxaban 20 mg (RR 0.07, 95% CI 0.00 to 1.98)
- Dabigatran 50 mg BD (RR 0.37, 95% CI 0.01 to 18.36)
- Dabigatran 75 mg BD (RR 1.11, 95% CI 0.01 to 100.95)
- Dabigatran 110 mg BD (RR 0.11, 95% CI 0.00 to 4.31)
- Dabigatran 150 mg BD (RR 0.35, 95% CI 0.01 to 17.26)

There may be little or no difference in the rate of major bleeding between apixaban 10 mg and the following interventions (low-certainty evidence; [Figure 3](#)).

- Rivaroxaban 5 mg (RR 1.06, 95% CI 0.31 to 3.64)
- Rivaroxaban 10 mg (RR 0.54, 95% CI 0.15 to 1.96)
- Rivaroxaban 15 mg (RR 0.37, 95% CI 0.07 to 2.11)
- Rivaroxaban 20 mg (RR 0.48, 95% CI 0.09 to 2.59)
- Dabigatran 50 mg BD (RR 2.55, 95% CI 0.19 to 35.05)
- Dabigatran 75 mg BD (RR 7.63, 95% CI 0.24 to 243.44)
- Dabigatran 110 mg BD (RR 0.77, 95% CI 0.08 to 7.17)
- Dabigatran 150 mg BD (RR 2.40, 95% CI 0.17 to 32.96)

There may be little or no difference in the rate of major bleeding between rivaroxaban 5 mg and the following interventions (low-certainty evidence; [Figure 3](#)).

- Dabigatran 50 mg BD (RR 2.41, 95% CI 0.18 to 31.53)
- Dabigatran 75 mg BD (RR 7.20, 95% CI 0.23 to 221.52)
- Dabigatran 110 mg BD (RR 0.72, 95% CI 0.08 to 6.40)
- Dabigatran 150 mg BD (RR 2.26, 95% CI 0.17 to 29.65)

There may be little or no difference in the rate of major bleeding between rivaroxaban 10 mg and the following interventions (low-certainty evidence; [Figure 3](#)).

- Dabigatran 50 mg BD (RR 4.74, 95% CI 0.35 to 64.14)
- Dabigatran 75 mg BD (RR 14.20, 95% CI 0.45 to 447.18)
- Dabigatran 110 mg BD (RR 1.42, 95% CI 0.15 to 13.08)
- Dabigatran 150 mg BD (RR 4.46, 95% CI 0.33 to 60.31)

There may be little or no difference in the rate of major bleeding between rivaroxaban 15 mg and the following interventions (low-certainty evidence; [Figure 3](#)).

- Dabigatran 50 mg BD (RR 6.85, 95% CI 0.40 to 118.00)
- Dabigatran 75 mg BD (RR 20.49, 95% CI 0.54 to 777.92)
- Dabigatran 110 mg BD (RR 2.06, 95% CI 0.17 to 24.99)
- Dabigatran 150 mg BD (RR 6.44, 95% CI 0.37 to 110.96)

There may be little or no difference in the rate of major bleeding between rivaroxaban 20 mg and the following interventions (low-certainty evidence; [Figure 3](#)).

- Dabigatran 50 mg BD (RR 5.32, 95% CI 0.32 to 89.19)
- Dabigatran 75 mg BD (RR 15.92, 95% CI 0.43 to 591.52)
- Dabigatran 110 mg BD (RR 1.60, 95% CI 0.14 to 18.82)
- Dabigatran 150 mg BD (RR 5.00, 95% CI 0.30 to 83.87)

Consistency assessment

To assess the consistency of the networks, we compared the direct and indirect evidence for all treatment comparisons. No significant inconsistency was observed in our analysis. The results from the direct and indirect evidence were consistent across all included studies, providing confidence in the validity of the NMA findings.

Ranking of treatments (different doses of NOACs)

All-cause mortality

The P scores indicate the following ranking of treatments (from lowest to highest risk of all-cause mortality): dabigatran 110 mg BD, dabigatran 150 mg BD, rivaroxaban 15 mg, dabigatran 50 mg BD, dabigatran 75 mg BD, rivaroxaban 10 mg, rivaroxaban 20 mg, apixaban 10 mg, rivaroxaban 5 mg, placebo, and apixaban 5 mg ([Table 6](#)).

Cardiovascular mortality

The P scores indicate the following ranking of treatments (from lowest to highest risk of cardiovascular mortality): dabigatran 150 mg BD, dabigatran 110 mg BD, rivaroxaban 15 mg, rivaroxaban 10 mg, rivaroxaban 20 mg, dabigatran 50 mg BD, apixaban 10 mg, dabigatran 75 mg BD, placebo, rivaroxaban 5 mg, and apixaban 5 mg ([Table 6](#)).

Major bleeding

The P scores indicate the following ranking of treatments (from lowest to highest risk of major bleeding): dabigatran 75 mg BD, apixaban 5 mg, placebo, dabigatran 50 mg BD, dabigatran 150 mg BD, rivaroxaban 5 mg, apixaban 10 mg, dabigatran 110 mg BD, rivaroxaban 10 mg, rivaroxaban 20 mg, and rivaroxaban 15 (Table 6).

HISTORY

Protocol first published: Issue 5, 2021

CONTRIBUTIONS OF AUTHORS

SAS was involved in the conception of the review, design of the review, co-ordination of the review, search and selection of studies for inclusion in the review, collection of data for the review, assessment of the risk of bias in the included studies, analysis of data, assessment of the certainty in the body of evidence, interpretation of data, and writing of the review.

KK was involved in data analysis.

WS was involved in the interpretation of data.

DA was involved in the search and selection of studies for inclusion in the review.

DD was involved in the interpretation of data.

RFS was involved in the interpretation of data.

CMG was involved in the interpretation of data.

DW was involved in the interpretation of data.

SA was involved in the co-ordination, search and selection of studies for inclusion in the review; assessment of the risk of bias in the included studies; assessment of the certainty in the body of evidence; and writing of the review.

All authors approved the final version of the review.

DECLARATIONS OF INTEREST

SAS: no conflicts of interest.

KK: no conflicts of interest.

WS: no conflicts of interest; works as an interventional cardiologist in Halifax.

DA: no conflicts of interest.

DD: speaker honoraria from Bayer Healthcare, Pfizer Canada Inc., Daiichi Sankyo; published opinions for Deutsche Medizinische Wochenschrift; works as a health professional at University Medical Center Mannheim, Germany.

RFS: consultant for Alnylam Pharmaceuticals, AstraZeneca, Bayer, Bristol Myers Squibb, Chiesi Farmaceutici, CSL Behring, Cytosorbents, GlyCardial Diagnostics, Hengrui, Idorsia, Intas Pharmaceuticals, Pfizer UK, Novartis, PhaseBio, Sanofi Aventis, Thromboserin; works as a health professional at Sheffield Teaching Hospitals NHS Foundation Trust.

CMG: consultant for AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., CSL Behring, Janssen Global Services, LLC, Johnson & Johnson Health Care Systems Inc.; Physician at Beth Israel Deaconess Medical Center.

DW: consultant for Bayer, AstraZeneca, ABIOMED, Novartis.

SA: no conflicts of interest; Cardiac Radiologist at Sheffield Teaching Hospitals.

SOURCES OF SUPPORT

Internal sources

- Internal sources, Other

No sources of support supplied

External sources

- National Institute for Health Research (NIHR), UK

This review was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis Programme (NIHR150853) Incentive Award Scheme 2021. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

Differences between the published protocol, [Al Said 2021](#), and this current review are as follows.

- We did not investigate heterogeneity through subgroup analyses because we identified few eligible studies.

- We were unable to create net heat plots to visualise inconsistencies between direct and indirect evidence because we identified few eligible studies.
- We were unable to assess the risk of publication bias with funnel plots to explore possible small-study biases for the primary outcomes because we identified few eligible studies.
- We were unable to analyse recurrent hospitalisation and health-related quality of life as none of the included studies reported these outcomes.
- We provided in our review the number needed to treat for an additional beneficial outcome (NNTB) and number needed to treat for an additional harmful outcome (NNTH).

INDEX TERMS

Medical Subject Headings (MeSH)

Anticoagulants; *Dabigatran; Hemorrhage; *Myocardial Infarction; Network Meta-Analysis; Platelet Aggregation Inhibitors; Rivaroxaban

MeSH check words

Humans